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4I. Abbrevations and Nomenclatures utilized
I.1: Abbreviations
A: alanine
aa: amino acid
BSE: bovine spongiform encephalopathy
CD: compact disc
CHO: chinese hamster ovary
CJD: Creutzfeldt-Jakob disease
CNS: central nervous system
CWD: Chronic Wasting Disease
D: aspartic acid
DC: dendritic cell
DNA: deoxyribonucleic acid
DRM: detergen resistant membrane
E: glutamic acid
EM: electron microscopy
ER: endoplasmic reticulum
fCJD: familial Creutzfeldt-Jakob disease
FDC: follicular dendritic cell
FFI: Fatal familial insomnia
FSE: feline spongiform encephalopathy
G: glycine
GALT: gut associated lymphatic system
GSS: Gerstmann-Sträussler-Scheinker syndrome
GPI: glycosylphophatidylinositol
GTP: guanosine triphosphate
H: histidine
HIV-1: human immunodeficiency virus 1
HLA: human leukocyte antigen
iCJD: iatrogenic Creutzfeldt-Jakob disease
IHC: immunohistochemistry
IHF: immunohistofluorescence
5K: lysine
kDa: kilo Dalton
M: molar
MALT: mucosa associated lymphatic system
MHC: major histocompatibility complex
mRNA: messenger RNA
N: asparagine
NaOH: sodium hydroxide
nm: nanometer
nvCJD: see vCJD
P: proline
PIPLC: phosphatidylinositol-specific phospholipase C
PK: proteinase K
PMCA: protein misfolding cyclic amplification
prion: proteinaceous infectious particles
prnp: prion gene
PrPC: cellular (i.e. wild type) prion protein
PrPSc: scrapie (i.e. infectious) prion protein
PrPres: resistant prion protein (i.e. resistant to proteinase K digestion)
Q: glutamine
R: arginine
rER: rough endoplasmic reticulum
RNA: ribonucleic acid
S: Svedberg
SDS: sodium dodecyl sulfate
SNS: sympathetic nervous system
sCJD: sporadic Creutzfeldt-Jakob disease
T: threonine
TGN: trans-Golgi-network
TME: transmissible mink encephalopathy
TSE: transmissible spongiform encephalopathy
TNT: tunneling nanotubes
UK: United Kingdom
USA: United States of America
6V: valine
vCJD: variant Creutzfeldt-Jakob disease
W: tryptophan
I.2: Nomenclature and definition of the different forms of PrP
PrP is an acronym standing for “protease resistant protein”. S. Prusiner coined the term
prion (acronym for proteinaceous infectious particle); this term usually describes the
infectious agent of the diseases Transmissible Spongiform Encephalopathies (TSEs).
PrPC: Cellular PrP, the wild-type form of PrP, expressed in a wide variety of cells such
as neurons, lymphoid system and others
PrPSc: PrP scrapie, the pathogenic and transmissible isoform of PrPC, causative agent of
TSEs
PrPsen: PrP sensitive to treatment with proteases. This term specifies that only a certain
percentage of PrPSc is resistant to treatment with proteases (Tzaban et al., 2002).
PrPres: PrP resistant to digestion with proteinase K (PK), opposite of PrPsen
PrP: Utilized, to indicate the whole pool of PrP-proteins, be it PrPC, PrPSc or a mixture
of both. Also utilized when differentiation between native and pathologic form is
impossible.
PrPmut: Derives from mutant PrP and describes a pathologic form of PrP caused by a
mutation in the prnp-gene, as found in inheritable TSEs in humans.
7II. A brief chronology of Transmissible Spongiform Encephalopathies (TSEs)
The first Transmissible Spongiform Encephalopathies (TSEs) were described in the
18th century in sheep (1732) and in goat (1772). Lacking deeper insight, the malady
was called scrapie, due to the typical behaviour of the diseased animals, suffering from
an intense pruritus and scraping themselves on walls, trees etc (Detwiler, 1992). The
first TSE in cattle had already been described in 1883, but was bound to remain a sole
and isolated case until the advent of the Bovine Spongiform Encephalopathy (BSE)
epidemic, also known as „Mad Cow Disease“, in the 1980s mainly in the United
Kingdom. The first cases of human TSEs were described by two German neurologists
Creutzfeldt (1885-1964) and Jakob (1884-1931) in the years 1920 and 1921, who also
became the eponyms for the most common of the TSEs in humans, the Creutzfeldt-
Jakob disease (CJD). An important contribution came from two French scientists in
1936, Cuillé and Chelle, who managed to prove the transmissibility of scrapie by
inoculating healthy animals with nervous tissue from diseased animals. In the 1950s-70s
Lindenbaum, Zigas and Gajdusek described the ailment Kuru, an endemic disease in the
Fore people of Papua New Guinea. Already in 1959, Hadlow reported that scrapie and
Kuru have common histopathological and clinical traits, making a link between an
animal and a human form of TSE for the first time (Hadlow, 1959; Hadlow, 1995). In
the same year, Gajdusek managed to transmit Kuru from brain material of deceased
humans to chimpanzees by intracerebral injection, while in the year 1961, Chandler
managed to pass scrapie to mice (Chandler, 1961). In 1976 Gajdusek received one of
three Nobel Prizes to be given to researchers in the TSE-field.
In 1979 Stanley Prusiner started to work on the concept of an infectious agent
completely devoid of DNA and judging from his results, entirely based on protein
(Prusiner et al., 1980a; Prusiner et al., 1980b). In 1982, when presenting for the first
time his heretical concept of the “prion”, an acronym of “proteinaceous infectious
particles“, he surely must have caused a stir in his audience and was awarded the Nobel
Prize for his work in 1997. In the early 1980’s, the first CJD-cases caused by transplants
are reported in the United States and Australia, as well as cases caused by cadaver-
derived growth hormone-treatments in Japan, the United States and France (Billette de
Villemeur et al., 1994). The cause being medical interventions, this type of disease was
called iatrogenic CJD (iCJD). Starting from 1985, the first BSE-cases were reported in
the United Kingdom (UK), the epidemic gaining momentum and peaking in 1992, when
8a total of 37000 cattle were found to test positive. Only four years later, in 1996, a link
was established between the consumption of BSE-contaminated foodstuff and the
emergence of a new form of CJD, termed variant or new variant CJD (vCJD/nvCJD).
This news produced a large economic commotion in the UK and Europe leading to
embargoes on beef and products deriving from cattle (e.g. cartilage) coming from the
UK. From 1996 on, many laboratories showed that the vCJD-agent is the same as found
in BSE and that foodstuffs can transfer the infectious particle. Since 2000 the numbers
of cases in the UK have subsided (Andrews et al., 2003).
9III. Introduction
III.1: On the nature of prions
Prions are able to propagate and multiply, nevertheless the cause for TSE seems to be a
very non-conventional pathogen, because it could not be shown to be associated with
any form of nucleic acid as a carrier of biological information and therefore does not fit
into any classical virological model. Its inability to be inactivated by classical
procedures utilized on viruses or bacteria (e.g. heat, irradiation with ultraviolet
radiation) led scientists to discard the theory that TSEs were caused by extremely slow
viruses and put forward a new “protein-only”-hypothesis, suggesting that prions consist
of only an infectious protein. Even today, despite strong support from various
laboratories (Castilla et al., 2005a; Legname et al., 2004), the proteinaceous nature of
prions is still contested by some researchers (Broxmeyer, 2004; Manuelidis et al.,
2007).
III.1.1: Prions are not easily inactivated by ionizing radiation: Is it therefore an
infectious protein?
The first researcher to study the unusual biochemical characteristics of prions was
Tikvah Alper, who described the unusually small size of prions (Alper et al., 1966). He
also found that scrapie-containing brain material remained infectious despite a harsh
treatment with ionizing radiation capable of destroying all nucleic acids (DNA and
RNA) (Alper et al., 1967; Latarjet et al., 1970).
Contrary to bacteria and viruses, prions are extremely resistant not only to irradiation
but resist all the other noxious treatments used in microbiology including humid or dry
heat, chemical inactivators such as alcohols or formalin (Fichet et al., 2004; Taylor,
2004) or incubation at 100°C in the presence of sodium dodecyl sulfate (SDS) or urea
and variations thereof. Efficacious means of inactivating prions align with procedures
aimed at destroying proteins and include phenols, 1N NaOH (for 1 hr at 20°C) (Ernst
and Race, 1993)), 4M guanidium hypochlorite or guanidium isothiocyanate, 2,5 %
Sodium Hypochlorite (1 hr at 20°C) (Brown et al., 1986), autoclaving with humid heat
at 136°C for 18 minutes (Kimberlin et al., 1983) or with dry heat at 160°C for 24 hrs
(Dickinson and Taylor, 1978).
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Even though Alper’s work lead him to conclude that prions might be deprived of
nucleic acids, it was Griffith a few years later who proposed that prions are proteins that
are capable of adopting an abnormal structure and autoreplicate themselves by
imprinting this new structure on to another protein (Griffith, 1967). His innovative and
revolutionary theory was negated for a long time, since none of the experts in the field
could imagine an infectious particle without storing its information in some form of
nucleic acid.
It was only fifteen years later (in 1982), that Stanley Prusiner was able to support the
ingenious hypothesis of Griffith by isolating the proteinaceous etiological agent of
TSEs termed prions, thus showing that prions are indeed deprived of nucleic acids
(Bolton et al., 1982; Prusiner, 1982) and that its infectivity can only be reduced by
agents which denature proteins (McKinley et al., 1983).
Fig. 1: The “protein-only” hypothesis proposes that the infectious entity in TSEs is an abnormal
isoform of PrPC, termed PrPSc. PrPC is an endogenous membrane-bound protein that traffics between
the plasma membrane and intracellular vesicles of cells (A). Upon exposure to and uptake by cells of
exogenous PrPSc, new PrPSc is produced through catalytical conversion from the pool of endogenous PrPC
(B) (Weissmann, 2004).
According to Prusiner’s “protein-only” hypothesis, prions, also termed PrPSc (Sc for
scrapie), are able to replicate by converting the regular endogenous protein PrPC (C for
cellular) into an abnormal toxic form, which accumulates in the cell and produces in
due time the amyloid deposits typical for TSEs (see Figure 1).
There are numerous lines of evidence that support the hypothesis put forward by
Prusiner and colleagues (Prusiner, 1998):
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a) Infectivity co-purifies with an identifiable macromolecule, PrPSc, which is the
pathogenic conformation (partially resistant to proteases, hence also PrPres (res
for resistant)) of a normal cellular protein called PrPC.
b) PrPSc accumulates proportionally with infectious titre without the augmentation
of its corresponding mRNA
c) Knock-out mice deprived of their endogenous PrPC are resistant to infection
with PrPSc.
d) Protein-denaturing agents reduce infectivity of infectious samples, while
treatments aimed at destroying the RNA/DNA contained in the samples show no
reduction in infectivity.
e) Certain mutations in the prnp-gene (on chromosome 20 in humans) lead to
pathological forms of its corresponding protein, PrPC, and lead to genetically
encoded forms of TSEs.
Strong support for the exclusively proteinaceous nature of prions has been recently
provided by two different laboratories, that were able to produce infectious prions in
vitro using different approaches. Legname and coworkers produced infectious prions
starting from a recombinant protein, while Castilla and colleagues succeeded to
multiply PrPSc-amounts starting from minimal amounts deriving from infected tissue
(Castilla et al., 2005a; Legname et al., 2004). The first group expressed a murine
truncated form of PrPC in E. coli and managed to polymerize a subset of this into
amyloid fibrils. These fibrils were shown to be protease-resistant similar to PrPSc and
induced neurological dysfunction when inoculated into mice (Legname et al., 2004).
These results demonstrated that infectious prions can be produced in an in vitro system.
However it must be mentioned that the mice used for the inoculation assays in this
work, were previously shown to spontaneously develop symptoms resembling TSEs
(Castilla et al., 2005a; Chiesa et al., 1998; Westaway et al., 1994). Strong arguments in
favour of the proteinaceous nature of prions also came from Castilla and colleagues
who developed a new procedure to produce de novo PrPSc with cycles of sonication
using PrPC as a substrate. They termed this procedure “protein misfolding cyclic
amplification” (PMCA, see Paragraph IX) and showed that this in vitro produced
material was infectious after inoculation in hamsters, which developed symptoms
strongly resembling TSEs (Castilla et al., 2005a). Additional surprising support for the
protein-only hypothesis came from a rather unexpected research field of biology.
Several groups were able to show that the yeast Saccharomyces cerevisiae among
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others produced anomalous forms of endogenous proteins (e.g. Ure2, Sup35, Rnq1)
with a tendency to convert and aggregate, resembling clustered prion-fibrils. Striking
structural parallels were recently shown for Sup35 from yeast and prions from humans
using X-ray microcrystallography (Sawaya et al., 2007). Furthermore, another research
group was able to produce yeast-prions in vitro (Brachmann et al., 2005). It is also
worthwhile to mention that the aggregates of these proteins are transmitted horizontally
by cytoplasmic mixing and mating and some seem to have a deleterious effect on the
carrier. Interestingly, these proteins and the phenotypes caused by them in yeast, are
considered to be rapid systems of adaptation to changes in the environment of the
organism and which, upon misfolding, behave like inheritable genetic elements
(reviewed in (Tuite and Cox, 2003)).
III.1.2: Prions: a viral agent?
In spite of the widely accepted theory on the proteinaceous nature of prions, the
alternative hypothesis of prions being a slow virus (Eklund et al., 1967; Manuelidis et
al., 2007) or a virino (a nucleic acid smaller than a virus, coated with host proteins and
therefore not raising an immune response by the infected organism (Dickinson and
Outram, 1988)), capable exploiting PrPC as its receptor (Mestel, 1996) (see Fig. 2) still
retains ardent supporters today.
The advocates of the viral theory believe that certain, very small viruses can escape
inactivation by irradiation and that infectivity is strongly reduced by chemical agents
negatively affecting viral core components but not PrPSc (Manuelidis, 2003). The viral
hypothesis would indeed explain some of the characteristics of prion-linked diseases,
but all experiments to purify a prion-specific nucleic acid have failed (Lansbury and
Caughey, 1996). The Manuelidis group, one of the leading supporters of the viral
hypothesis, showed that some nucleic acids copurify with the infectious material found
in CJD, and that it is possible to separate the majority of PrPSc from the infectious
fraction in human brain-samples (Akowitz et al., 1993; Sklaviadis et al., 1992).
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Fig. 2: The virino model. The infectious agent is a TSE-specific nucleic acid packaged in PrPSc. Upon
uptake the nucleic acid is replicated by the host machinery, associates with endogenous PrPC-molecules
and converts these to PrPSc. (from (Weissmann, 2004)).
These studies conclude that the fraction containing the majority of PrPSc is much less
infectious than the fraction containing little PrPSc and the nucleic acids, suggesting that
infectivity is not contained in the protein but in the nucleic acids (Manuelidis et al.,
1995). Consequently this group identified the nucleic acids specific for CJD
(Manuelidis and Fritch, 1996) and propose that the infectious agent belongs to the class
of retroviruses (Dron and Manuelidis, 1996). These results are further corroborated by
more recent studies reporting that the rate of conversion of prions is higher in the
presence of DNA (Cordeiro et al., 2001) or RNA (Deleault et al., 2003). Additionally, it
is postulated that PrPC might have a 3D-structure favourable for binding nucleic acids
(Radulescu and Korth, 1996), and it has been recently shown that PrPC interacts with
viral RNAs and has chaperoning properties, similar to the nucleocapsid proteins NCP7
of HIV-1 (Gabus et al., 2001a; Gabus et al., 2001b; Moscardini et al., 2002). It was also
demonstrated that co-expressed PrPC and HIV-1 interfere with each other: the amount of
expressed cellular PrPC negatively influences the amount of produced HIV-1, while the
production of HIV-1 leads surprisingly to production of PrPres by an unknown
mechanism (Leblanc et al., 2004). The latest results from the same group show that
retroviral infection strongly enhanced the release of scrapie infectivity into the
supernatant of cultured cells, once more emphasizing the link between viruses and
prions (Leblanc et al., 2006).
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III.2: TSE in animals
The TSEs are diseases characterized by their specific lesions in the central nervous
system (CNS). By nature, both human and animal forms are transmissible, shown in
experimental conditions with rodents and primates. In spite of these data, this group of
diseases is not regarded to be contagious.
III.2.1: Clinical signs of TSEs
The clinical presentations of these diseases is characterised by a very long
asymptomatic incubation period preceding the onset of first symptoms a rapid
progression of the disease, leading to neurodegeneration and inevitable death of the
organism. The neurodegeneration is associated with very specific clinical symptoms,
typical for each type of TSE and include perturbations of the locomotor -- and sensory
system, rapid progressive dementia with clinical visual or cerbellar signs and akinetic
mutism (i.e. passivity and inability to speak). Behavioural changes in humans manifest
early in the disease and may vary but commonly include personality changes, such as
psychiatric problems like depression, lack of coordination, in some cases also unsteady
gait (ataxia). Patients can also produce uncontrolled jerking movements termed
myoclonus and suffer from insomnia, confusion or memory problems (Collinge, 2001).
III.2.2: The histopathology of TSEs
Autopsy of afflicted animals shows non-inflamed degenerative lesions of the CNS,
particularly affecting the cerebellum. Typical for these lesions are vacuoles, conferring
a spongiform appearance, with a loss of neurons and astrogliosis as an invariable feature
(see Figure 3).
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Fig. 3: Characteristic neuropathologies of TSEs. Analysis of grey matter from brain sections of a CJD-
victim shows spongiform vacuoles (left, staining with hematoxylin), activation and proliferation of
astrocytes (center, IHC with antibody anti-GFAP) and PrPSc-deposits (left, IHC with antibody anti-PrP)
(adapted from (Glatzel and Aguzzi, 2001).
Due to the absence of the immune response, the histological exams do not reveal
infiltration of lymphocytes and macrophages. With biochemical techniques it is possible
to reveal the presence of PrPSc (see later). To date diagnostic methods are restricted to
the clinical phase and post-mortem diagnostics, but preclinical assessment from blood
samples has been recently reported, giving rise to the possibility of early diagnosis of
TSE-diseases (Castilla et al., 2005b).
III.2.3: The main forms of TSEs
In the following paragraph an outline of the different TSEs will be given, focusing on
the different forms manifesting in various animal hosts, as well as on the different forms
found in humans.
III.2.3.1: Scrapie in sheep and goat
III.2.3.1.1: Description
Scrapie in sheep and goats was the first TSE-disease to be described (1732 in England,
1759 in Germany) and was shown to be experimentally transmissible as early as the
1930’s by Cuillé and Chelle. The aetiology of scrapie was debated since the beginning
of the 19th century but remains unanswered. Some authors suggested spontaneous
appearance and concomitant transmissibility, while other supposed it to be caused by
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ill-defined pathogens, such as amoeba by Girard in 1830. Due to extensive protective
measures preventing introduction of scrapie from imported sheep, Australia and New
Zealand are the sole sheep-raising countries considered to be free of scrapie
(MacDiarmid, 1996). The disease afflicts animals between two and five years of age
and the clinical phase lasts between two and six months (Kimberlin, 1981). The disease
has a major economic impact due to its high incidence in the main breeding regions
(e.g. the United Kingdom), but no transmission of scrapie to humans has ever been
observed (Jeffrey and Gonzalez, 2004). The natural scrapie disease initially manifests
itself with mildly impaired social behaviour such as unusual restlessness and
nervousness, often only recognized by experienced shepherds (Dickinson, 1976). Later
stages are manifesting with either intense pruritus coming from the animal’s try to
relieve an intense irritation, leading to loss of fur and skin. Despite ataxia, infected
sheep will walk long distances to indulge in attacks of scratching, coining in German
the name of the disease “traberkrankheit” (trotting disease) (Dickinson, 1976). In the
very late stages of scrapie, affected sheep waste away, walk only short distances and are
easily agitated by even the mildest stress. Animals have normal appetite, but loose the
ability to feed themselves. In goat an additional form manifesting a lethargic phenotype
has been reported and is transmissible to sheep (Brugere-Picoux and Chatelain, 1995).
The pathogenic agent in affected organisms is distributed in the CNS, the amygdala, the
spleen (Race et al., 1998) and the placenta (Onodera et al., 1993). The vertical
transmission is probably caused by the presence of scrapie in the placenta (Andreoletti
et al., 2000; Andreoletti et al., 2002; Tuo et al., 2002). Recently it was also shown that
the accumulation of PrPSc in neuro-muscular fasci, precedes the occurence of clinical
signs but that infectivity associated with the muscle tissue is minimal (Andreoletti et al.,
2004).
III.2.3.1.2: Susceptibility
The individual susceptibility of each sheep is defined by a genetic predisposition,
caused by the existence of different alleles coding for PrPC (Baylis and Goldmann,
2004). Polymorphisms at amino acid (aa) position 136 (A or V), 154 (R or H) and 171
(Q or R) of PrPC in the animal are directly responsible for its susceptibility. Animals
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homozygously expressing the VRQ-combination in the respective positions are,
independent of race or geographic position, much more likely to succumb to scrapie,
while animals expressing homozygously the ARR-combination and some other aa-
substitutions have never been found to be affected by scrapie (Goldmann et al., 1991;
Hunter et al., 1996; Hunter et al., 1997; Vaccari et al., 2007). Due to these results, the
European Union developed some years ago a programme with the intent to eliminate all
VRQ-haplotypes by completely exchanging the stocks with ARR-expressing animals.
The long-term success of this plan still needs to be proven, especially since it was
shown that the genetic resistance in the ARR-variant sheep could be overcome with
high doses of bovine-derived prions (Houston et al., 2003). Additionally, some cases of
atypical scrapie (in respect to deposition and glycotype of the scrapie forms detected in
brain material) were found in animals considered to be resistant (Benestad et al., 2003).
Thus, while genetic susceptibility is clear in the case of the VRQ-haplotype, more
research is required in order to determine the full spectrum of genetic susceptibility to
scrapie strains in these animals.
III.3: Bovine Spongiform Encephalopathy (BSE)
As previously mentioned, the first cases of BSE occured in the United Kingdom in
1986, peaking in 1992 when about 37000 cattle were tested positive for the disease
(Jeffrey and Gonzalez, 2004).
18
Fig. 4: Distribution of BSE in the world. (from(Belay et al., 2004))
In the time period between 1987 and 1999, approximately 200,000 cattle tested positive
for BSE in the UK and the bleak number of 200,000,000 BSE-positive cattle is
estimated to have entered the food chain with much less detected outside of the UK (see
also Fig. 5).
Fig. 5: Numbers of BSE-infected cattle reported in the UK and outside over the years. Shown in
blue are the numbers of cattle reported only in the UK, while the numbers of infected cattle from EU-
countries excluding the UK as well as Canada, Israel, Japan, Switzerland and USA are indicated in
orange (from (Aguzzi et al., 2007)).
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Animals show first symptoms at an average age between 3 and 6 years with a striking
resemblance to sheep with scrapie, while the clinical phase afterwards is much shorter
and lasts 1 to 6 months. They also present an altered behaviour (apprehension and
sometimes aggressiveness), ataxia (uncoordinated gait with occasional falling) and
abnormal responses to touch and sound (dysesthesia). Epidemiologic studies point to
forage mixed with carcass meal as the main culprit for the spread of the BSE-disease
(Wilesmith et al., 1992), however the real origins of the disease remain unknown but
are supposedly linked to scrapie in sheep (rev. (Balter, 2001)).
The ban of carcass meal-usage in forage, established in 1988 in the UK as a prompt
reaction to the outbreak, resulted in a marked decrease of BSE-cases starting from 1993.
In spite of these measures, several cases of BSE were reported in cattle born after the
ban, suggesting horizontal transmission of infection by other foodstuffs or vertical
infection from the infected mothers. Placental transfer has been shown to be inefficient
but possible (10% of calves born from infected mothers are infected) (Wilesmith and
Ryan, 1997) and to be dependent on the phase of progression of the disease in the
mother (Donnelly et al., 1997), while other reports suggest that bovine placenta is not
infectious (rev. in (Wrathall, 1997)). However, prions seem to be concentrated merely
in the distal ileum and the CNS of infected animals (Aguzzi and Polymenidou, 2004). In
light of recent results other ways of transfer of infection could be envisioned: urinary
excretion due to nephritis of the kidneys (Seeger et al., 2005) and excretion by the
mammary glands in connection with mastitis (Ligios et al., 2005). Recently, it was also
reported that prions could persist and remain infectious in soil and aqueous soil extracts
for at least 29 months (Seidel et al., 2007), rendering the possibility of infection of new-
borns by excreta quite plausible. Susceptibility differences due to genetic factors as
shown in sheep, have not been discovered yet. Very recently a group succeeded in
producing cattle lacking the prion protein (Richt et al., 2007), which appeared to be
physiologically normal. Brain tissue homogenates from these cattle, tested for prion
propagation by protein misfolding cyclic amplification (PMCA) were resistant,
suggesting that these cattle could be used for making BSE-resistant herds.
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III.4: Chronic Wasting Disease (CWD)
CWD is found only in the US and Canada and affects only cervids (i.e. deer, elk and
moose) (Baeten et al., 2007; Miller and Williams, 2004). This disease appeared initially
in the 1960s in Colorado, but was recognized to belong to the family of TSEs only in
1978. As shown in Figure 6, the cases have a strong geographic focus in the Rocky
Mountains of Colorado. CWD is notorious for its rapid spread within herds in North
America.
Fig. 6: Distribution and spread in time of CWD in the US. (from (Belay et al., 2004))
The majority of cases develop at 3-4 years of age, and animals succumb to the disease
very quickly over the course of 2 weeks to 8 months. The routes of transmission of
CWD remain unknown. Experiments with humanized mice (i.e. expressing human
PrPC) indicate a species barrier for CWD in humans suggesting that a species barrier for
infection of humans with CWD exist (Belay et al., 2004; Kong et al., 2005). Recently
caribou were also shown to host the prion protein gene (Happ et al., 2007). Additionally
bank voles (Clethrionomys glareolus), a wild rodent species, were found to have a high
susceptibility to prion infections so that they are currently under investigation as a new
experimental system (Cartoni et al., 2005; Nonno et al., 2006; Zanusso et al., 2007).
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III.5: Other animal transmissible encephalopathies
Animal prion diseases in addition to those mentioned above have also been reported.
Transmissible mink encephalopathy (TME) was the first TSE to be identified in non-
domestic animals. Captive mink (Mustela vison) develop TME very rarely and it is
believed to be associated to exposure of BSE-contaminated feed (rev. in (Williams and
Miller, 2003)). Other very rare TSE-diseases include the feline spongiform
encephalopathy of zoological and domestic cats (FSE), TSE in bovids and TSE in non-
human primates. All these subforms appear to be linked to the BSE epidemic (rev. in
(Sigurdson and Miller, 2003)).
III.6: Human encephalopathies
The human forms of prion related disease have different aetiologies (Table 1). These
include sporadic, genetic and acquired subtypes. The sporadic forms were the first to be
described in the 1920’s by Creutzfeldt and Jakobs and are the most frequent forms.
Genetic prion diseases include Creutzfeldt-Jacobs-Disease (CJD), Gerstmann-
Sträussler-Scheinker syndrome (GSS) and Fatal Familial Insomnia (FFI). Finally,
human TSEs can be acquired by ingestion of contaminated foodstuffs or by iatrogenic
infection during surgical procedures (rev. in (Collinge, 2001)).
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Type Cause
Aquired forms
Kuru
iatrogenic CJD
new variant CJD
ritual cannibalism
Use of prion-contaminated surgical instruments and prion
contaminated transplants (e.g. dura mater, cadaveric growth
hormones, etc.)
probable infection with BSE
Sporadic forms
sporadic CJD
Sporadic Fatal Familial
Insomnia
Spontaneous conversion of PrPC into PrPSc or somatic mutation
Familial forms
CJD
Gerstmann-Sträussler-Scheinker
syndrome (GSS)
Fatal Familial Insomnia (FFI)
Germinal mutation of the prnp-gene
Germinal mutation of the prnp-gene
Mutation D178N of the prnp-gene in association with M129
polymorphism
Table 1: Human forms of TSEs.
III.6.1: The sporadic forms
Sporadic CJD represents about 80-85% of all CJD cases. The incidence rate is between
1-1,67/million people per year and is homogenously distributed over the world without
any sexual preference and without any apparent link with scrapie or BSE (Johnson and
Gibbs, 1998; Ladogana et al., 2005; Linsell et al., 2004). The aetiology is not believed
to be infectious, since surgeons, pathologists, abattoir workers, butchers and cooks are
not overrepresented among CJD-patients (Harries-Jones et al., 1988). Furthermore,
long-term exposure to afflicted individuals does not seem to increase the risk of
infection, with only one conjugal case documented (Brown et al., 1998). Lifelong
vegetarians have also been reported to develop sporadic CJD (Matthews and Will,
1981), suggesting that development of disease is not linked to exogenous infection by
contaminated foodstuffs. The average onset of disease is at 60 years with occasional
cases occurring in individuals less than 40 years of age or older than 80 years (Brown et
al., 1994). The median time to death in sporadic cases is only 4-5 months (Johnson and
Gibbs, 1998). The pathology is limited to the brain and spinal cord. Neuronal loss
occurs with vacuolisation in cell bodies and dendrites giving the cerbral cortex a
spongiform phenotype with absence of amyloid plaques (Fig. 7).
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Fig. 7: Histopathology of sporadic CJD in a post-mortem brain biopsy. Note the spongiform
vacuolisation of the tissue. Staining with cresyl violet, 300x (from(Johnson, 2005)).
III.6.2: Familial or hereditary prion diseases
Heritable disease represents about 15% of all cases of human TSEs. All hereditary
forms are linked to mutations in the prnp-gene situated on chromosome 20 in humans.
More than 50 mutations have been identified to date and all are inherited in an
autosomal-dominant fashion (Fig. 8).
Fig. 8: Overview of most frequent genetic mutations and of polymorphic sites in the human prnp-
gene (from (Prusiner, 1998)).
The most prominent marker of susceptibility to CJD is a polymorphism at codon 129 of
the prnp-gene, which contains either methionine or valine. It was reported that more
than 80% of patients with sporadic CJD are homozygous for methionine at this site in
comparison to only 49% of healthy controls, suggesting an inheritable genetic
predisposition for sporadic CJD (Palmer et al., 1991). This polymorphism is also
predictive of the subtype of disease, developed by carriers of the mutation D178N
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(exchange of aspartic acid to asparagine at aa-position 178): Individuals homozygous
for valine at position 129 develop fCJD, while individuals homozygous for methionine
at this region develop FFI (Goldfarb et al., 1992; Monari et al., 1994). The reason for
this genetic link is still unclear, but it is widely believed that the silent polymorphism at
position 129 influences the tertiary structure of the pathologic isoform of PrP. Four of
the point mutations found in familial CJD (fCJD), affecting the codon positions: 102,
178, 200 and 210 and insertions of 5-6 octapeptide repeats, account for 95% of all
familial cases (Capellari et al., 2005). Onset of disease is usually between 50-65 years
of age, while the clinical phase lasts from 1 to 13 months. The most common fCJD
mutation occurs at position 200 (Hsiao et al., 1991), followed by lower occurrences at
numerous others at positions: 105, 148, 160, 178, 180, 183, 187, 188, 198, 198, 203,
210, 212, 208, 210, 211, 212, 217, 232, 238 (compare with Fig. 8). In terms of onset
and progress of disease, forms of familial CJD (fCJD) generally develop earlier and
have a longer clinical course than sporadic CJD. Nevertheless this does not apply
generally, since the most common fCJD-mutation at codon position 200 for instance,
resembles more the pathology of sporadic CJD (Mastrianni et al., 2001).
Quite a few of these mutations give a phenotype distinguishable from fCJD, which
resulted in the arborisation of the inheritable TSEs into different subtypes with distinct
names.
Gerstmann-Sträussler-Scheinker syndrome (GSS) affects 1 person/10 million per year.
The most common mutation occurs at position 102 (Hsiao et al., 1989), while others
have been found at codon position 105, 117, 145 and 217 (Fig. 8). GSS is characterised
by onset of disease between 20 and 40 years of age and symptoms include progressive
cerebellar ataxia, spastic paraparesis with the course of disease being very long (5-11
years). Plaque depositions with microglial cells present therein were also described, but
the pattern of depositions varies between families (Liberski and Budka, 2004).
The third subtype, belonging to the inheritable TSEs, is Fatal Familial Insomnia (FFI),
which was described for the first time in 1986 (Lugaresi et al., 1986). Doubtless, FFI
has the strangest phenotype of inheritable TSEs, since one of its hallmarks is
progressive insomnia, accompanied by autonomic dysfunction and dementia.
Neuropathology shows loss of neurons and mild astrocytosis in the thalamus and the
brainstem accompanied by very little vacuolisation (Montagna et al., 2003). Generally
this form of disease is linked to a mutation at position 178 of the prnp-gene (see Fig. 8)
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and depends upon the homozygous expression of methionine at position 129 (Gambetti
et al., 1993; Goldfarb et al., 1992).
Usually, post-mortem specimens of hereditary TSE-patients contain PrPSc-molecules. In
order to study the characteristics of PrPSc derived from hereditary TSEs, scientists had
to transfer these point mutations into animals and cell-systems. Hsiao and colleagues
were one of the first to establish the production of transmissible pathologic prions in a
murine system. When mice expressed the amino-acid exchange P101L (proline to
leucine at aa position 101), they developed a spontaneous neurological disease,
reminiscent of the analogous P102L-mutation found in human GSS. Therefore, by
genetic engineering, the neurodegenerative process found in humans could be
transferred to mice and showed that the aa-exchange suffices to destabilize PrPC-
molecules and/or render it susceptible to pathological conversion into PrPSc (Hsiao et
al., 1990). One of the forerunner laboratories for studies of point mutations from
inheritable TSE-diseases was the Harris group who used Chinese Hamster Ovary cells
(CHO) for their experiments. They found that cells produce PrPSc-like molecules, when
they host aa-mutations analogous to human hereditary TSEs (Daude et al., 1997;
Lehmann and Harris, 1995; Lehmann and Harris, 1996a; Lehmann and Harris, 1996b).
Numerous mutations found in human hereditary diseases have been studied also in in
vitro-systems, including those at position 105, 117, 145, 180, 200, 232 as well as
various insertions, allowing for the characterization of disease-associated alleles but
have also sometimes yielded ambiguous results ((Campana et al., 2006; Daude et al.,
1997; Lehmann and Harris, 1995; Lehmann and Harris, 1996a; Lehmann and Harris,
1996b) see also Manuscript 1 and references therein).
III.6.3: Acquired human TSEs
The group of acquired prion diseases contains at least three subgroups with the common
denominator that affected people acquire the disease exogenously regardless of PrP
haplotype without hosting any genetic mutation in the prnp-gene.
The oldest of these diseases documented is kuru, a disease found in a tribe from New
Guinea, called the Fore people. Kuru was described in 1957 and is caused by ritual
cannibalism (Gajdusek and Zigas, 1957). The typical clinical progression for kuru is
progressive cerebellar ataxia, evolving in few months with a very broad incubation
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period of 4 to 40 years. Vertical or lateral spread of kuru could not be demonstrated:
women with the disease, which delivered and suckled their babies, did not transmit the
disease to their offspring. The suppression of cannibalism reduced the numbers of
diseased people to a minimum (D'Aignaux et al., 2002).
The second group of acquired TSEs consists of the transmission of hereditary CJD to
healthy subjects by medical interventions and are pooled by the name of “iatrogenic
CJDs”. The accidental transmission occurred by different medical interventions: tissues
deriving from undiagnosed CJD-patients such as corneal transplants (Gandhi et al.,
1981), dural grafts (Preusser et al., 2006), blood transfusion (Aguzzi and Glatzel, 2006)
or cadaver-derived growth hormones (Billette de Villemeur et al., 1994) were
transplanted or transfused to non-CJD patients, who subsequently developed CJD.
Additionally, contaminated neurosurgical instruments such as metal electrodes and steel
wires (Fichet et al., 2004; Flechsig et al., 2001), previously used on CJD-patients and
not properly sterilized thereafter, were also suspected for accidental infection of non-
CJD patients. The incubation time can be up to 15 years, while the average time
between onset and death is 15 months.
The last and possibly most interesting group of this disease belonging to the acquired
forms is the variant CJD (vCJD). Described for the first time in 1996 in the UK (Will et
al., 1996), the country with the highest incidence, this form counts up to now about 150
reported cases. Afflicted individuals have no mutation in the prnp-gene differently from
the inheritable forms but host a haplotype resulting in genetic predisposition (see later).
The vCJD-form is quite well to discern from sporadic CJD (Fig. 9).
Fig. 9: Comparison of characteristics of variant and sporadic CJD. (from (Johnson, 2005)
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Patients are young at the onset of disease (average onset is at 29 years), have a
significant longer disease course, present florid plaque deposits in the brain and are
homozygous for methionine at position 129 in the prnp-gene. Of public concern and
scientific interest is the last characteristic, since this suggests a genetic susceptibility for
succumbing to vCJD.
Because prions from patients with vCJD and prions from BSE-cattle gave in
experimentally infected mice similar pathological and biochemical characteristics (e.g.
incubation period and localization in brain), researchers concluded that the most likely
cause for vCJD in humans was the consumption of BSE-contaminated beef (Bruce et
al., 1997; Hill et al., 1997). It is estimated that 750000 BSE-positive cattle were
consumed in the years between 1986-1996. Despite this alarmingly high number,
mathematical models estimate that the peak of human casualties might have passed
already (Valleron et al., 2001). However due to the large number of variables in these
models, these estimations are likely inaccurate and should be considered with caution.
Fortunately, some of the bleakest predictions basing on the genetic predisposition
(Ghani et al., 2000), which prognosed about 136000 human casualties in the UK by
1999, turned out to be wrong (Alperovitch and Will, 2002). Other more conservative
models, predicting a number of exceeding not more than 100 casualties seem to be more
accurate (d'Aignaux et al., 2001; Ghani et al., 2003; Valleron et al., 2001). Nevertheless
cases of positive biopsies from hospitalized non-CJD patients (e.g. from tonsils) suggest
a higher number of subclinical infections that may or may not develop into an epidemic
of clinical disease in the future (Hilton et al., 2004).
III.6.4: Susceptibility to vCJD
The genetic susceptibility to vCJD is based on the polymorphism at position 129 of the
prnp-gene. Studies in Caucasians showed that, 50% of people are heterozygous
(Met/Val), 40% are homozygous (Met/Met) and only 10% are homozygous Val/Val at
this position (Owen et al., 1990). Interestingly the ratios of this polymorphism are quite
different when healthy populations are compared to those with disease (Table 2 and
(Palmer et al., 1991).
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healthy CJD vCJD
Met/Val 50% 10% 0
Met/Met 40% 79% 100%
Val/Val 10% 11% 0
Table 2: Polymorphisms of codon 129 and its effect on CJD/vCJD occurrence. (adapted from (Hill et
al., 2003))
Table 2 illustrates that Met/Met homozygosity at position 129 of the prnp-gene results
in a high genetic predisposition for vCJD and an increased predisposition for other
CJD-subtypes with all vCJD cases to date being Met/Met homozygotes at codon 129
(Collinge et al., 1996). Similar results were found in mice expressing the human PrP-
protein containing the Met/Met polymorphism, which were the only ones to develop the
disease when intracerebrally infected with vCJD (Asante et al., 2002). Altogether, these
data suggest that the Met/Met homozygosity at codon 129 favours the development of
vCJD and CJD while heterozygosity and Val/Val homozygosity determines resistance
against infection by unknown mechanisms.
III.6.5: Physiopathology
One of the hallmarks of the TSEs is the complete absence of toxic effects, e.g. lesions
or vacuolization in the periphery of the organism (i.e. aside of the brain). Brain
histopathology studies reveal spongiosis, astrocytosis, microgliosis, gliosis and most
importantly neuronal loss (see Figure 3). Depending on the disease neuronal loss is
linked to amyloid plaque deposits in different regions of the brain (Fig. 10).
Additionally, during peripheral invasion of the organism, TSEs do not produce fever or
a humoral immune response (Kubler et al., 2003).
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Fig. 10: Scheme of a human brain depicting the regions affected by different TSE-diseases. Kuru
and GSS affect brainstem, CJD the cerebral cortex, FFI the thalamus and BSE the medulla oblongata
(from S.Prusiner’s Nobel prize lecture, 1997 available online at http://nobelprize.org/ nobel_prizes/
medicine/laureates/1997/press-1.gif).
III.7: The cellular PrP (PrPC)
III.7.1: The prnp-gene
In 1985 researchers were surprised to discover that the gene for the believed toxic agent
of TSEs was encoded in the host genome, of both healthy and diseased people
(Chesebro et al., 1985; Oesch et al., 1985). Since the primary structure encoded by the
genes from healthy and diseased animals did not differ, it was suggested that the
different properties of PrPC and PrPSc derived from post-translational events (Basler et
al., 1986). This was substantiated when scrapie-associated fibrils (SAF) were isolated
and demonstrated to have the sequence of endogenous PrP (Hope and Chong, 1994).
The sequencing of the PrP-gene of numerous mammalian species (including Homo
sapiens) revealed an 80% sequence-homology between species as well as high
structural homologies, suggesting a strong genetic conservation in evolution (Oesch et
al., 1991).
Depending on the species, the gene contains 2 to 3 exons, of which only one is utilized
in protein expression (Puckett et al., 1991). Interestingly, the first or the first two small
exons are transcribed but not translated. Very little is known about the regulatory
elements controlling the expression of the prnp-gene, only that expression is controlled
by ubiquitous transcription factors (Baybutt and Manson, 1997; Puckett et al., 1991).
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III.7.2: Expression of PrPC
III.7.2.1: The site of expression
The expression of the prnp-gene is particularly high in neurons (Brown et al., 1990;
Cagampang et al., 1999), the choroid plexus (Brown et al., 1990) and in glial cells
(Moser et al., 1995). Studies in hamsters showed its expression in the central nervous
system (CNS) is prominent in neocortical neurons, the olfactory bulb, thalamus and
hippocampus (Brown et al., 1990) but is also found in the peripheral nervous system,
(e.g. dorsal root ganglia, sympathetic ganglia and nerves and afferent nerves in the skin)
(Bendheim et al., 1992; Ford et al., 2002). While its expression in synaptic axon
endings has been shown by light- and electron microscopy, none was found in the
neuronal perikaryon (Sales et al., 1998). Certain dopaminergic neurons were also shown
to not express PrPC (Ford et al., 2002), while all studies found that glial cells have a
high expression level of PrPC. Outside the CNS, haematopoietic cells (except for
eosinophils) were found positive for PrPC-expression (Barclay et al., 2002). Similarly
the lymphoreticulum was also shown to be positive for PrP-expression (Lotscher et al.,
2003) with particularly high amounts on the surface of lymphocytes and of follicular
dendritic cells in lymph nodes, in the spleen and in Peyer’s Patches (Cashman et al.,
1990; Ford et al., 2002). Additionally murine PrPC is expressed in the lamina propria of
the aerodigestive tract, in the intestinal enterocytes (Morel et al., 2004), in the gut
associated lymphatic system (GALT) and mucosa associated lymphatic system
(MALT), the intestinal nervous system and its associated Schwann cells (Follet et al.,
2002; Ford et al., 2002).
By more sensitive techniques such as Northern - and Western Blot, expression of PrPC
in different organs was shown to occur in the heart, lungs, pancreas, testis and kidneys
of rodents (Moudjou et al., 2001; Oesch et al., 1985; Robakis et al., 1986). Expression
of PrPC in the muscle and uterus and to a lesser extent in the liver (Horiuchi et al., 1995)
was shown for ovines.
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III.7.2.2: The regulation of PrPC expression
In the course of murine embryonal development, PrPC-expression starts in the vitelline
membrane (i.e. extra-embryonic) at day 6,5 and starting from day 13,5 in neuronal and
non-neuronal cells of the embryo (Manson et al., 1992). Particularly high expression
was reported during neuritogenesis in the synaptic region (Sales et al., 2002; Sales et al.,
1998). Although some studies in human neuroblastomas had shown that the expression
of PrPC is inducible by !-IL1, "-TNF and #-INF, the majority of cell models suggest a
constitutive expression (Satoh et al., 1998). However, its expression has also been
linked to the activation state of lymphocytes, because PrP-presence on the cell surface is
increased in activated lymphocytes (Cashman et al., 1990). Changes in expression-
levels of the protein were not found during the development of prion pathology neither
in ex vivo-experiments nor in animal systems (Chesebro et al., 1985; Oesch et al.,
1985).
III.7.3: The structure of the PrPC-protein
PrPC contains 253 aminoacids (aa) in humans, 254 aa in mice and hamsters, 256 aa in
sheep and 264 aa in bovines and migrates as a band at approximately 35 kDa in SDS-
PAGE (Prusiner, 1991). Its N-terminus contains a 22 aa-long signal peptide, accounting
for its translocation into the rough endoplasmatic reticulum (ER). Aminoacids 23-120
comprise a flexible, non-structured region (Donne et al., 1997; Lopez Garcia et al.,
2000), followed by 4-8 repetitive octapeptides with the consensus sequence
PHGGGWGQ, which are implicated in its interaction with divalent cations. The central
region contains a conserved hydrophobic domain (TM1), which in some cases can span
the membrane serving as a trans-membrane anchorage, leading to different PrPC
topologies (see paragraph III.13.2.2). Usually the membrane anchor is a
glycosylphosphatidylinositol (GPI)-anchor, a post-translational modification, attached
after the removal of the C-terminal part of the protein (Fig. 11).
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Fig. 11: Primary structure of PrPC. Schematic diagram of human PrPC, showing the signal peptide
(black, left), the hydrophobic region (grey), the "-helical regions (H1-3) and the !-sheets (B1-2). Also
indicated are the N-glycosylation sites (Asn181, Asn 197), a hydroxylation site (Pro44) and the
proteolytic cleavage site (Lys112/His113). The cysteines at positions 179 and 214 produce a disulfide
bond (adapted from (van Rheede et al., 2003)).
The combined use of the trans-membrane anchorage and the GPI-anchor can result in a
form attached to the lumenal side of membranes by its GPI-anchor and with the N-
terminal part in the cytoplasm and was linked to pathology (Hegde et al., 1998) (see
also paragraph III.13.2.2).
The production of recombinant PrPC gave to the researchers the opportunity to study the
structure of the protein by infrared spectroscopy and circular dichroism (Hornemann et
al., 2004). These studies indicated that PrPC contains a globular structure (core) (see
Figs. 11 and 12), characterized by a low content (3%) of !-sheets (two antiparallel !-
sheets called B1 and B2 at residues 128-131 and 161-164) (Zahn et al., 2000) and a high
content (approximately 40%) of "-helical regions (H1, H2 and H3) situated at positions
144-154, 173-194 and 200-228 (Fig. 12).
Fig. 12: A. Scheme of the secondary structure of PrPC. B. Structure of PrPC in solution obtained by the
Wüthrich-laboratory at the Swiss Federal Institute of Technology (Riek et al., 1996). Shown are three "-
helices, a !-sheet towards the C-terminal part and the flexible, unstructured segment at the N-terminal
part of the protein.
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PrPC contains two complex sialylated oligosaccharides attached to two asparagines
(positions 180, 196) in humans. The first site of N-glycosylation is in the second "-helix
(H2 in Fig. 11), while the second is in the connector-region between helix 2 and 3. The
disulfide bond between "-helices 2 and 3 is indispensable for the stabilization of the
tertiary structure (Miura et al., 1996).
Fig. 13: Schema of the structural domains of PrPC inserted in the plasma membrane. NMR-studies
on recombinant PrP showed that the C-terminal region (aa124-230) is structured, while the N-terminal
part is not. The N-glycans can occupy an area bigger than the protein itself, while the GPI-anchor keeps
the PrP-protein at a distance of 9-13 Å from the cell membrane.
III.7.4: Possible function(s) of PrPC
In spite of the numerous studies on molecules interacting with PrPC (discussed below),
its function still remains enigmatic and is subject of ongoing debate. The protein has
been proposed to be involved in the metabolism or uptake of copper- or zinc-ions
(Brown, 2003; Cui et al., 2003; Pauly and Harris, 1998; Watt and Hooper, 2003),
protection against oxidative stress (Brown, 2003; Cui et al., 2003), cell-signalling
transduction (Chiarini et al., 2002; Mouillet-Richard et al., 2000), synaptic transmission
and excitability of membranes (Collinge et al., 1994; Mallucci et al., 2002),
neuritogenesis (Graner et al., 2000a), apoptosis (Solforosi et al., 2004), transendothelial
migration (Viegas et al., 2006) and very recently in the regulation of !-site APP
cleaving enzyme (BACE1) (Parkin et al., 2007) and in the signal-transduction of
nociceptive stimuli (Meotti et al., 2007).
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III.7.4.1: PrP-/- knock-out mice and the possible role of PrPC in synaptic signalling
Mice with no expression of the prnp-gene, (i.e. knock-outs at the germinal level (Bueler
et al., 1992; Manson et al., 1994) or conditional knock-outs with an induced prnp-
inactivation after birth (Mallucci et al., 2002)) are perfectly healthy animals and do not
present obvious phenotypes, aside from being resistant to infection with prions
(Prusiner, 1998). This suggests that the function of PrPC is dispensable for normal
function, which seems contradictory to its high genetic conservation over several phylii
as well as the high degree of conservation of its tertiary structure (Premzl et al., 2004).
Therefore, it is believed that the function of PrPC is redundant and might be
compensated by other proteins. Nevertheless some subtle differences in the phenotype
of conditional knock-out mice have been described: these include alterations in the
circadian rhythm and sleep regulation (Tobler et al., 1996), electrophysiological
changes in the pyramidal cells of the hippocampus (Colling et al., 1997; Mallucci and
Collinge, 2004) weakened GABA (gamma-aminobutyric acid type A) receptor-
mediated fast inhibition as well as aberrant long-term potentiation of neuronal synapses
(Collinge et al., 1994). These findings lead to the hypothesis that PrPC might be
involved in synaptic function such as signalling/activity of neurons. Whether this is
really due to the presence of PrPC in neurons is debated since there are reports of normal
functionality of the hippocampus even in mice deficient for the prion protein (Lledo et
al., 1996).
III.7.4.2: The possible involvement in the metabolism of copper and oxidative
stress
In its flexible N-terminal part, PrPC-protein contains a repetition of octapeptides rich in
histidines, shown to bind divalent cations, e.g. Zn2+, Co2+, Mn2+ and especially Cu2+
(Kramer et al., 2001; Miura et al., 1999; Viles et al., 1999; Whittal et al., 2000) (see also
Figs. 12 and 14). Another site, binding Cu2+ with high affinity, was found in the human
PrPC-form within aa’s 96-111. These binding sites were proposed to be involved in the
stabilization of the protein when performing diverse functions (Miura et al., 1996;
Wong et al., 2000) or as an ionic receptor responsible for the uptake of divalent ions,
especially copper (Prado et al., 2004) (Fig. 14). The implication in the uptake of copper,
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was deduced from the finding that binding of Cu2+ stimulates the endocytosis of the
PrPC-protein and thereby also the endocytosis of the extracellular ions (Lee et al., 2001;
Pauly and Harris, 1998; Perera and Hooper, 2001). Consequently it was shown that
knock-out mice had two times less copper than control mice in presynaptic vesicles,
suggesting that the protein could be involved in the regulation of copper-uptake in
neuronal synapses (Kretzschmar et al., 2000). Recently, it was also shown that the
presence of extracellular copper leads to the dynamic down regulation of PrPC,
emphasizing its possible role in copper-homeostasis (Nishimura et al., 2004; Toni et al.,
2005). Because copper and zinc regulate the activity of the superoxide dismutase
(SOD), an enzyme involved in protection from oxidative stress (Milhavet and Lehmann,
2002) the interaction of PrPC with copper also hints at another function in reactive
oxygen species (ROS) metabolism. Mice lacking expression of PrPC, were shown to
have a reduced SOD activity in cerebral tissues (Brown and Besinger, 1998) and were
more susceptible to oxidative stress (Wong et al., 2000), suggesting that PrPC could play
a role in the regulation of SOD-activity or even have SOD-activity itself (Brown et al.,
1999). Evidence suggests that the N-terminal part of PrPC is responsible for the
regulation of SOD-activity (Sakudo et al., 2005; Sakudo et al., 2003).
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Fig. 14: Models of how PrPC could interact with divalent ions.
A. PrPC acts as a receptor for divalent ions. Situated on the cell surface, PrPC binds divalent ions from the
extracellular space and assists in their intracellular sequestration by transferring these to specialized
membrane transporters. B. PrPC is directly involved in intracellular uptake of Cu2+. After binding divalent
ions, PrPC is endocytosed and upon acidification in the endosomal pathway releases the divalent ions
intracellularly. Next, specific transporters transfer the ions from the endosomal compartment, while PrPC
returns to the cell surface for a new cycle. C. PrPC acts as a sensor for divalent ions. Too high
concentrations of extracellular ions leads to a transduction signal which allows the cell to respond to the
toxic levels of these ions. (adapted from (Watt and Hooper, 2003))
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III.7.4.3: Implication of PrPC in signal transduction, cell adhesion and neuronal
survival
Numerous GPI-anchored proteins are situated in specific membrane subdomains called
lipid rafts (see paragraph III.14.1.3) in which they participate in various signal
transduction cascades (Simons and Toomre, 2000). The facts that PrPC is inserted into
the plasma membrane, its presence in rafts and the accessibility of its N-terminus to
ligands in the extracellular space could give this protein a role in cell-signalling
cascades. A study on 1C11 cells (neuronal precursors, differentiable into either
serotoninergic or noradrenergic neurons), showed that the activation of surface PrPC by
cross-linking with antibodies, induced the dephosphorylation (probably mediated by
caveolin 1) and hence activation of Fyn, a tyrosine-kinase from the Src-family
(Mouillet-Richard et al., 2000). The same group reported links between the activation of
PrPC and the PKA-enzyme, the PI-3-Kinases/Akt and the MAPK/ERK-kinases
(Schneider et al., 2003). Another group showed that PrPC interacts with Grb2 and
synapsin Ib (Spielhaupter and Schatzl, 2001), both of which are involved in signal
transduction in neurons. The finding that the expression of PrPC during development is
tightly controlled in terms of time and localization on growing axons suggests its
implication in the development of axons and synapses (Hajj et al., 2007; Sales et al.,
2002).
On the other hand, PrPC could be involved in intercellular communication (Chen et al.,
2003) and cell-adhesion (Mange et al., 2002). It was reported that PrPC could bind
extracellular proteins like laminin (Graner et al., 2000a; Graner et al., 2000b) and N-
CAM (Schmitt-Ulms et al., 2001), which play a role in the proliferation and
differentiation but also in neuronal death. Due to its interaction with N-CAM, PrPC can
promote the growth of neurites through a signal-transduction cascade involving the
molecule Fyn (Santuccione et al., 2005). Most recently binding of PrPC to E-, P- and L-
selectins, molecules important for migration and adhesion, was also shown (Li et al.,
2007a).
The PrPC molecule also binds to the 67 kDa laminin receptor (LRP) (Rieger et al., 1997)
and to its 37 kDa-precursor (Gauczynski et al., 2001) and it was also shown that PrPSc-
propagation in neuronal cells requires the presence of the 37 kDa/67 kDa laminin
receptor (Leucht et al., 2003).
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A number of groups have also reported a role of PrPC in neuronal survival.
Nevertheless, the role of PrPC in this process is hotly debated: some argue for a pro-
apoptotic role in neuronal models while others favour a protective role for PrPC.
Neuronal cell culture models showed that the presence of PrPC made neurons more
susceptible to staurosporine induced death involving caspase 3 activation and apoptosis
(Paitel et al., 2002; Paitel et al., 2004). More recent studies showed also that the cross-
linking of PrPC by antibodies produced a pro-apoptotic cascade in vivo (Solforosi et al.,
2004).
On the other hand evidence for a neuroprotective role of PrP is suggested by data
showing interaction of PrPC with Stress-inducible protein 1 (Zanata et al., 2002). The
neuroprotective role probably involves signalling by cyclic adenosine monophosphate
(cAMP)/ and protein kinase A (PKA) (Chiarini et al., 2002). Another putative interactor
was shown to be Bcl-2 (Kurschner and Morgan, 1995) an interaction which protected
hippocampal neurons from death by serum deprivation (Kuwahara et al., 1999) and
from apoptotic death mediated by Bax (Bounhar et al., 2006; Roucou et al., 2003).
In the light of these abovementioned numerous proposed roles for PrPC it is difficult to
discern a clear function, especially considering that knockout mice do only present
subtle behavioural changes. Further analysis of these mice and more detailed studies,
possibly using RNAi and high-throughput screening approaches, might be able to shed
some light on the enzymatic function of PrPC.
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III.8: The pathological prion protein: PrPSc
III.8.1: The structure of PrPSc
Studies utilizing circular dichroism and nuclear magnetic resonance (NMR) revealed
that PrPSc contains a significantly higher amount of !-sheet content than PrPC (42% in
PrPSc and 3% in PrPC) (see also Fig. 12). Recent studies propose a model in which PrPSc-
polymers produce a structure with !-sheets derived from three PrPSc-molecules on the
inside of aggregates and all "-helices oriented to the outside (Fig. 15 and reviewed in
(Riesner, 2003)).
Fig. 15: A. Scheme of PrPSc enriched in !-sheets depicted in green and red. B. Structure of PrPSc-
oligomers, received from the reconstruction of electron microscopic analysis of two-dimensional crystals
(from (Riesner, 2003))
III.8.2: The physico-chemical traits of PrPSc
The particular conformation of PrPSc confers characteristics very different to its
normally folded counterpart:
In contrast to PrPC, the solubility of PrPSc is diminished in non-ionic detergent (Caughey
and Raymond, 1991; Meyer et al., 1986), a trait, which renders its purification and
crystallographic study very difficult (Table 3).
A
B
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Protein PrPSc PrPC
Structure globular stretched
Resistance to proteases yes no
Production of fibrils yes no
Turnover of protein days hours
Table 3: Comparison of PrPSc and PrPC
The high content of !-sheets of PrPSc renders the protein more stable and resistent to
digestion by proteases, especially by proteinase K (PK). In contrast to PrPC, which is
completely digested by PK, only the N-terminal part of PrPSc (specifically the first 67
aa) are hydrolyzed. This hydrolysis leaves a large part of the protein undigested and
results in an electrophoretic product that migrates now at the characteristic height of 27-
30 kDa and is therefore called PrPres (res for resistant to digestion) or PrP 27-30. This
intrinsic resistance to digestion with PK is a hallmark of PrPSc that distinguishes it from
PrPC (Fig. 16).
Fig. 16: PrPSc is partly resistant to digestion with PK. Upon addition of PK (+PK) a N-terminal
truncated PrP-form remains undigested in the case of PrPSc, migrating on a polyacrylamide gel at a height
of 27-30 kDa. Please note that while PrPC is completely digested, PrPSc gives three bands, which remain
nearly undiminished in terms of intensity but shifted to a lower molecular weight. The three distinct
bands represent the three glycosylated forms of PrP (un-, mono and diglycosylated). (from (Riesner,
2003))
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III.9: The conformational change in vivo
Two models were proposed to explain how PrPSc is propagated by conversion of
endogenous PrPC (Fig. 17 and (Come et al., 1993; Harper and Lansbury, 1997; Prusiner,
1991; Prusiner, 1998)).
Fig. 17: Models for the conformational conversion of PrPC to PrPSc. A. Depicted in A is the
“template-directed refolding model” also termed “template assistance”, which hypothesizes an interaction
between the exogenously introduced PrPSc and the endogenously produced PrPC. This interaction induces
PrPC to adopt the malconformation of its interactor and turn itself into PrPSc. A high energetic barrier
prevents the spontaneous transconformation of PrPC to PrPSc. B. The “seeded nucleation” model also
termed “nucleation-polymerization model” proposes a reversible thermodynamic equilibrium between
PrPC and PrPSc in cells. Only when PrPSc monomers organize themselves into a so-called “seed” do PrPSc-
molecules reach an increased stability and become capable of recruiting new PrPSc monomers in order to
form an amyloidal structure. The fragmentation of aggregates of PrPSc increases the number of seed-
nuclei, which once again can recruit, and stabilize PrPSc-monomers and thereby achieve a replication of
the agent (from (Aguzzi and Polymenidou, 2004)).
The “refolding” or “template-directed” model (Fig. 17, A) proposes that PrPSc is a
template or matrix for the conversion of PrPC into new PrPSc monomers (Prusiner,
1991). On the other hand the “seeded nucleation model” (Fig. 17, B), posits that PrP can
spontaneously adopt different conformations (those of PrPC or PrPSc) that exist in
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equilibrium. Under physiological conditions the PrPC-conformation is highly favoured,
due to the high activation energy, which is necessary for the acquisition and
maintenance of the PrPSc-conformation (Come et al., 1993; Harper and Lansbury, 1997).
The presence of a PrPSc-aggregate shifts this equilibrium towards PrPSc by stabilizing
this conformational form and achieves a rapid accumulation of new monomers to the
aggregate (Jarrett and Lansbury, 1992).
This hypothesis fits well with the experimental finding that the conversional activity
and infectivity are specifically associated with the aggregates and not with the
monomers of PrPSc (Weissmann, 2004). Indeed, it was reported that disaggregation and
denaturation of PrPSc (but not the reversible loss of conformation) coincided with the
loss of conversional activity and infectivity (Morillas et al., 2001). As a consequence,
while the process of spontaneous misfolding of PrPC might be a slow event, the
pathological conversion with the help of a PrPSc-molecule would be a quick process,
suggesting that it is the aggregates, which induce the formation of prions. The
occasional fragmentation of aggregates could also explain the exponential growth of
PrPSc during infection (Orgel, 1996). In addition more recently it has been proposed that
oligomeric PrPSc might be just as infectious and toxic as bigger aggregates (Chiesa and
Harris, 2001; Novitskaya et al., 2006; Silveira et al., 2005; Simoneau et al., 2007).
It is possible that in the case of sporadic CJD and genetic TSEs, mutations in the gene
prnp generate a protein whose structure is more favourable to conversion, while in the
infectious form it is the contact with exogenous PrPSc, which leads to progressive
misfolding.
Elegant in vivo and in vitro studies have shown that sequence homology plays a very
relevant role for pathological conversion of PrPC to PrPSc. Mice co-expressing a murine
and a hamster prion-form, but infected with mouse-prions produced only PrPSc
containing mouse-prions, while infection of littermates with hamster-prions resulted in
the production of PrPSc containing only hamster-prions (Prusiner et al., 1990).
Furthermore, co-expression of a nonconvertible PrP-deletion mutant in scrapie-
producing MNB-cells lead to a reduction of the infectious protein in these cells
(Holscher et al., 1998) underlining that protein homology is required for the process of
conversion and infection.
Another variable influencing the conversion reaction is the speed of synthesis of PrPSc
from PrPC: continuous exposure of infected scN2a cells to phosphatidylinositol-specific
phospholipase C (PIPLC), an enzyme which cleaves all GPI-anchored proteins from the
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cell membrane (including PrPC but not PrPSc) resulted in depletion of membranous PrPC,
and leading to the cure of these cells (Enari et al., 2001). Charles Weissmann put these
findings into perspective in his model of “dynamic susceptibility”, in which he proposes
that the capacity of cells to sustain and propagate infection by prions depends on
equilibrium between synthesis and degradation of PrPSc (Weissmann, 2004).
According to this model, if the rate of synthesis of PrPSc is not at least equal to or twice
superior to its rate of degradation, prions will be eliminated from infected cells. Only
when the synthesis rate is two times higher than its degradation rate, can it overcome its
dilution by cell division and manage to accumulate in cells. Prions manage to propagate
only by keeping this delicate balance. This model explains why certain cell systems are
not susceptible to prion infections (Race et al., 1987; Rubenstein et al., 1984; Schatzl et
al., 1997; Vilette et al., 2001; Vorberg et al., 2004a; Vorberg et al., 2004b) however this
does not explain why some cell lines are immune to some prion strains but susceptible
to others (Bosque and Prusiner, 2000; Nishida et al., 2000; Race et al., 1987).
III.10: Prion strains and the species barrier phenomenon
By the 1920’s the existence of two different scrapie-forms in sheep was described: one
was called the “nervous” form while the other was termed the “pruritic” form. Even
though the existence of prion strains is now quite well established (Bruce, 1993), this
remains one of the most poorly understood phenomena of prion research and is
especially hard to reconcile with the protein-only hypothesis. Work with different prion
strains began in the early 1970’s (Dickinson et al., 1968), by infecting laboratory
animals with infectious material derived from wild animals. This technique quickly
established itself as the standard procedure for the study, propagation and ultimately
characterization of prion strains: Wild-type prion strain isolates are inoculated into
murine animal models and are successively passaged to genetically identical animals
utilizing the same amount of infectious agent, until the properties of the strain stabilizes
in this new host species.
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The criteria serving to define a new prion strain are:
i) The time of incubation of the strain once stabilized. This information is linked to the
nature of the strain, the genetic predisposition of the host mice and the amount of the
inoculum.
ii) The lesion profile caused by the infection in the brain of the host animal. This
corresponds to its spatial distribution (and deposition) in the brain, as well as to the
severity of the vacuolization. It is worthwhile to mention that the same isolate can lead
to the isolation of different strains. The most interesting example of this was found
when an isolate from a mink hosting transmissible mink encephalopathy (TME) was
inoculated into Syrian golden hamsters. Infection of littermate hamsters resulted in two
clearly distinguishable syndromes, termed hyper (HY) and drowsy (DY). These two
strains are distinguishable by several key features: incubation period (HY: 65 days; DY:
168), clinical signs (HY: hyperaesthesia; DY: lethargy), titres of infection (HY: 109,5
LD50/g of tissue; 107,4 LD50/g of tissue) and pathogenesis (only the DY strain retained
virulenece in mink) (Bessen and Marsh, 1992).
These types of studies also enabled researchers to find similarities between BSE and
new variant CJD (nvCJD), supporting the notion that these two strains are closely
related and giving the opportunity to distinguish them from sporadic CJD (Bruce et al.,
1997).
Nevertheless this approach also has some disadvantages. First, it is time consuming,
since some strains require passaging for a few years until properly stabilized. Secondly,
it is costly, since hundreds of mice have to be kept at a high security level and third it is
also complex, since the isolation of strains and analysis of their properties are
challenging tasks not necessarily giving consistent results.
Alternative methods, basing on a biochemical approach (see below), aim at a much
faster and easier characterization of the different prion species.
III.10.1: Molecular features of different prion strains
In the absence of nucleic acids coding for strain specifity, researchers hypothesized that
strain characteristics were encoded in the different conformational isoforms of PrPSc
(Weissmann, 2004). PrPSc can show characteristic biochemical variations depending on
the strain. Additionally, biochemical analysis of cellular extracts or of infected tissue
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digested with proteinase K reveals different biochemical profiles for PrPSc, depending
on the source of origin. These profiles enabled the classification of different prion
species. For instance, in the case of human TSEs, this analysis allowed researchers to
distinguish four groups (type I-IV) of human prions depending on their respective
electrophoresis profiles (Fig. 18) (Collinge et al., 1996). Type I gives a dominant
monoglycosylated band at approximately 30 kDa while type II reveals a non-
glycosylated band at 21 kDa and a monoglycosylated band slightly lower than the
corresponding band for type I. Type III, displays prominent mono- and unglycosylated
bands just as type II, however bands show differences in electrophoretic mobility.
Finally, type IV has a strong diglycosylated bands and only minor amounts of the other
two.
Fig. 18: Differentiation of PrPSc type I-IV in human TSEs. A Western blot is shown revealed with the
monoclonal antibody 3F4 and depicts type I-IV of PrPSc from human TSEs. Type I-III were isolated from
patients with classical CJDs, i.e. sporadic or iatrogenic. Type IV is unique to patients who succumbed to
the new variant CJD-form (nvCJD) (adapted from (Collinge et al., 1996)).
Interestingly, the type IV profile was also found in brains from cattle, macaques and
mice infected with the BSE-strain or with the nvCJD strain (Hill et al., 1997). The
resemblance of these two strains and their conservation when raised in different animals
lends strong support to the notion that nvCJD originates from the bovine agent BSE
(Bruce et al., 1997; Hill et al., 1997).
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The classification of human CJDs into four types is probably not exhaustive, since a
fifth and a sixth type of PrPSc have recently been described (Gambetti et al., 2003;
Zanusso et al., 2001). Furthermore biochemical characterization is still hotly debated
since some researchers believe that the differences partly derive from pH-differences
during tissue/sample preparations (Cali et al., 2006).
Different biochemical profiles that distinguish different prion strains can also be applied
to other species. For instance, even the two species HY and DY found in Syrian hamster
(described above) present different biochemical characteristics. After PK-digestion the
non-glycosylated band of PrPSc migrated at 21 kDa for HY and at 19 kDa for DY
(Bessen and Marsh, 1992). These prion strain-differences were recently also
demonstrated for BSE-derived prions, suggesting that various BSE-strains may coexist
in cattle (Beringue et al., 2006).
Another criterion used for distinguishing strains is the degree of resistance of PrPSc to
PK-digestion (Kuczius and Groschup, 1999). It is believed that the resistance to
digestion derives from differences in structure and folding of PrPSc, resulting in different
accessibility of proteolytic enzymes to prion aggregates.
A test allows for prion strain classification based on their conformational stability. This
approach, termed CDI (conformation-dependent immunoassay) was utilized on prions
derived from hamsters, allowed the classification of eight different strains in four
distinct subgroups. The CDI-test measures the binding of PrPSc-specific antibodies
recognizing different epitopes that are not accessible in the protein’s native
conformation. The exposure of the protein to a chaotropic agent results in its
denaturation and exposes previously hidden epitopes with a kinetic that is specific for
each of the tested prion strains. Therefore, this test allowed the establishment of a
“biochemical map” for each of the prion strains based on the different affinities of the
specific antibodies (Peretz et al., 2001; Safar et al., 1998). The ideal test for the prion
strain-hypothesis was to see whether strains conserved their characteristics after in vivo
or  in vitro passaging (Fig. 19). Indeed, at least in some cases, glycosylation and
conformational differences were preserved after transmission into mice (Telling et al.,
1996) or after de novo formation in a cell-free system (Bessen et al., 1995; Eiden et al.,
2006; Iniguez et al., 2000). The existence of different prion-strains was an unanticipated
aspect of TSE-diseases. The difference of strains appears to be enciphered in the
conformational variants of PrPSc and not by nucleic acid sequence as with traditional
pathogens such as bacteria and viruses. Although technically challenging, researchers
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have developed tools for characterizing prion strain varieties and allow the
identification of the likely origin of infectious material. Development of more rapid and
sensitive biochemical strain typing methodologies should prove useful for identifying
subclinical disease as well as tracking infectious outbreaks of TSEs in agriculture and in
natural environments.
Fig. 19: Prion strain variation and preservation of characteristics upon serial passages in hosts.
Transmission of different prion strains to animals results in an incubation time and lesion profile specific
for each strain. Additionally, biochemical features persist upon serial passage to animals, as tested by PK-
digestion and electrophoresic mobility assays (adapted from (Aguzzi et al., 2007)).
III.10.2: Interspecies transmission of prions and the species barrier
As just discussed, one of the characteristics of prions is the existence of different strains
(see Fig. 19), having distinct incubation times and distinct neuropathological
characteristics (Bruce, 1993; Bruce, 2003; Bruce et al., 1994). Yet, the finding that
interspecies transmission of prions is less efficient (and sometimes even impossible)
than intraspecies transmission and that different attack rates (i.e. efficiency of infection)
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exist for different prion-strains, suggested the existence of a species barrier (Bruce,
1993; Bruce et al., 1994).
The species barrier is characterized by an adaptation of the inoculated strain in the new
host, which is measured by its increasing penetrance (i.e. number of animals developing
symptoms upon inoculation) and by the reduction of incubation time after serial
passages in the new host (Fig. 20). In some cases the initial species barrier can be
overcome by increasing the amount of PrPSc administered.
Fig. 20: The species barrier phenomenon. Transspecies infection of prions results in prolonged
incubation times or the complete abrogation of disease transmissions. The shortening of incubation times
after serial passages is called adaptation (A). Polymorphisms of the prnp gene represent another kind of
hurdle and are termed transmission barriers (B). Some species barriers are insurmountable as a
consequence some species do not show any clinical disease (C). Their brain isolates remain nevertheless
infectious for the original host species, indicating the existence of subclinical carriers (adapted from
(Aguzzi et al., 2007)).
The finding that only some prion strains can be transmitted in hosts of different species
(e.g. to the murine system) indicates that the stringency of the interspecific barrier
varies depending on the strain itself (Hill and Collinge, 2004). This was manifested by
reports, showing that only 1/3 of naturally occurring scrapie strains were transmissible
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to C57/BL/6 mice (Bruce et al., 2002; Hunter et al., 1997). The same was reported for
human strains, which were found to be only partly transmissible to mice, while others
were not (e.g. strains found in sporadic CJD (sCJD)) (Hill et al., 1997). In order to
overcome species barriers a high homology between the PrPC-proteins of the two
animals plays a relevant role. A report from Prusiner et al., showed this very
conclusively: wild-type mice expressing natural endogenous murine PrPC, proved to be
resistant to infection with a prion strain adapted to hamster (263K) but sensitive to the
infection with murine-adapted prion strains. Only when mice were engineered to
express hamster PrPC instead of murine PrPC, did they succumb to infection by the
hamster prion strains (Prusiner et al., 1990). The importance of the contribution of PrP-
homology to the species barrier is exemplified by the finding that only one amino acidic
mutation can protect of interspecies transmission in in vivo assays (Priola and Chesebro,
1995)  and in vitro conversion assays (Priola et al., 2001). These initial findings, both
from mice and in cell culture, were extended further to humans, bovines, ovines and
cervids by other laboratories (Browning et al., 2004; Crozet et al., 2001; Scott et al.,
1997; Telling et al., 1995; Vilette et al., 2001).
Nevertheless, it must be stressed that sequence homology between the inoculum and the
host PrPC-form is required but not always sufficient for species barrier crossing.
Transgenic mice expressing the human version of PrPC were very poorly infected with
prion-strain isolates from nvCJD (Vilotte and Laude, 2002), suggesting that additional
factors, possibly interacting with PrPC, are implicated in establishing the species barrier.
The search for these putative interactors proved to be a non-trivial question, because
only PrPC was found to interact strongly and co-precipitate with PrPSc in cell lysates,
thus suggesting that the interaction with other participants, aiding in the process of
transconformation, might be very transient (Horiuchi and Caughey, 1999).
Kimberlin and colleagues proved that a prion strain can be transmitted to other species,
despite sequence differences between the two host PrP-forms (Kimberlin et al., 1987),
contradicting the hypothesis of the sequence homology requirements and possibly
implying that PrP molecules with different amino acidic sequence could acquire the
same conformation. This apparently contradictory finding underlines that the species
barrier phenomenon as it is established today is more complex and only superficially
understood making additional research in this field necessary.
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III.11: In vitro conversion of PrPC to PrPSc
Final proof for the much-contested protein-only hypothesis first put forward by Stanley
Prusiner would be an experiment demonstrating conformational conversion of PrPC to
PrPSc in an in vitro cell-free system. Although many studies tackled this question of
conformational transition (reviewed in (Riesner, 2003)) and have managed to elucidate
some aspects of prion replication, all have failed to conclusively produce infectivity in
vitro. One of the first attempts aimed at studying the refolding process of infectious
natural PrPres 27-30 with varying concentrations of detergents at a neutral pH (Riesner
et al., 1996). Conversion of PrPSc into an "-helical, non-infectious and oligomeric
protein and even a rapid reconversion into a !-sheet-enriched, aggregated and partially
PK-resistant form was reported (Post et al., 1998). However, although this latter form
displayed the main characteristics of PrPSc, it was no longer infectious, suggesting that
merely conformational conversion is not sufficient for establishing infectivity.
Nevertheless, these experiments showed that the conversion process consisted of three
main steps: a rapid switch from "-helices to !-sheets and dimerization within the first
minute followed by slow formation of larger oligomers after 20 minutes and ultimately
the production of proteolysis-resistant, large multimers after several hours. Several
groups demonstrated that denaturing agents used at acidic pH could promote the
production of the scrapie-conformation and that at acidic pH the !-sheet-enriched form
is more stable and aggregation is favoured (Baskakov et al., 2001; Hornemann and
Glockshuber, 1998; Morillas et al., 1999). All these reports agreed on the fact that
PrPSc-conformation is thermodynamically more stable at pH 7 and below (i.e. acidic),
and that the entire conformational transition process is slow (days to weeks) (Riesner,
2003). Other groups have tried to produce prions in cell-culture systems, either by co-
expression of PrPC with hereditary pathological mutants (Chiesa et al., 1998; Lehmann
and Harris, 1996a; Lehmann and Harris, 1996b) or with refolding assays of recombinant
PrP-proteins (Baskakov et al., 2000; Jackson et al., 1999; Lee and Eisenberg, 2003;
Zhang et al., 1995), however the results proved to be either negative or inconclusive.
One of the first assays to convert mammalian prions in a cell-free system consisting of
purified constituents succeeded in showing that purified PrPSc could catalyze the PrPC-
to-PrPSc conversion process. Unfortunately, when compared to the amount of template
used, very little product was obtained and rendered the assessment of its infectious
proprieties impossible (Kocisko et al., 1994). Interestingly it was found that chaperones
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like GroEL or Hsp104 (DebBurman et al., 1997)  as well as elevated temperature in
combination with sulphated glycans like heparan sulphates or pentosan polysulphates
could all positively influence the conversion process (Wong et al., 2001).
Recently, two reports from this field have received much attention:
In the first report, Legname and coworkers showed that recombinantly produced mouse
prions consisting of aa89-230 polymerized into amyloid fibrils and produced
neurological dysfunction after intracerebral inoculation in mice expressing the same
truncated PrP-form. Additionally, brain material from these mice proved to be
infectious to wild-type FVB mice in a second passage (Legname et al., 2004). This
work showed for the first time the infectious properties of in vitro-produced,
recombinant protein, supporting the protein-only hypothesis. Nevertheless, one cannot
rule out that some co-purifying factor from bacteria contributed to the conversion
process and it is worth mentioning that the transgenic mice used in this study were
reported by others to develop spontaneous prion diseases after long observation times
(Chiesa et al., 1998; Westaway et al., 1994).
In a second report Castilla and colleagues presented an optimized protocol for
converting PrPC to PrPSc in a cell-free system. In this report, addition of minute amounts
of PrPSc to a large pool of PrPC-template followed by repeated sonication and incubation
steps (termed PMCA for protein misfolding cyclic amplification, Fig. 21) produced
large amounts of PrPSc (Castilla et al., 2005a; Saborio et al., 2001). The misfolded
protein produced by this process, resembled in its structural and biochemical properties
the hamster brain template and proved to be infectious in wild-type hamsters.
Furthermore, the pathology of the hamsters infected with this material was identical to
that of animals inoculated with the original template. These data are up to now the most
conclusive evidence of in vitro generation of prions, and therefore strongly support the
protein-only hypothesis.
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Fig. 21: The Protein Misfolding Cyclic Amplification (PMCA) as a means for in vitro conversion
and amplification. A small amount of PrPSc-template (yellow dots) is added to a large pool of PrPC-
substrate (green dots) (A). Multiple sonication and incubation-steps allow for increased conversion of
PrPC-molecules to PrPSc (B and C). Inoculation into permissive host verifies the infectivity of in vitro
produced PrPSc (D) (adapted from (Saborio et al., 2001)).
In spite of these impressive results the involvement of other factors coming from the
utilized brain homogenates cannot be excluded.
The idea that some additional co-factors might be participating in the conversion
process is not surprising since it was shown that addition of mammalian RNA
preparations to the PMCA-process increased the stoichiometric transformation rate of
PrPC to PrPSc in vitro (Deleault et al., 2003).
Very recently spontaneous de novo generation of PrPSc molecules was shown (Deleault
et al., 2007). In these experiments prions formed spontaneously at low frequency in the
presence of polyanionic components such as poly(A) RNA-substrates and could
thereafter be amplified by PMCA. Accidental contamination was ruled out by utilizing
only new or prion-free equipment and source materials in a prion-free laboratory. The
produced prions were infectious and lethal when inoculated intracerebrally in wild-type
hamsters (Deleault et al., 2007).
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III.12: Possible interactors for the PrP-proteins
The existence of potential cofactors participating in the conversion process were
initially invoked to explain results obtained from transmission assays of human prions
to transgenic mice (Telling et al., 1995) and also in order to explain the protective effect
of some PrP-polymorphisms found in humans and ovines (Shibuya et al., 1998). Telling
and colleagues observed that mice co-expressing a human and a murine version of PrPC
were resistant to infection by human prions, while mice expressing either the human
PrPC or a chimeric PrP-version (termed Mhu2M and containing the murine C-terminal
part attached to the N-terminal human part) were susceptible to infection. From these
results they concluded that the murine allele inhibited the transmission of human prions,
but had only a minor effect on the conversion of the chimeric protein (Telling et al.,
1995). These findings lead to the hypothesis that a murine host protein (termed Protein
X) is indispensable for the conversion process but binds with a higher affinity to the
murine PrPC-protein than to the co-expressed human PrPC-form. Therefore human PrPC
would not be available for the conversion process by inoculated human PrPSc. Because
only a diminished resistance could be seen when infecting animals expressing the
chimeric protein, it was concluded that Protein X would interact with the C-terminus of
murine PrPC.
Successively, putative interaction sites between Protein X and PrPC were described.
Because substitutions at aa-sites 167, 171, 214 and 218 of PrPC rendered this protein
resistant to conversion by PrPSc it was proposed that these mutations abrogate or
diminish the interaction between Protein X and PrP-proteins (Perrier et al., 2002).
However, in spite of intense research, the putative chaperone of prion-conversion,
Protein X remained elusive (Fig. 22).
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Fig. 22: The potential role of chaperones in the aggregation process of prions. Molecular chaperones
(red triangles) could influence the equilibrium between PrPC (blue dots) and PrPSc (blue rectangles) by
catalyzing the production of amyloids (1) or sequestering free PrPSc-oligomers (5) and thereby achieving
a steady production of these molecules. Additionally they could assist in breaking up amyloidal
multimers (3) or by stabilizing amyloidal structures and fibrils (4) (from (Bousset and Melki, 2005)).
The hypothesis of an interactor also received support from the field of cell biology.
Endocytosis studies on the PrP-protein from chicken (chPrP) showed that it was
dependent on clathrin-coated pits for recycling from the plasma membrane into the cell.
Since chPrP does not contain any cytoplasmic domain to interact directly with the
intracellular endocytosis machinery, it was suggested that some additional
transmembrane protein containing an internalization signal for coated pits could guide
chPrP on its endocytic path into coated pits (Shyng et al., 1994). More recently, several
studies reported the interaction of PrPC with a wide variety of proteinaceous and non-
proteinaceous molecules possibly involved in the PrPC to PrPSc conversion process
(summarized in Table 4). Molecules that were suggested to promote conversion include:
nucleic acids (RNA as well as DNA) (Cordeiro et al., 2001; Deleault et al., 2003),
glycosaminoglycans (GAGs) and sulphated glycans (Pan et al., 2002; Priola and
Caughey, 1994; Wong et al., 2001) and lipids (Kazlauskaite and Pinheiro, 2005;
Kazlauskaite et al., 2003; Sanghera and Pinheiro, 2002).
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Table 4. Molecules to interact with PrP.
Name of
molecule
Proposed function/known
function
Interacting
with which
isoform of
PrP
Exp. system tested Intracellular
compartment
Bip
Calnexin
Calreticulin
Hsp60
ST1
nucleic acids
lipids
Laminin
GAG
37- / 67-kDa
rec Laminin
Aplp1
Caveolin1
p75-NTR
CK2
N-CAM
Pint1
Flotillins
Grb-2
Synapsin 1b
Plasminogen
Bcl-2
Nrf2
GFAP
chaperone
chaperone
chaperone
aggregation
signal transduction,
neuroprotection
chaperone
chaperone/aggregation
neurite growth
internalization
internalization
unknown
signal transduction,
internalization, concentration
apoptosis, internalization,
transport
modulator, internalization,
concentration
neurite growth, internalization,
signal transduction,
internalization, transport
signal transduction, raft carrier
internalization, concentration
signal transduction,
internalization, concentration
activator of plasminogen
unknown
unknown
unknown
PrPC/PrPm
PrPC
PrPC
recPrP/ PrPC
PrPC
PrPC
"-/!-PrP/
PrPC/PrPSc/
PrPm
PrPC
recPrP/PrPC
PrPC
PrPC
PrPC
PrPfrag
recPrP
PrPC
recPrP/
PrPC
PrPC
recPrP/PrPC
recPrP /PrPC
PrPSc
PrPC
PrPC
PrPC/PrPSc
cells
cells
cells
cDNA library, in vitro
cells, in vitro
celluls, in vitro
artificial microsomes
cell membranes
cells, in vitro
cells, in vitro
cells
cDNA library, in vitro
cells
cells
in vitro
cells
cells
cells
cells
cells
in vitro
cells
in vitro, brain extracts
ER
ER
ER
unknown
PM
nucleus
rafts/membrane
PM
PM
PM
PM
PM
PM, caveolae
caveolae
PM, caveolae
unknown
rafts
vesicles
vesicles
rafts/extracellularly
unknown
unknown
unknown
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Identifying the minimal requirements for PrPC to PrPSc conversion is complicated also
because many different intracellular compartments seem to be involved in prion-
production (Campana et al., 2005; Harris, 2003). Therefore different molecules may
interact with PrPC or PrPSc at different intracellular sites. As summarized in Table 4,
numerous potential interactors of PrPC have been found at the level of the
endoplasmatic reticulum (ER), in endosomes or lysosomes and on the plasma
membrane (PM). The sheer number of potential interactors suggests that a
macromolecular complex rather than one single factor would be involved in the
internalization and/or conversion of the PrP-proteins and leaves many unanswered
questions on the nature and function of this complex.
III.13: Pathogenesis and cytotoxicity
Why PrPSc harms the central nervous system producing neuropathological lesions and
neuronal death remains obscure, in spite of intense research for almost ninety years
(reviewed in (Chiesa and Harris, 2001; Roucou and LeBlanc, 2005; Tatzelt and Schatzl,
2007)). The roles of PrPC or PrPSc in neurodegeneration are still undefined and it is still
unclear whether other forms of PrP—possibly of transient nature, could be involved in
cytotoxicity.
III.13.1: The role of PrPSc
In an oversimplified view one might say that the appearance of PrPSc correlates
(spatially and temporally) with neurodegeneration (Jeffrey et al., 2001; Parchi et al.,
1996). However, upon closer inspection the picture gets less clear and shows exceptions
to the rule. In some situations preclinical symptoms (suggesting initial deterioration of
the CNS) were described in diseased animals that contained little to no amounts of PrPSc
in the brain. For instance C57BL/6 mice intracerebrally inoculated with BSE-derived
prions developed pathology even though only 55% produced PrPSc as tested by western
blot and immunohistochemistry (Lasmezas et al., 1997). Similar results were reported
for mice infected with CJD-derived prions (Manson, 1999). Another study reported that
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mice overexpressing PrPC and inoculated with low prion doses showed only preclinical
symptoms, never progressing to terminal disease but containing high amounts of PrPSc
deposits in the brain (Thackray et al., 2002). The same was seen when mice were
infected with a specific hamster prion strain (Sc237). The animals showed accumulation
of PrPSc in the brain but remained asymptomatic and lived as long as the control animals
(also called a subclinical form of the disease, see Fig. 20) (Hill and Collinge, 2002; Hill
et al., 2000). Altogether these observations could lead to the following hypothesis: (a)
PrPSc is not the sole factor responsible for cytotoxicity or (b) the production of PrPSc is
actually a means of neurons to protect themselves, as had been suggested for the
amyloid production in Alzheimer or Parkinson disease (Rao et al., 2006).
Therefore it is probable that PrPSc is not the molecule causing neurotoxicity, but may be
only an inert by-product of a reaction producing another neurotoxic component.
Researchers proposing this view believe that the neurotoxic components are the
oligomeric PrPSc-forms (Bucciantini et al., 2002; Novitskaya et al., 2006; Simoneau et
al., 2007). This is yet another hotly debated topic in prion-research, since others believe
that oligomers fulfil a protective role, sequestering the monomeric PrPSc-forms, which
in their opinion are the true culprits of neurotoxicity (Chesebro et al., 2005).
III.13.2: A possible role for PrPC in cytotoxicity
III.13.2.1: Cytoplasmic intermediates of PrPC involved in toxicity
When misfolded many proteins (such as PrP), which traffic through the endoplasmic
reticulum (ER), are retrogradely transported to the cytosol in order to be degraded by
the proteasome in a process known as Endoplasmic Reticulum (ER)-associated protein
degradation (ERAD). A growing number of reports show that perturbing proteasome
activity (due to aging, cellular stress or the like) or inducing ER-stress initiates the
accumulation of cytosolic forms of PrP, which turned out to be toxic in neurons (Fig.
23) (Orsi et al., 2006). Ma et al. could show in vitro that the increase of cytosolic PrP-
forms produces a toxic effect in cultured cells and causes severe ataxia and cerebellar
degeneration in transgenic mice (Ma et al., 2002). It is important to mention that the
PrP-forms described in this report differed from PrPSc-molecules insofar as this
cytosolic and proteasome-resistant form retains its secretory leader peptide and does not
acquire a glycosylphosphatidylinositol (GPI)-anchor, suggesting that the molecules
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never enter the endoplasmatic reticulum (Drisaldi et al., 2003). Furthermore, it was
shown that this cytosolic PrP-form might convert PrPC-molecules in an autocatalytic
manner, thereby sustaining further accumulation in the cytosol (Ma and Lindquist,
2002). What is puzzling about this cytosolic form is its toxic effect in neurons but the
complete absence of toxicity in fibroblast.
Fig. 23: Cytosolic PrP (cyPrP): a key player in neurotoxicity? The vast majority of PrPC is
translocated into the ER and correctly subjected to post-translational modifications (e.g. addition of
sugar-residues (green)) and correctly inserted into the membrane (blue). Some minor population of PrP
(red) may enter the cytoplasm by different routes: retro translocation of incorrectly folded forms (1),
aborted translocation into the ER (2) or generation of transmembrane forms leading to cell death (3). This
transient (in parentheses) cytosolic form (cyPrP), which is usually quickly destroyed by the proteasome,
could prolong its stay in the cytosol by forming protease-resistant PrPSc or aggregation and thereby exert a
toxic effect in the cell (adapted from (Hegde and Rane, 2003)).
Cytosolic forms of PrP-proteins have also been reported in vivo in mouse hippocampus,
neocortex and thalamus as described by Mironov et al. using electronic microscopy
(EM). However cytotoxicity was not the focus of this work (Mironov et al., 2003).
Additionally, abnormally folded, cytosolic PrPC was reported to occur upon treatment of
cells with cyclosporin A (CsA) (Cohen and Taraboulos, 2003). Cyclosporin A is usually
utilized as an immunosuppressant and inhibits the cyclophilin family of peptidylprolyl
cis-trans isomerases (PPIases). Cells treated with CsA accumulated proteasome resistant
PrP-species, that were deposited in cytosolic structures termed aggresomes and
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reminiscent of protein deposits found in some GSS-linked hereditary forms of TSE-
diseases (Mishra et al., 2003).
Nevertheless, these findings are somewhat contested by some recent publications,
which questioned the neurotoxicity of these cytosolic PrPC-forms, since induction of
apoptosis upon proteasomal inhibition occurred even in neurons not expressing PrP,
showing that this process is not necessarily PrP-protein related (Fioriti et al., 2005).
Additionally, increase of the cytosolic forms was readily induced in cell lines and
primary neurons with drugs simulating ER-stress by multiple pathways (such as
thapsigargin, tunicamycin and brefeldin A) but no clear findings of cytotoxicity were
reported (Orsi et al., 2006). Another group showed that cells overexpressing PrPC
produced cytosolic PrPC-aggregates when the proteasome was mildly inhibited.
Surprisingly this seemed to have a neuroprotective effect on a healthy immortalized
neuronal cell-line (GT-1), while turning proapoptotic and therefore neurotoxic in the
PrPSc-infected version of these cells (scGT-1) (Kristiansen et al., 2005). In sum this
suggests that the neurotoxic effects described above are probably not linked to the
aberrant cytosolic localization of PrP-proteins but rather to the context in which this
happens: Healthy cells do not encounter any disadvantages or might even be protected
by cytosolic PrP-forms, while infected cells induce proapoptotic pathways thereby
leading to increased cell-death. The reasons for these mechanisms are not understood
and need further investigation.
III.13.2.2: Transmembrane forms of PrPC involved in toxicity
PrPC is a protein that is very heterogeneous in its appearance. In addition to the GPI-
anchored form (by definition fully translocated into the ER-lumen), two other forms
have been reported to exist. These two forms have a transmembrane topology and are
called CtmPrP and NtmPrP (the first having the C-terminus inside the ER-lumen, the latter
with the N-terminus inside) (Fig. 24) and were reported to represent approximately 10%
of total PrPC. These two forms can be produced due to a hydrophobic domain (TM1,
aa111-134), which competes with the N-terminal signal peptide for chaperone binding
in the ER. If the chaperones do not intervene after the synthesis of the N-terminus,
NtmPrP and CtmPrP-forms can be produced by insertion of TM1 into the ER-membrane.
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Both transmembrane forms utilize TM1 for insertion into the membrane, but have a
different orientation after insertion. The N-terminus of the NtmPrP-form is exposed into
the ER-lumen and is neither glycosylated nor GPI-anchored (Hegde et al., 1998). The
topology of the CtmPrP-form is such that its C-terminus is exposed to the ER-lumen
receiving a GPI-anchor and retains its signal peptide ((Stewart et al., 2001; Stewart and
Harris, 2001).
Fig. 24: Schematic of the three topological forms of PrPC. The two transmembrane forms are named
for the C- or N-terminal part exposed to the lumen of the ER; the GPI-anchored form is called secPrP by
some scientists because of its ability to be shed into the cell supernatant by a process termed GPI-
shedding (from (Stewart and Harris, 2001)).
The transmembrane forms represent about 10% of the cellular PrPC-population under
normal conditions, but were found to be present in higher amounts in some hereditary
TSEs. While the NtmPrP-form was only described in cell culture systems, two mutations
within TM1 associated with human hereditary TSE-diseases (P105L and A117V) and
were found to augment the production of the CtmPrP-form (Hegde et al., 1998; Stewart et
al., 2005). Transgenic mice expressing a PrP-form exclusively in the CtmPrP-orientation
were reported to develop fatal neurological illnesses reminiscent of TSEs; interestingly
pathology was dependent on co-expression of wild-type PrPC (Stewart et al., 2005).
This information combined with post mortem data from A117V-mutation carriers
(Hegde et al., 1998) lead to the hypothesis that the CtmPrP-form is involved in
neurodegenerative TSE-diseases.
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III.13.2.3: Mutated PrPC-forms involved in toxicity
Some mutations of PrPC (P101L, PG14, A117V) proved to be neurotoxic in mice but
never showed infectious traits (Chiesa et al., 2000; Chiesa et al., 1998; Hsiao et al.,
1990). These mice showed spontaneous neurodegeneration strongly reminiscent of the
human pathologies. The finding that development of neurodegeneration is not linked to
the infectious element strongly suggests that the two forms are not necessarily the same
biochemical entity.
Some TSE-linked mutations produce certain metabolic anomalies as found in cell
culture studies. Among others characteristics, these mutated forms were shown to
become insoluble and resistant to mild protease-digestion (in contrast to PrPC), were
transported in lesser amounts to the plasma membrane (PM) and were retained in
intracellular organelles including the ER and the Golgi-compartment (Ivanova et al.,
2001; Lehmann and Harris, 1996a; Lehmann and Harris, 1996b; Lorenz et al., 2002;
Stewart et al., 2001; Stewart et al., 2005; Wegner et al., 2002).
Interestingly, many studies demonstrated a strong requirement for co-expressed PrPC,
for the development of toxic effects. Brandner and colleagues showed that only PrPC-
overexpressing nervous tissue, homografted into PrP0/0-mice, developed
histopathological alterations upon infection (Brandner et al., 1996). Another approach
chosen by Malucci and coworkers, demonstrated that interrupting the expression of
PrPC post-infection could stop the progress of the infection, prevent neuronal loss and
even reverse mild neurophysiologic dysfunctions caused by the disease (Mallucci et al.,
2002; Mallucci et al., 2007).
The origin of PrPC-neurotoxicity could also be mediated by its role as a signal cascade
transducer: Antibody-induced crosslinking of PrPC situated on the plasma membrane of
hippocampal and cerebellar neurons triggers extensive and rapid neuronal death by
apoptosis (Solforosi et al., 2004).
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III.14: Intracellular trafficking of the PrP-proteins
III.14.1: The cell-biology of PrPC
III.14.1.1: Biosynthesis in the ER
This aspect in prion research has been the subject of numerous publications utilizing a
wide variety of cell-types, such as neuronal cell lines (Beranger et al., 2002; Magalhaes
et al., 2002; Marella et al., 2002; Nunziante et al., 2003; Shyng et al., 1993; Walmsley
et al., 2003), epithelial cell lines (Ivanova et al., 2001; Morel et al., 2004; Peters et al.,
2003; Sarnataro et al., 2004; Sarnataro et al., 2002; Vilette et al., 2001) and primary
neurons (Fioriti et al., 2005; Madore et al., 1999).
Like for other GPI-anchored proteins, PrPC is synthesized on the rough Endoplasmic
Reticulum (RER), transits through the Golgi apparatus where it undergoes the
posttranslational modifications and is finally delivered to the plasma membrane
(reviewed in (Harris, 2003)). The N-terminal signal peptide is cut off following
translation into the ER lumen. Subsequently oligosaccharides rich in mannose are added
(Caughey et al., 1989) onto two asparagines (aa181 and 197 in humans) of the nascent
protein (Haraguchi et al., 1989). At this stage, the oligosaccharides of PrPC are still
sensitive to digestion by endoglycosidase H (EndoH), a characteristic of immature,
core-glycosylated molecules. On its way through the RER, a disulphide bond is formed
between the two cysteine-residues (aa179 and 214 in humans), a prerequisite for proper
folding and trafficking (Yanai et al., 1999). Finally, the C-terminal hydrophobic domain
is cut off by a transamidase also catalyzing the addition of a GPI-anchor onto a serine
(aa 231) (Stahl et al., 1990; Walmsley et al., 2001). During the course of its biosynthesis
at the RER, about 10% of translated proteins are folded incorrectly (Lehmann et al.,
1999; Ma and Lindquist, 2002) and are degraded by the proteasome through the ERAD-
pathway (Endoplasmic Reticulum (ER)-associated protein degradation) (Ma and
Lindquist, 2002; Wang et al., 2005; Yedidia et al., 2001). As previously mentioned
proteasome inhibition leads to accumulation of cytosolic forms of PrPC and can result in
neurotoxicity (Ma and Lindquist, 2002; Ma et al., 2002). Nevertheless, the involvement
of the proteasome in the destruction of PrPC (and some of its mutant forms) is still
debated. In contrast to earlier studies, which suggested the involvement of the
proteasome, more recent publications show that neither PrPC nor its mutants are major
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substrates of the proteasomal pathway. Indeed it appears that only a minor amount of
PrP was unable to translocate into the ER (possibly caused by overexpression in the
system tested), gets ubiquitinated and is thereafter destined for destruction by the
proteasome in the cytosol (Campana et al., 2006; Drisaldi et al., 2003; Fioriti et al.,
2005). Also occurring in the ER is the insertion of PrPC into the membrane which gives
rise to the existence of different topological forms of PrPC (see III.13.2.2).
During the passage of PrPC through the Golgi apparatus, the two core-oligosaccharides
mature by the addition of sialic acids, rendering them insensitive to EndoH treatment
and sensitive to treatment with neuraminidases. The electrophoretic migration pattern of
PrPC on gels reveals three characteristic bands corresponding to its three main
glycosylation states: the non-glycosylated protein (at a height of 25 kDa), the mono-
glycosylated protein (28 kDa) and the mature, di-glycosylated protein (33 kDa). Under
some circumstances a fourth band can be observed which represents the di-glycosylated
but immature protein-form (Sarnataro et al., 2004; Sarnataro et al., 2002). Additionally,
the relative abundance of un-, mono- and di-glycosylated forms can vary with respect to
one another (Moudjou et al., 2001). These characteristics have been useful for strain
typing (see paragraph III.10).
III.14.1.2: The role of PrP-glycosylation in conformational stability and in
intracellular trafficking
Several lines of investigation suggest that glycosylation of the PrP-protein could play a
role in its conformational stability. Computational modelling-studies revealed that the
sugars at the second glycosylation-site in particular assist indirectly in stabilizing PrP-
conformation, by reducing the mobility of the surrounding water molecules (Zuegg and
Gready, 2000). Support for these findings came from studies with fragments of human
PrP (aa175-195), showing that once glycosylated, these fragments have significantly
reduced tendencies to produce fibrils (Bosques and Imperiali, 2003). Furthermore, cells
treated with tunicamycin, a drug that inhibits glycosylation during de novo-synthesis of
proteins, accumulated increased amounts of malconformed PrPC-forms, with
characteristics reminiscent of PrPSc, indicating the importance of the glycosyl-residues
for the correct folding of the PrP-protein (Lehmann and Harris, 1997). In vitro results
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also showed a facilitated misfolding of un-glycosylated PrP-protein (Priola and Lawson,
2001).
However in vivo results contradict these findings. Transgenic mice engineered by site-
directed mutagenesis to produce either an un-glycosylated PrPC-form, or mono-
glycosylated forms with sugars only at either the first or the second glycosylation site
were not affected with respect to PrP maturation and stability. Additionally, these
animals did not develop any spontaneous pathology nor was PrPSc-like protein found in
the brain of mice expressing only the un-glycosylated PrP-form (Cancellotti et al.,
2005), a result which is at odds with the in vitro findings and warrants further
investigation.
Glycosylations were also shown to play a role in the trafficking of the PrP-protein. Cell-
culture experiments with glycosylation mutants similar to the ones described above in
mice, revealed that mutations in both glycosylations sites or at position aa 181 affected
the trafficking of PrPC such that increased retention of the protein inside of the ER and
Golgi apparatus was observed. In contrast, abrogation of glycosylation at position aa197
did not affect its transport to the plasma membrane (Cancellotti et al., 2005; Lehmann
and Harris, 1997; Sarnataro et al., 2004).
Additionally, the glycosylation of PrP is believed to be involved in the tropism of
different prion strains for different cerebral zones (DeArmond et al., 1997). The
conversion-process affects all different glycoforms but with different efficiencies. This
lead to the hypothesis that glycosylation might determine the diverging characteristics
of prion strains by affecting their respective protein conformations (see paragraph
III.10).
III.14.1.3: The association of PrP-proteins with membrane lipid microdomains
Like other GPI-anchored proteins, PrPC is enriched in specific detergent-resistant
membrane domains (DRMs), termed lipid rafts (Gorodinsky and Harris, 1995;
Taraboulos et al., 1995).
65
III.14.1.3.1: The concept of lipid rafts
Based on the fluid mosaic model from Singer and Nicholson (Singer and Nicolson,
1972), a series of experimental results indicated that the plasma membrane is a mosaic
of lipids and proteins organized in a bilayer, exhibiting high lateral mobility in a two-
dimensional plane (reviewed in (Vereb et al., 2003)). The concept of lipid rafts,
restricted domains inside the membrane, (Simons and Ikonen, 1997) proposes that rafts
represent small domains sequestering lipids with specific characteristics, resulting in a
non-homogeneous plasma membrane organized in discrete compartments in the plane
of the bilayer. These lipid-based assemblies derive from the lateral segregation of
glycosphingolipids and sphingolipids due to their long and saturated fatty acid chains,
resulting in a more ordered state. These structures are believed to be dynamic and to
also contain specific membrane proteins with higher affinities for these domains
(Edidin, 2003; Simons and Ikonen, 1997) (Fig. 25). By utilizing a biochemical
approach, based on the extraction in cold detergents (see below), it has been shown that
detergent resistant membranes (DRMs) are characteristically enriched in
glycosphingolipids, cholesterol and particular types of proteins, which seem to have an
increased affinity for the lipids of the rafts. Some examples of proteins enriched in
DRMs are given here: GPI-anchored proteins, proteins with lipid acyl chains as tyrosine
kinases of the Src-family, palmitoylated proteins and some transmembrane proteins like
the !-secretases and BACE (Brown and Rose, 1992) (Fig. 25). Presently, diverse
hypotheses on the nature and size of rafts exist (reviewed in (Edidin, 2003; Zurzolo et
al., 2003)). Simons and Ikonen proposed rafts to be small structures of about 50 nm
(Simons and Ikonen, 1997); due to fine tuned techniques today’s estimations are even
smaller but also more divergent (5-350 nm) (Nohe et al., 2006; Yethiraj and Weisshaar,
2007). Alternatively, the lipid shell hypothesis models rafts as proteins, which nucleate
a “shell” of lipids around themselves (Anderson and Jacobson, 2002). In the same line it
has been proposed that rafts are derived by the clustering of specific lipids in restricted
areas as result of the clustering of raft associated proteins (Helms and Zurzolo, 2004;
Paladino et al., 2004).
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Fig. 25: Schematic of the organizations of rafts and caveolae in the plasma membrane. The
membrane (blue) contains subdomains, termed rafts (red) in which unsaturated phosphatidylcholine is
mainly on the exoplasmic side of the membrane and which also contain a higher amount of cholesterol. a)
Lipid Rafts contain GPI-anchored membrane proteins, which are attached to the exoplasmic side of the
plasma membrane, then proteins which are attached by acyl chains (the kinase Yes from the Src-family
serves here as an example) and also proteins which contain a long hydrophobic transmembrane domain
(the protein hemagglutinin of the influenza virus is shown here). b) The bi-layer of lipid rafts is also
asymmetric with respect to the outer and inner leaflets. Sphingomyelin and glycosphingolipids (all red)
are enriched in the outer layer, while glycerolipids such as phosphatidylserine and phosphatidyl
ethanolamine (all green) are found in the cytoplasmic layer. Cholesterol (grey) is present in both layers
and intercalates between the other elements. c) Caveolae form from rafts where molecules auto-associate
with caveolin, which forms an invagination. Binding of cholesterol and the acylation of C-terminal
cysteines mediate the rafts-interactions (from (Simons and Ikonen, 1997)).
III.14.1.3.2: Detergent resistant membranes (DRMs) and rafts in living cells
One of the main methods for isolating and defining the composition of rafts in cell
membranes was their resistance to extraction with non-ionic detergents as Triton X-100
at cold temperatures followed by buoyancy in sucrose gradients (Edidin, 2003; Zurzolo
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et al., 2003). Utilizing these criteria, researchers could show that some proteins and
lipids from both artificial membranes and cells were resistant to the action of detergents.
It is important to stress that DRMs isolated by this technique are not equal to lipid rafts
in native membranes, which appear to be much more complex in terms of their
composition, content and organization and therefore only serve as an approximation
(Edidin, 2003; Zurzolo et al., 2003). In fact many researchers caution against or even
oppose the equation of DRMs with discrete membrane microdomains known as lipid
rafts (Brown and London, 1998; Heerklotz et al., 2003; Lichtenberg et al., 2005). Since
detergents influence the interactions between proteins and lipids obtained
experimentally from DRMs, these reveal some biochemical characteristics but cannot
provide any information about the organization of these components in living cells.
Nonetheless, when complemented with other approaches, the criterion detergent
resistance serves as a useful means for receiving hints at the composition and
organization of membrane microdomains and is by now an accepted technique in
molecular biology (London, 2005; Schuck et al., 2003). Due to their elusive existence,
but also due to their small size and dynamic structure (reviewed in (London, 2005;
Shaw, 2006)) researchers began to develop additional techniques for studying the lipids
and proteins of lipid rafts with respect to their function and dynamics in living cells
(reviewed in (Helms and Zurzolo, 2004)). Today, quantitative and dynamic
measurements can be additionally done by techniques such as electron microscopy,
single particle tracking, optical tweezers, FRAP (fluorescence recovery after
photobleaching) and FRET (fluorescence resonance energy transfer).
III.14.1.3.3: The presence of PrPC in DRMs and the nature of their interaction
PrPC is localized in DRMs (Gorodinsky and Harris, 1995; Sarnataro et al., 2004;
Taraboulos et al., 1995) and its association to DRMs has been studied in neurons
(Madore et al., 1999) (Fig. 26).
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Fig. 26: Model explaining how graded ordering of lipids due to phase partitioning, affects the
localization of proteins in the surface membrane. A) Diagram of a cellular plasma membrane with the
extracellular part highest. Sphingolipids (straight lipid chains, underneath red bracket) form a highly
ordered domain, which contains proteins such as Thy-1. This highly ordered island is surrounded by less
ordered membrane containing fluid glycerolipids with unsaturated (kinked) lipid chains and
transmembrane proteins. Between the fully-fluid domain on the outside and the fully-ordered part on the
inside is a phase of transition termed semi-ordered lipid domain, which also contains PrPC. B)
Hypothesised relative degree of lipid order (in arbitrary units) corresponding to the membrane shown in
A (adapted from (Madore et al., 1999)).
In contrast to other GPI-anchored proteins, the association of PrPC to rafts can not only
be mediated by the GPI-anchor (Kaneko et al., 1997; Taraboulos et al., 1995) but also
by the N-terminal region of its ectodomain (Campana et al., 2007; Walmsley et al.,
2003). Different studies also showed that the loss of the GPI-anchor does not abrogate
the affinity of PrPC for cholesterol and sphingolipids (Baron and Caughey, 2003;
Campana et al., 2007; Mahfoud et al., 2002; Sanghera and Pinheiro, 2002; Walmsley et
al., 2003). When formulating the lipid raft-hypothesis it was proposed that lipid rafts
could be vehicles to transport GPI-anchored proteins to the plasma membrane (Simons
and Ikonen, 1997). This does not seem to be the case for PrPC, since destabilizing its
association with these microdomains does not affect its exocytic transport or its
polarized distribution in the plasma membrane (Campana et al., 2006; Sarnataro et al.,
2002). Recent results from our laboratory suggest that rafts have a role in PrPC-
endocytosis (see paragraph III.14.1.5.1) but also in the maturation and correct folding of
this protein (Campana et al., 2006; Sarnataro et al., 2004). It appears that the nascent
PrPC-protein associates with cholesterol-enriched rafts earlier than other GPI-anchored
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proteins, during its synthesis at the rough endoplasmatic reticulum (RER). This
association is obligate for its correct folding, since cholesterol depletion increased the
misfolding of the protein. Additionally, cholesterol and sphingolipids have different
roles during the maturation of PrPC, since only cholesterol depletion slowed down its
maturation rate and increased its misfolding (Sarnataro et al., 2004). The role of
cholesterol in folding of PrPC may be direct or indirect: (a) cholesterol is an integral part
of lipid rafts, and the microdomain-environment is needed for the correct folding of
PrPC or (b) cholesterol is directly participating in the folding process as a lipochaperone
(Bogdanov and Dowhan, 1999; Campana et al., 2006; Campana et al., 2005; Sanders
and Nagy, 2000).
III.14.1.4: The distribution of PrPC on the plasma membrane
The distribution of PrPC on the plasma membrane of polarized cells depends on the cell
type. In some cellular models, such as in primary cerebellar granule neurons (CGN)
from wild-type mice (Madore et al., 1999), transgenic for ovine PrPC (Cronier et al.,
2004) or expressing pathogenic forms of murine PrPC (Fioriti et al., 2005) the protein
appears to be homogeneously dispersed on the cell body as well as on the neurites and
axons. Contrasting this are findings from experiments utilizing primary hippocampal
neurons where PrPC localizes to axons in mature neurons (Galvan et al., 2005). Also in
polarized epithelial cell lines like MDCK, FRT and Caco-2/TC7 as well as in primary
enterocytes localization of the protein occured to a greater degree on the basolateral side
(Morel et al., 2004; Sarnataro et al., 2004; Sarnataro et al., 2002). However the
localization of PrPC could be dependent on the cell system or on the origin of the
expressed protein since human PrPC was recently found to be apically-situated in
MDCK and Caco-2 cells (De Keukeleire et al., 2007).
III.14.1.5: Internalization and recycling
Neosynthesized PrPC reaches the plasma membrane of the murine neuroblastoma N2a
cells in approximately one hour (Borchelt et al., 1990). One hour is also required for the
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internalization and continuous recycling of the protein (Harris, 2003). Others have
shown that the internalization process is inducible by the addition of zinc or copper
ions, leading to the hypothesis that PrPC could serve either as a receptor for the uptake
of these ions (Lee et al., 2001; Pauly and Harris, 1998; Watt and Hooper, 2003) or be
involved in signal transduction processes caused by these ions (Mouillet-Richard et al.,
2000). It is still unclear whether the mechanism of ion-uptake utilizes the same
molecular machinery as for its constitutive endocytosis (Lee et al., 2001; Magalhaes et
al., 2002; Pauly and Harris, 1998).
The mechanism for PrPC-internalization is currently debated and seems to use different
pathways depending on the cell types utilized (see below).
III.14.1.5.1: Overview of the different mechanisms of endocytosis
The endocytosis of plasma membrane components can be accomplished by different
molecular mechanisms mainly distinguishable by their dependence or independence
from clathrin, one of the main proteins involved in endocytosis (Ehrlich et al., 2004;
Kirchhausen, 2000; Robinson, 2004).
The endocytosis by clathrin coated invaginations represents a lipid-raft independent and
selective cellular mechanism used for diverse functions such as the internalization of
nutrients, transduction of signals or recycling of synaptic vesicles. The mechanism
utilizes clathrin-lattices on the inside of the endocytosed membrane (hence clathrin
coated pits) to induce membrane curvature, which quickly disperses upon vesicle-
formation due to the involvement of molecules such as Hsc70 and auxilin (Fotin et al.,
2004).
The clathrin-independent mechanisms are less well characterized; however the best
known among them is the endocytosis involving caveolae. These invaginations are
flask-shaped and resemble small caves (hence the Latin-derived name caveolae) of 50-
100nm in length, initially identified by electron microscopy in a wide variety of cells
and tissues (Stan et al., 1997) and are often exploited by pathogens to enter and infect
cells (van der Goot and Harder, 2001). Caveolae were shown to fractionate as detergent
resistant microdomains (DRM). In contrast to those DRMs previously described
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enriched in GPI-anchored proteins, they contain caveolin-proteins, which serve as a
marker for this subgroup of DRMs (Schnitzer et al., 1995).
The invaginations of caveolae are probably directed by the polymerization of the
caveolin-protein family, which consists of three members, type 1, 2 and 3. In particular
Caveolin-1 seems to have an obligate role in the formation-process, since its absence
also causes the abrogation of caveolae in cells (Fra et al., 1995; Schnitzer et al., 1995).
GPI-anchored proteins can be internalized by diverse mechanisms. The majority of
them are constitutively internalized by a clathrin independent, dynamin- and lipid rafts-
dependent mechanism (Mayor and Riezman, 2004). In contrast to this, cross-linked
GPI-anchored proteins can be internalized by caveolae. When interacting with
transmembrane proteins possessing a signal for clathrin-dependent endocytosis, GPI-
anchored proteins also utilize the clathrin-dependent pathway (Mayor and Riezman,
2004).
III.14.1.5.2: Mechanisms of endocytosis of PrPC
Despite its association with rafts, clathrin-dependent endocytosis of PrPC was shown in
neuroblastoma cells (Martins et al., 1997; Shyng et al., 1995; Sunyach et al., 2003),
neurons (Sunyach et al., 2003) and in epithelial cells cells (Shyng et al., 1994) (Fig. 27).
Utilizing electron microscopy, PrPC has also been described in clathrin-coated vesicles
(Madore et al., 1999; Shyng et al., 1995; Sunyach et al., 2003). When cells are
incubated with a hypertonic sugar solution (used to destroy clathrin lattices) inhibition
of PrPC endocytosis can be accomplished (Shyng et al., 1995).
Since PrPC, as a GPI-anchored protein, does not possess a cytoplasmic domain to
interact with clathrin-molecules or with adaptor molecules (Sunyach et al., 2003), other
membrane-associated proteins were recently proposed to serve as a mediator of the
signal, including formyl-peptide-receptor-like-1 (FPRL1) (Brandenburg et al., 2007),
low-density lipoprotein receptor-related protein 1 (LRP1) (Taylor and Hooper, 2007)
and apolipoprotein E (Gao et al., 2006).
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Fig. 27: Mechanisms of internalization of PrPC. The main mechanism for PrPC internalization is
clathrin-dependent and lipid raft-independent (i) involving Rab5-positive vesicles for endocytosis and
Rab4 for recycling. In addition, caveolin-mediated endocytosis has been shown in glial cells (ii). A third
way of endocytosis, clathrin- and caveolin-independent but lipid raft-dependent has also been proposed
(iii) (adapted from (Campana et al., 2005)).
The N-terminal region of PrPC seems to be indispensable for its localization in clathrin-
coated vesicles and therefore for its internalization, since deletion of this region gives a
strong reduction in the internalization-rate (Shyng et al., 1995). Therefore it was
suggested that this region could interact with proteins guiding PrPC into clathrin-coated
vesicles.
In contrast to this, other reports show that caveolae or caveolae-like domains are
utilized for PrPC internalization (Marella et al., 2002; Peters et al., 2003; Vey et al.,
1996) (Fig. 27) as has already been described for other GPI-anchored proteins (Mayor
et al., 1994). In CHO-cells expressing caveolin-1, PrPC is found to be enriched in
caveolae, both at the plasma membrane or in the trans-Golgi network (TGN) but is
surprisingly absent from clathrin-coated vesicles (Peters et al., 2003). Recent data from
our laboratory show that rafts and clathrin but not caveolae are utilized for
internalization in polarized epithelial cells (Sarnataro et al., in preparation). Additionally
it was shown in mature primary hippocampal neurons that PrPC internalization is
dependent on DRMs and cholesterol (Galvan et al., 2005).
Altogether, it appears that PrPC can be internalized by at least two pathways, clathrin-
dependent and raft-dependent endocytosis. Another possibility is that PrP might be
internalized by a pathway that is both raft- and clathrin-dependent, as previously shown
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for several bacterial toxins and surface receptors (Abrami et al., 2003; Puri et al., 2005;
Shogomori and Futerman, 2001; Stoddart et al., 2002).
In the course of its endocytosis, PrPC pinches off from the plasma membrane, reaches
early endosomes, either recycles back through recycling endosomes to the plasma
membrane or proceeds to late endosomes and lysosomes (Brown and Harris, 2003; Lee
et al., 2001; Magalhaes et al., 2002; Marella et al., 2002; Peters et al., 2003) (Fig. 27).
Independent of the mechanism utilized for endocytosis (either rafts- or clathrin-
dependent), PrPC arrives in late endosomes and, if not recycled to the plasma
membrane, is degraded in lysosomes. However, it has also been shown that PrPC could
be relocalized to the trans-Golgi-network and even to the endoplasmatic reticulum
(Beranger et al., 2002) in the presence of dominant-negative Rab4 or constitutively
active Rab6. Very recently, one group reported that a truncated form of PrPC (aa 23-
230) accumulated in the nucleus interacting with chromatin in living cells and to not be
cytotoxic (Crozet et al., 2001).
In conclusion PrPC seems to enter many different organelles during its intracellular
trafficking and this appears to be a fine-tuned mechanism, which can be disturbed with
the overexpression of certain Rab-proteins (e.g. Rab4 or Rab6) in cells.
III.14.6: Proteolytic cleavage and release by GPI-shedding
In the course of its internalization, PrPC can be submitted to several proteolytic events,
producing C-terminal fragments of 27, 22 and 18 kDa in size (highly-glycosylated,
intermediate and un-glycosylated forms respectively) (Chen et al., 1995; Mishra et al.,
2002; Shyng et al., 1993). Additionally 1-5% of the protein can be cut near the GPI-
anchor while situated on the plasma membrane and therefore liberated into the
extracellular medium, by a process called GPI-shedding. This is probably mediated by
phospholipases or copper-dependent proteases (Parkin et al., 2004; Toni et al., 2005).
The relevance of these processes is not well understood and needs further investigation.
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III.14.2: The cell biology of PrPSc
Establishing a system, permitting prion propagation in cell culture, gave researchers the
opportunity to study the biosynthesis of PrPSc, the mechanisms of infection and the
conversion-process (Campana et al., 2005; Harris, 1999a; Solassol et al., 2003) as well
as the discovery of potential therapeutic molecules (Beringue et al., 2004; Gilch et al.,
2007; Touil et al., 2006). The few cell lines, utilized in prion-research today, are mainly
of neuronal origin: N2a-cells are murine neuroblasts (Butler et al., 1988; Race et al.,
1987) while GT-1-cells derive from murine hypothalamus (Schatzl et al., 1997) and
SMB-cells are unspecified scrapie mouse brain-cells (Clarke and Haig, 1970). An
exception to the rule is an epithelial cell line derived from rabbit ectopically expressing
ovine PrPC (Vilette et al., 2001). Unfortunately only a few experimental prion-strains
can be propagated in these lines. Additionally these cell lines do not show any
cytotoxicity, which on one hand allows working with chronically infected cultures but
on the other hand is not quite adequate for studying the neurotoxic mechanisms of
TSEs. Until lately, no cellular system proved capable of replicating and propagating
prions originating from natural prion strains.
Another common tool in today’s molecular biology are antibody-based techniques.
Production of PrPSc-specific antibodies (i.e. discerning between the cellular form of the
PrPC-protein and the malconformed counterpart) was not very successful and appears to
be restricted in their use (Korth et al., 1997), therefore making advances in research on
PrPSc slow. To circumvent this, animals/cell systems with knocked-out PrPC had to be
created on one side (Bueler et al., 1992; Manson et al., 1994; Sakaguchi et al., 1996)
and protocols for augmenting the immunoreactivity in immunofluorescence-
experiments had to be established on the other side (Taraboulos et al., 1990). Due to
these technical problems, the study of the cell biology of PrPSc is restricted to
biochemical analysis and microscopy with little sensitivity; therefore results from these
experiments must be interpreted with caution (rev. in (Campana et al., 2005)).
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III.14.2.1: Synthesis and subcellular localization of PrPSc
As shown by a study with N2a cells, the synthesis kinetics of PrPC and PrPSc are
different. PrPC is synthesized and degraded rapidly (half life of 5 hours), while PrPSc is
more slowly synthesized (15 hours) (Borchelt et al., 1990) with a half-life longer than
24 hours (Caughey and Raymond, 1991). Additionally, PrPSc accumulated inside of
infected cells as shown by several reports (Borchelt et al., 1990; Caughey and
Raymond, 1991; Taraboulos et al., 1992). Using both biochemical and
immunofluorescent techniques, PrPSc was revealed in the Golgi apparatus (Taraboulos
et al., 1990) and by electron microscopy (EM) in the endolysosomal compartment
(Arnold et al., 1995; McKinley et al., 1991; Mironov et al., 2003). This intracellular
distribution pattern corresponds to findings in post mortem brain-samples from CJD-
patients and from mice infected with scrapie (Grigoriev et al., 1999; Laszlo et al.,
1992). Minor amounts of PrPSc were also found on the plasma membrane of cells
(Caughey and Raymond, 1991; Jeffrey et al., 1992; Vey et al., 1996). Nevertheless its
membrane attachment seems to be different to PrPC, since PrPSc is inefficiently released
by the enzyme phosphatidylinositol-specific phospholipase C (PIPLC), contrasting to
the findings obtained with PrPC (Borchelt et al., 1990; Caughey et al., 1990; Stahl et al.,
1990). Since the anchor of PrPSc becomes fully susceptible to PIPLC when the protein is
denatured in SDS, researchers suggest that the aggregation state or the association with
other molecules renders the GPI-anchor physically inaccessible to cleavage (Narwa and
Harris, 1999).
PrPSc was also revealed in the nucleus of some chronically infected cells and interacting
there with chromatin in living cells (Mange et al., 2004) as recently reported for a
truncated PrPC-form (Crozet et al., 2006). The physiopathological implications from
these findings are not yet understood.
As a conclusion, it is clear, that the synthesis and half-life appear to differ between PrPC
and PrPSc, suggesting that the change in conformation also modifies these traits.
Additionally, in spite of its partial membrane localization, PrPSc appears to aggregate
differently or to associate with other molecules, rendering it inaccessible to cleavage by
PIPLC. Its intracellular localization in the Golgi apparatus and in the endo-lysosomal
compartment is similar to the localization of PrPC (discussed above). Possible
differences in localization appear to be more quantitative than qualitative by nature but
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need further investigation and better tools need to be developed to investigate these
issues.
III.14.2.2: Cellular compartments where PrPC to PrPSc conversion could occur
III.14.2.2.1: The endoplasmatic reticulum (ER)
One of the “hot-topics” in prion-research is the quest for the site or organelle where the
process of conversion from PrPC to PrPSc occurs. This event might occur on the plasma
membrane, the first site where endogenous PrPC and exogenous PrPSc are presumed to
interact, or immediately after internalization, in the endolysosomal compartment
(Borchelt et al., 1992; Prado et al., 2004) (Fig. 28).
One intriguing possibility could be that once internalized, PrPSc undergoes retrograde
transport to the Golgi apparatus and/or the ER, where it could perturb the biosynthesis
of PrPC and imprint its malconformation directly on the nascent wild-type protein (Fig.
28).
Rab6 is a GTPase involved in the retro-transport from Golgi apparatus to ER (rev.
(Darchen and Goud, 2000)). The idea of possible PrPC-PrPSc interaction in the ER is
supported by a report in which increased retrograde transport of PrPC was achieved by
expression of constitutively active Rab6-GTPase (Fig. 28), which also led to augmented
amounts of PrPSc in infected cells (Beranger et al., 2002). This suggests that the ER
could have an important role in the conversion-process. One could also argue that a
high amount of potential substrate for the conversion-process transits through the ER. It
is also possible that nascent PrPC is more prone to malconformation than mature protein
(Campana et al., 2005). The role of the ER in pathological conversion is also supported
by data indicating that some hereditary mutant forms of PrPC produce biochemically
identifiable intermediates, the first of which is generated in the ER (Harris, 1999b;
Harris, 2003) (Fig. 28). To this aim, CHO cells (Chinese hamster ovary) overexpressing
pathological mutants were metabolically labelled so that it was possible to monitor the
kinetics of the acquisition of three characteristic traits of PrPSc (resistance to PIPLC,
detergent-insolubility and resistance to protease-digestion). This enabled a kinetic
description of the conversion process: within minutes after synthesis (with the protein
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still in the ER) PrP acquires PIPLC-resistance, typical of PrPSc as discussed above. After
one hour, it acquires the second PrPSc-trait, insolubility in detergents, which reflects the
aggregation state of the proteins. This was confirmed with sucrose gradients, which
showed a gradual decrease in signal sedimenting at 4S (i.e. monomeric PrP) within
time, as well as a gradual accumulation of PrP-species sedimenting at more than 20S
(i.e. aggregates of more than 30 molecules of PrP). The third and final phase-
characteristic, that these PrP-molecules acquire, is the notorious resistance to proteases,
which reaches a maximum only after hours of labelling (Harris, 1999b; Harris, 2003).
This lead to the hypothesis that the PIPLC-resistance, which occurs while the protein is
still present in the ER, might be the first characteristic for the conformational change
while detergent insolubility and protease-resistance are only second and third trait to
change and happen only later.
Fig. 28. Possible sites for the production of PrPSc. PrPC (green circles) is synthesized in the ER.
Possible interacting proteins like misfolded PrP and pathological mutants (blue rectangles) are also found
here and are retrotranslocated to the proteasome. PrPC passes through the Golgi apparatus to the surface
where it might interact with exogenous PrPSc (blue triangles) either inside or outside of lipid rafts. During
its lifetime PrPC recycles between membrane and intracellular compartments and might therefore interact
with its malconformed counterpart in the endolysosomal pathway. Abrogation of PrPC-transport to the
surface (i) abolishes infection of cells, the same is achieved by induction of shedding of PrPC from the
cell surface (ii). Reduction of internalization of PrPC (iii) also decreases the amount of produced PrPSc
(adapted from (Campana et al., 2005)).
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Altogether these data suggest that the ER may have two roles in the conversion process.
Firstly the ER could be directly involved in the case of hereditary TSEs, where
malconformed PrP-forms may intimately interact with nascent proteins in the ER.
Secondly, in the case of infectious TSEs, the ER could be the site of amplification for
PrPSc, previously produced at other sites in the cell (reviewed in (Campana et al.,
2005)).
III.14.2.2.2: On the way to the plasma membrane
Several studies indicate that conversion of PrPC can only occur once the protein has
reached the plasma membrane (Caughey and Raymond, 1991; Taraboulos et al., 1992).
Consistent with this, it has been shown that infection of cells can occur by bringing
them into contact with a simple metal rod on which PrPSc had been previously adsorbed
(Weissmann et al., 2002), suggesting that extracellular contact on the plasma membrane
suffices. Reports supporting this notion showed that removal of PrPC from the plasma
membrane (either by inducing endocytosis by antibody-crosslinking or by enzyme-
induced shedding) (Fig. 28) cured chronically infected cells and prevented de novo
infection (Caughey and Raymond, 1991; Enari et al., 2001; Taraboulos et al., 1992). In
addition treatment with suramin, a compound, which induces PrP-accumulation in a
post ER/Golgi compartment and therefore blocks its expression on the plasma
membrane, was able to cure chronically infected cells (Gilch et al., 2001; Taraboulos et
al., 1992).
Why the presence of PrPC on the plasma membrane is a prerequisite for the conversion
process is not clear, but a few theories have been proposed: i) Post-translational
modifications (such as glycosylation-maturation in Golgi apparatus) could be required
for the conversion process; ii) the lipid environment of the plasma membrane could be
relevant for the refolding process itself or for enabling the interaction between PrPC and
PrPSc; iii) finally one could envision the involvement of a yet to be discovered local
factor supporting the conversion process (Campana et al., 2005; Gilch et al., 2001;
Prusiner, 1998).
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III.14.2.2.3: The endocytic compartment
Some experimental results are compatible with the notion that the endolysosomal
pathway is the site of scrapie conversion. Blocking the internalization of PrPC by low
temperatures also eliminates PrPSc from the membrane of infected cells in culture,
suggesting that internalization is required (Borchelt et al., 1992; Caughey and
Raymond, 1991; Horonchik et al., 2005; Taraboulos et al., 1992). Additionally, it was
reported that PrPSc is proteolytically trimmed at its N-terminus in an acidic compartment
immediately after its synthesis and in some cases accumulates in late endosomes
(Arnold et al., 1995; McKinley et al., 1991; Taraboulos et al., 1992), which supports the
role of endocytic compartments in conversion. Another finding is that expression of the
dominant negative version of the GTPase Rab4, which inhibits recycling to the plasma
membrane (Fig. 27) (thereby leading to an increase of PrP-protein in the endolysosomal
compartment), resulted in increased production of PrPSc (Beranger et al., 2002). It could
be that the conversion process requires partially denaturing conditions such as those
found in compartments with acidic pH (i.e. lysosomes or late endosomes) (Prusiner,
1996).
Involvement of clathrin-coated vesicles in the conversion process was also suggested by
some reports (Kaneko et al., 1997; Peters et al., 2003; Sunyach et al., 2003; Vey et al.,
1996). Since the endocytosis mechanism of PrPC is still unclear (discussed above) this
possibility needs to be further investigated.
III.14.2.2.4: The role of lipid rafts in the conversion process
Evidence that lipid rafts are involved in human pathologies abounds (reviewed in
(Fantini et al., 2002; Simons and Ehehalt, 2002)). As shown for other pathogens it has
been hypothesized that prions exploit lipid rafts for entering cells (Simons and Ehehalt,
2002; van der Goot and Harder, 2001) (Fig. 28 and Fig. 29).
It seems that lipid rafts are a key element for the formation of PrPSc. Although the exact
mechanisms remain obscure and are debated by researchers, some models could be
envisioned.
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1) Lipid rafts could act as transport platforms for taking PrPC to specific
intracellular compartments where it could encounter PrPSc (Fig. 29A). Data
from our own laboratory show that in transfected cells, treatments that
destabilize the association of PrPC with lipid rafts does not alter its exocytic
transport to the plasma membrane (Sarnataro et al., 2002), but slows down
its endocytosis (Sarnataro et al., in preparation). These data support the
hypothesis that rafts could be involved in regulating PrPSc conversion during
endocytosis.
2) Lipid rafts might contain machinery such as proteins or lipids that are
indispensable for the formation of PrPSc (Fig. 29B). This would be supported
by the factor X-hypothesis (see paragraph III.12).
3) Lipid rafts may facilitate the encounters between PrPC and PrPSc molecules
(e.g. by clustering the molecules) and therefore favour conversion (Fig.
29C). In this hypothesis in which lipid rafts serve as a meeting place, is
indirectly supported by work from Baron et al., which showed that PrPC
could be converted into PrPSc only upon insertion into contiguous
membranes (Baron et al., 2002).
4) Another alternative could be that the interaction of PrP with different lipids
produces different kinds of conformations (Fig. 29D). In this model, the
different lipids could act as lipochaperones and facilitate/preserve the
unfolding of "-helical or the refolding into !-helical conformations.
The notion that lipid domains somehow participate in the conversion process came at
first from reports showing that both PrPC and PrPSc are associated with DRMs (Baron
and Caughey, 2003; Baron et al., 2002; Botto et al., 2004; Naslavsky et al., 1997;
Taraboulos et al., 1992; Taraboulos et al., 1995). Additionally it was shown that prion-
aggregates contained low amounts of two sphingolipids (galactosylceramide and
sphingomyelin) usually found in lipid rafts (Klein et al., 1998b). It is important to stress
that in some cases different lipid rafts appear to be hosting PrPC versus PrPSc and that
these can be separated by solubilization and density floatation techniques (Naslavsky et
al., 1997). This suggests that the conversion process is not just a matter of refolding the
participating PrPC-protein but that PrPSc actively influences the surrounding lipid raft-
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compartment (Fig. 29A) or that the two proteins have distinguishable affinities for
different DRMs (maybe due to their folding differences) (Fig. 29B).
One interesting piece of evidence hinting at the role of rafts in conversion was a report
showing that a transmembrane form of PrPC does not localize to lipid rafts anymore.
This form was also resistant to the conversion process while co-expressed normal PrPC
was not (Kaneko et al., 1997; Taraboulos et al., 1995). The destabilization of lipid rafts
by depleting cholesterol in living cells also resulted in inhibition of PrPSc-production
(Mange et al., 2000; Taraboulos et al., 1995); however depletion of sphingolipids
resulted in an increase of PrPSc-replication (Naslavsky et al., 1997). This suggests that
lipid rafts might support the transconformation process.
Fig. 29: Two proposed models of how PrPC and PrPSc could interact with lipid rafts. Depending on
their conformation, PrP-proteins could interact with different lipid rafts. A) PrPC is normally sequestered
in lipid rafts. Exogenous PrPSc interacts with PrPC inside of lipid rafts and converts it; this leads to a
change of PrP-interaction with the lipids of the rafts and therefore gives rise to the formation of distinct
lipid rafts. B) Exogenous PrPSc has an affinity for lipid rafts that differs from PrPC and therefore gives rise
to different lipid rafts. Coalescence of these different lipid rafts leads to transfer of PrPSc, conversion and
formation of a bigger PrPSc-specific lipid raft (adapted from (Campana et al., 2005)).
On the other hand, other reports speak against this hypothesis and for a protective role
of DRMs. Utilizing a cell free conversion system, Baron et al., showed that GPI-
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anchored PrPC is present in DRMs and resistant to conversion by PrPSc, unless its GPI-
anchor is cleaved by PIPLC-treatment, which results in the release of PrPC from DRMs
into the medium. Conversion of PrPC could also be achieved by promoting the fusion of
different membranes containing PrPC or PrPSc by high levels of polyethylene glycol.
Interestingly this treatment also disrupts raft structures (Baron et al., 2002). Results
obtained in our laboratory showed that cholesterol-depletion increased the amounts of
misfolded PrPC (PK-resistant PrP) in the endoplasmatic reticulum and would therefore
argue for a role of DRMs in stabilizing the tertiary structure of the cellular protein
(Campana et al., 2006; Sarnataro et al., 2004).
Two independent reports suggested that lipids could act as lipochaperones and
participate in the folding/misfolding of proteins (Bogdanov and Dowhan, 1999; Sanders
and Nagy, 2000). Others reported that binding to membranes containing the
monoganglioside GM1 supported the refolding of Alzheimer amyloid peptide A beta
(1-40) towards a !-sheet enriched structure (Choo-Smith and Surewicz, 1997). The
influence of lipids on conversion was also the subject of a recent report from Wang et
al., who found that lipid interaction with recombinant PrP-protein initiated conversion
of full-length "-helix-enriched protein to different forms, as well as to a !-sheet
enriched form which was resistant to proteinase K digestion (Wang et al., 2007).
Recombinant PrP-protein was also utilized for studies on differences in lipid-affinity.
Critchley et al., showed that PrPC-resembling, "-helix-enriched PrP-forms ("-PrP)
binds in decreasing order of affinity to membranes enriched in palmitoyl-phosphatidyl-
glycerol (POPG), di-palmitoyl-phosphatidyl-choline (DPPC) and with lowest affinity
lipids from lipid rafts (POPG > DPPC > lipids from lipid rafts), suggesting that at
steady-state PrPC might be situated outside of rafts (Critchley et al., 2004). Other studies
reported that binding of PrPC to lipid rafts stabilizes the "-helical structure of PrP, while
interaction with negatively charged lipids (as found in higher amounts outside of lipid
rafts) increases the content of !-sheets and even produces a disruptive effect on
membranes (Sanghera and Pinheiro, 2002). The same group also reported that !-sheets
enriched PrP is unfolded upon insertion into “lipid raft-like membranes” and is
converted into fibrils (Kazlauskaite et al., 2003) arguing for a chaperone-like activity
for lipids and a potentially protective role for lipid rafts in the conversion of PrPC-
protein (discussed above).
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It appears that the binding of PrPC to rafts could induce the folding of the unstructured
N-terminal part of the protein and thereby stabilize the wild-type conformation of the
protein. This notion is strengthened by findings that PrPC situated inside lipid rafts is
more resistant to conversion to PrPSc (Baron et al., 2002)  and also that the inhibition of
sphingolipid-synthesis, and thereby perturbation of lipid raft composition, increases the
production of PrPSc (Naslavsky et al., 1997). The appearance of exogenous PrPSc might
negatively affect the stabilizing effect of lipid rafts or might be not available when PrPC
exits lipid rafts during its endocytosis (Sunyach et al., 2003).
Data from our own laboratory in which lipid rafts were perturbed by cholesterol
depletion, argue for a model in which lipid rafts act as a protective surrounding for PrPC
and agrees well with the aforementioned reports that lipid rafts confer protection by
stabilizing the "-helical folded form of the protein both in the case of PrPC and of some
mutants (Campana et al., 2006; Sarnataro et al., 2004).
In contrast recombinant !-sheet-enriched protein has an altered affinity for lipid rafts
and tends to produce fibrils therein (Kazlauskaite et al., 2003), showing that the role of
lipid rafts in the pathogenesis is still unclear.
III.15: Exogenous prion-invasion and their dissemination in organisms
III.15.1: Dissemination in organisms: a short overview
In experimental conditions, prions can be introduced exogenously into animals from the
periphery (intraperitoneal or oral inoculation) or directly into the central nervous system
(CNS) (intracerebral inoculation). Medical intervention represents an accidental way of
infection of patients (e.g. blood transfusion, intracranial surgery) and is therefore called
“iatrogenic”, deriving from ancient Greek, meaning “caused by a medical doctor” (see
paragraph III.C.5.c). In the case of naturally occurring infections it is widely believed
that prions are most commonly contracted by the oral route ingesting contaminated
foodstuffs. (rev. in (Mabbott and MacPherson, 2006)). The exogenously derived TSE-
forms are summarized in Table 5.
Following oral challenge, prions radiate away from the entry site in a characteristic way,
concentrating in the adjacent secondary lymphoid organs and ending in the spleen (Fig.
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30) within days and reaching a plateau after a few weeks (Bruce, 1985; Bueler et al.,
1993; Rubenstein et al., 1991). This strongly suggests the involvement of the lymphoid
system (discussed below) in the initial steps of invasion. The peripheral sympathetic
neuronal system (SNS in Fig. 30) is believed to play a decisive role in the “switch”
from the initially involved immune cells to the neuronal system. This is underlined by
findings that sympathectomy in animals right before or after oral challenge significantly
delays the onset of disease, while sympathetic hyperinnervation of the spleen and other
lymphoid organs leads to a significant shortening of the incubation period (Clarke and
Haig, 1971; Glatzel et al., 2001). Additionally, intraperitoneal challenge with prions
leads to their first appearance in neurons of the thoracic spinal cord in regions
corresponding to the entry site of the splanchnic nerves of the sympathetic nervous
system (Beekes et al., 1996; Cole and Kimberlin, 1985). Prions were also shown to
accumulate in sympathetic ganglia (McBride and Beekes, 1999), emphasizing once
more the probable involvement of the peripheral sympathetic neuronal system.
Fig. 30: Overview of chronological steps following oral challenge with PrPSc. Shortly after
transferring the intestinal epithelium, prions are found in secondary lymphoid structures emanating away
from the entry site, (i.e. first in adjacent Peyer’s Patches, later in the spleen and on follicular dendritic
cells (FDCs)). The sympathetic nervous system (SNS neurons) plays a relevant role in the transfer to the
peripheral neuronal system. Once prions arrive in the central nervous system (CNS) the progression of
disease is independent of the immune system (adapted from (Nicotera, 2001)).
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Nevertheless it is worthwhile to mention that even sympathectomized mice succumb to
the disease, suggesting either incomplete sympathectomy or the existence of another,
less efficient entry route, as proposed for the vagal nerve (Baldauf et al., 1997; Beekes
et al., 1998). Additionally it must be stressed that the enteric nervous system was also
assigned an important role in different forms of TSE-diseases, as suggested for scrapie
in sheep (Heggebo et al., 2003; van Keulen et al., 2000) and vCJD in humans (Haik et
al., 2003) making prions quite “promiscuous” (i.e. without any apparent tropism, when
invading the CNS of organisms from the periphery.
Table 5: Overview of exogenously caused TSE-diseases (adapted from (Mabbott and MacPherson,
2006)).
III.15.2: Cells (possibly) involved in dissemination of prions prior to neuroinvasion
III.15.2.1: M cells and gut epithelium
The acidic environment of the stomach cannot fully protect against ingested prions
(Martinsen et al., 2002). It is widely accepted that entry into the affected organism
occurs over the gut epithelium, probably involving microfold cells (M cells), a cell type
specialized in transepithelial transport of particles and macromolecules from the lumen
TSE disease Natural host species
affected
Route of transmission
Variant CJD Humans Ingestion of BSE-contaminated food.
Iatrogenic CJD Humans Usage of CJD-contaminated surgical instruments,
vCJD-infected blood donors
Kuru Humans Ritualistic cannibalism
Scrapie Sheep, goats and
mouflon
Ingestion, horizontal transmission
BSE Cattle Ingestion of BSE-contaminated meat and bone meal
Chronic wasting
disease (CWD)
Mule deer, elk and
moose (and others)
Ingestion, horizontal transmission
Transmissible mink
enceph.
Farmed mink Ingestion, source unknown
Exotic ungulate
enceph.
Zoological greater
kudu, nyala and oryx
Ingestion of BSE-contaminated food
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of the intestine. The involvement of M cells has been shown in in vitro experiments
(Heppner et al., 2001) (Fig. 31, A), yet still awaits confirmation from in vivo studies.
Nevertheless, other mechanisms of passing the gut epithelium could be envisioned:
Ferritin, a molecule abundantly found in meat and absorbed by the intestine was shown
to complex with fragments of PrPSc. In vitro, these complexes were readily transported
in vesicles through an epithelial monolayer of Caco-2 cells, a model, which simulates
an intestinal epithelium (Mishra et al., 2004) (Fig. 31, B).
Dendritic cells might also acquire antigens directly from the intestinal lumen by
“wiggling” dendrites through the epithelial barrier into the lumen and sample PrPSc, as
has been shown with lumenal bacteria (Rescigno et al., 2001) (Fig. 31, C).
Fig. 31: Proposed mechanisms of how PrPSc could cross the intestinal epithelium.
Orally ingested PrPSc could traverse the intestinal epithelium by passage through M cells, a cell type
specialized for transcytosis (A). PrPSc-fragments could cross the intestinal epithelium complexed to
ferritin molecules (B). Dendritic cells (DCs) could insert dendrites through the epithelial barrier and
sample PrPSc directly from the lumen (C). Macrophages (pink) or dendritic cells (orange), or other cells as
discussed below, could sample prions once these have passed through M cells (adapted from (Mabbott
and MacPherson, 2006)).
Material, which is transcytosed by M cells, exits on the non-lumenal side into the so-
called intra-epithelial pocket of M cells (Fig. 31, A). It is believed that passage through
M cells is the main mechanism by which PrPSc crosses the intestinal epithelium. If this
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is the case, then data suggest that the cell-type sampling the molecules from the intra-
epithelial pocket decides on the fate of PrPSc (i.e. degradation or preservation and
spreading) (Fig. 31, A). The other cells possibly involved in the steps following
transcytosis are examined in the paragraphs below:
III.15.2.2: Lymphocytes
Although they sample proteins from underneath M cells, T-cells and B-cells do not
acquire measurable levels of PrPSc-protein upon intra-intestinal challenge (Huang et al.,
2002). Furthermore T-cells seem to not be needed for prion conversion and do not play
a role in TSE-diseases, since PrP-expression directed by the T-cell specific Lck-
promoter in PrP knockout mice did not allow prion replication in the thymus, spleen or
brain following intraperitoneal inoculation (Raeber et al., 1999).
B-cells, on the other hand, do not require endogenous PrPC-expression for allowing
prion-invasion (Klein et al., 1998a) and ablation of B-cells slows down prion infections.
This seems to be due to their contribution to the organization of secondary lymphoid
tissue architecture (Montrasio et al., 2000; Tumanov et al., 2002). Thus, lymphocytes
appear to play only an indirect role in prion invasion as shown for B-cells.
III.15.2.3: Macrophages
Macrophages were among the first cells to be studied in the context of prion-related
diseases (Lavelle et al., 1972; Narang et al., 1972). However, despite of many studies,
their role remains uncertain (see below). Upon oral challenge, deposition of PrPSc in
lysosomes of macrophages was reported in several organs such as in Peyer’s Patches
from hamsters (Beekes and McBride, 2000), in splenic B-cell follicles from sheep
(Herrmann et al., 2003)  as well as from murine spleens (Jeffrey et al., 2000) or mule
deer’s tonsils (Sigurdson et al., 2002). Due to the degradative role of lysosomes, this
finding suggests that macrophages are involved in the degradation of sampled prions,
rather than in their spreading. This was also confirmed by older reports that utilized
peritoneal macrophages and challenged them with prions in vitro, showing that these
cells readily sampled prions (Carp and Callahan, 1981) and that infectivity decreased
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with extended incubation of scrapie-charged macrophages (Carp and Callahan, 1982).
More recently, two in vivo studies supported the role of macrophages in clearing prion
infection. These studies utilized dichloromethylene biphosphonate, a drug known to
deplete macrophages transiently, and could show that depletion of these cells right
before oral or intraperitoneal challenge with prions lead to a precocious increase of
PrPSc in lymphoid tissues, thus arguing in favour of a protective role for macrophages
(Beringue et al., 2000; Maignien et al., 2005).
III.15.2.4: Follicular dendritic cells (FDCs)
This somewhat exotic cell-type seems to play a very relevant role for TSE-diseases and
therefore requires a few introductory phrases. FDCs are believed to derive from non-
haematopoietic stromal precursor cells, are non-phagocytic and non-migratory and
therefore by origin and phenotype not related to and not to be confused with dendritic
cells (DCs) (rev. in (Imazeki et al., 1992; Shortman and Liu, 2002)). Highly immobile
and long-lived, these cells reside in primary B-cell follicles and produce numerous fine
dendrites used for trapping antigens on their surface, without internalizing them
(Mandel et al., 1981). On these dendrites are located receptors, recognizing the Fc-
region of antibodies (Fc-receptors) and also complement receptors CR1 and CR2, which
are responsible for surface-retention of opsonized antigen, generation of high-affinity
antibodies and maintenance of immunological memory (Kosco-Vilbois, 2003; Yoshida
et al., 1993).
In the context of TSE-diseases, these cells were shown to express high amounts of PrPC
(Brown et al., 1999) and it was described that they accumulate PrPSc-protein in the
initial steps of infection on the plasmalemma and within the extracellular spaces around
their dendrites. However, it is not clear whether these cells produce new PrPSc-
molecules (Jeffrey et al., 2000; Kitamoto et al., 1991; van Keulen et al., 2000).
Additionally it was reported, that depletion of FDCs caused by administration of a
soluble Lymphotoxin-!-Receptor-construct led to decreased prion-susceptibility (i.e.
lower penetrance) and delayed neuroinvasion (Mabbott et al., 2000; Mabbott et al.,
2003; Montrasio et al., 2000). For these reasons it is uncontested that FDCs play a
relevant, yet unclear role in TSE-diseases. However, since FDCs are highly immobile,
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they cannot be involved in transporting prions from the intestinal entry-site to secondary
lymphoid structures. Additionally they were not found to be closely juxtaposed to the
peripheral sympathetic neuronal system; rather they occupy anatomical sites different
from sympathetic nerve endings in spleen (Fig. 32) (Defaweux et al., 2005; Dorban et
al., 2007; Lorton et al., 1991). Therefore they are probably not involved in the direct
process of peripheral neuroinvasion but may act as a PrPSc-reservoir, as suggested by
others (Aguzzi et al., 2003; Glatzel and Aguzzi, 2001).
III.15.2.5: Dendritic cells (DCs)
DCs are one of the cell types found in intraepithelial pockets of M cells (Fig. 31) (Liu
and MacPherson, 1993) and are specialized to sample antigens in the periphery and
delivering them to lymphoid tissues for starting an immune response (rev. in (Shortman
and Liu, 2002)). As mentioned before (Fig. 31, C) DCs can acquire pathogens and
antigens without the assistance of M cell by a fascinating process in which they insert
their dendrites between the cells of the intestinal layer (Niess et al., 2005; Rescigno et
al., 2001). Antigens transcytosed by M cells and surrounding DCs are continuously
endocytosed by their membrane veils but are not necessarily degraded in the lysosomal
department (see below). Firstly, DCs can reduce the acidification of their early
phagosomes by sustained activity of a NADPH-oxidase therein, called NOX2 (Savina et
al., 2006), in a Rab27a-dependent manner (Jancic et al., 2007), resulting in an increased
alkalinization of these organelles (Delamarre et al., 2005). Secondly, DCs were reported
to possess receptors of the Fc#RIIB-class, which are utilized for binding and uptake of
antigens. Interestingly it was reported that antigens bound by this type of receptors are
not directed to the lysosomal compartment but are rerouted into a nondegradative
intracellular compartment and recycled to the cell surface for presentation to the B-cell
receptor (BCR) on B cells (Bergtold et al., 2005). Thus, DCs with both degradative and
nondegradative pathways are ideally suited for antigen uptake; furthermore they are
mobile and are also found in the intraepithelial pockets of M cells. Nevertheless, their
role remains unclear with respect to their interaction with prions due to partially
contradicting reports. Indeed, it has been shown that myeloid DCs and skin-derived
DCs sample readily PrPSc in vitro and also quickly degrade it (Luhr et al., 2002; Mohan
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et al., 2005) in a cysteine protease-dependent manner (Luhr et al., 2004) thus
questioning the role of DCs in prion-diseases.
In a different approach, Lymphocytic Choriomeningitis Virus (LCV), a virus, which has
a tropism for and is toxic for CD11c-positive DCs, was utilized to deplete DCs in vivo.
Upon oral or intraperitoneal challenge with prions, LCV-treated mice succumbed to the
disease as quickly as did the control-mice. Since the DC-specific viral ablation did not
alter the kinetics of scrapie-neuroninvasion, the group contested the role for DCs in
TSEs (Oldstone et al., 2002). For the sake of completeness it has to be stressed that in
this study a particularly high amount of prions was used, probably flooding the
organism and overcoming all possible cell-based incubation differences.
In contrast with these reports, it was shown that DCs capture and retain PrPSc in its
native state without degrading it (Huang et al., 2002) and that DCs from infected mice
were sufficient for de novo infection when adoptively transferred into healthy animals
(Aucouturier et al., 2001). Additionally prion-protein fragments were shown to act as
chemoattractants for dendritic cells (Kaneider et al., 2005; Kaneider et al., 2003) and the
involvement of dendritic cells in transporting PrPSc from the intestinal entry site to the
secondary lymphoid structures was reported (Huang et al., 2002).
Intriguingly, in contrast to FDCs, dendritic cells have been frequently reported to
physically interact with peripheral nerve endings (Goehler et al., 2000; Goehler et al.,
1999; Hosoi et al., 1993) and have often been proposed to be involved in transferring
TSE-agents to the peripheral nervous system (Aucouturier et al., 2001; Defaweux et al.,
2005; Dorban et al., 2007). Additionally, these cells are in close contact with
sympathetic neurons, when extravasating from the blood circulation and homing to the
spleen. The spleen is a lymphoid organ in which sympathetic nerve endings ensheath
the splenic artery with highest density at the splenic central arteriole (Fig. 32).
Once DCs have exited the central arteriole, they come in close contact with T-cells in
the white pulp for initiating an immune response (Shortman and Liu, 2002)  (Fig. 32);
however a minor group has been shown to also enter B-cell follicles (Berney et al.,
1999; Yu et al., 2002).
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Fig. 32: Innervation of the spleen and positioning of immune system cells therein. The upper part
depicts a cross section of spleen with the relevant regions of the trabeculae, by which arterioles enter the
spleen, which are closely ensheathed by a web of sympathetic neurons. Sympathetic neurites terminate at
central arterioles (CA) in the white pulp region (lower part). Close to the central arteriole and to the
sympathetic nerve endings are T cells (green) and dendritic cells (yellow) found. B cells (red) and
Follicular dendritic cells (FDCs) (violet) are situated in the so-called B-cell follicles at a distance from the
central arteriole and sympathetic nerve endings. A very minor group of DCs were reported to localize
also to B-cell follicles but are not shown here (adapted from (Mabbott and MacPherson, 2006)).
III.15.3: Intercellular transfer of PrPSc
Once prions are transported into close proximity of nervous endings (be it the enteric
nervous system, parasympathetic system or the sympathetic system as described above),
they must be taken up by neurons. If prions are to be actively delivered to neurons by
cells such as those of the immune system a mechanism for intercellular transfer of
proteins is required. The mechanism by which this occurs is still not understood but
some possibilities have been proposed, as outlined below.
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III.15.3.1: Transfer by exosomes
Quite a number of cell-types, such as DCs, lymphocytes, mast cells, platelets and
epithelial cells, have been shown to actively exocytose small vesicles of 30 to 100 nm in
diameter. These vesicles, termed exosomes, derive from multivesicular endosomes and
appear to be enriched in cell-specific proteins (rev. in (Thery et al., 2002)). Although
their function is unclear, a number of recent reports show that exosomes might be used
for disposal of obsolete proteins and antigen presentation and induction of immune
responses (Segura et al., 2005; Segura et al., 2007). Additionally researchers showed,
albeit indirectly, that human immunodeficiency virus (HIV) might utilize exosomes as a
“Trojan horse” (Gould et al., 2003; Nguyen et al., 2003): This was achieved by
comparing the protein profile deriving from purified exosomes-membranes with that of
HIV-membranes. Intriguingly, cells infected with PrPSc secreted exosomes containing
prions and purified exosomes from these cells have been shown to be infectious for
healthy animals when inoculated intracerebrally (Fevrier and Raposo, 2004). Still, one
has to mention that in this report proof for the exosome-hypothesis as a means to spread
infection was administration of highly enriched exosome-fractions intracerebrally (and
not peripherally) in animals and therefore did not address directly the question of
intercellular transfer.
III.15.3.2: Transfer by coated viruses
Membrane-coated viruses were described to contain pieces of host-membrane and host-
proteins therein upon exiting an infected cell (Ott, 1997; Pelchen-Matthews et al., 2003;
Raposo et al., 2002). Recently it was shown that the supernatant of cells, coinfected
with prions and moloney murine leukemia virus (MoMuLV), contained prions in the
excreted viral particles and that viral infection lead concomitantly to an increased
exocytosis of prions in exosomes (Leblanc et al., 2006). This lead to the proposal that
membrane-coated retroviruses, upon exiting cells, co-infected by the virus and with
prions, could carry PrPSc over into a new host cell. Therefore it was proposed that
membrane-coated viruses could serve as a vector for intercellular prion transfer.
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III.15.3.3: Transfer by GPI-painting
GPI-painting describes the process of post-translational transfer of
glycophosphoinositol-anchored (GPI-anchored) membrane proteins inserted into the
outer membrane layer from one cell to another when closely juxtaposed. This somewhat
ill defined and even less understood intermembrane transfer of GPI-anchored proteins
was first described between murine red blood cells and endothelial cells in vivo
(Kooyman et al., 1995) where it occured with a surprisingly high efficiency. The
process of GPI-painting has also been specifically described for the GPI-anchored PrPC-
protein (Liu et al., 2002). Although this work limited itself to the study of PrPC only,
one can envision that PrPSc could also transfer intercellularly utilizing the same
mechanism, since PrPSc retains its GPI-anchor and is also partially found on the outer
plasma membrane layer (Jeffrey et al., 1992; Stahl et al., 1990; Turner, 1990).
III.15.3.4: Uptake of infectious apoptotic remnants
Two papers described the intercellular transfer of PrPSc without offering an obvious
mechanism for this process (Kanu et al., 2002; Paquet et al., 2007). Kanu et al. showed
that the medium of infected cells by itself was not infectious to healthy cells (therefore
excluding exosomes) and that physical separation of healthy and infected cells by
porous filters also abrogated transfer. Additionally the group could show that dead
infected cells are still able to infect acceptor cells when in close contact to each other
(Kanu et al., 2002). Paquet et al. also showed that closely positioned cells are more
easily infected than cells further away from the infective donor cells (Paquet et al.,
2007). The findings from these two articles suggests that a cell-to-cell contact is needed
for the prion transfer and could be explained as being due to the uptake of infectious
apoptotic remnants by living healthy cells.
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III.16: Tunneling nanotubes (TNTs)
Recently a novel way of cell-to-cell communication has been described (rev. in (Gerdes
et al., 2007)). Immortalized cell lines as well as primary cells of epithelial, neuronal and
immunologic origin were found to produce very fine membrane channels between them
in in vitro cultures (rev. in (Gerdes et al., 2007)). Depending on the cell-type used in the
studies, the diameter and the length of these connections, termed tunneling nanotubes
(TNTs), were very heterogeneous. The diameter of TNTs in the case of PC12 cells (rat
pheochromocytoma cells) varied between 50 to 200 nm (Rustom et al., 2004), while
those of macrophages were thicker in diameter (! 700 nm) (Onfelt et al., 2004); human
endothelial progenitor cells and neonatal rat cardiac myocytes produced connections
which ranged between 50 to 800 nm in diameter (Koyanagi et al., 2005) and DU 145
human prostate cancer cells produced the thickest described TNTs at more than 1000
nm in diameter (Vidulescu et al., 2004). The length of these structures ranged from a
few microns up to 800 µm (Onfelt et al., 2004; Vidulescu et al., 2004).
One hallmark of these connections is that they are not attached to the substratum but are
suspended freely above the substratum and connecting cells at their nearest distance
(Fig. 33) (Hodneland et al., 2006; Rustom et al., 2004).
Strikingly, TNTs permitted the active intercellular exchange of plasma membrane
components like surface receptors (HLA-A, B and C as well as MHC I) as well as a
variety of vesicular structures, such as lysosomes, and mitochondria (Fig. 33) (rev. in
(Gerdes et al., 2007)).
Fig. 33: Proposed model for organelle transfer by TNTs. A cell initiates the build-up of a TNT
(termed donor, cell 1 in upper panel) and connects to another cell (termed receptor, cell 2 in upper panel).
Once established, the TNT-connection can transfer organelles (green circles) intercellularly. A hallmark
of TNTs is that they are not attached to the substratum but are suspended freely in the cell culture
medium (blue arrow in lower panel) (adapted from (Rustom et al., 2004)).
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The mechanism of TNT-formation and their functional role are not yet clear, however it
appears that they contain cytoskeletal filaments involved in stabilizing the connections
between cells. In most of the reported cases actin-filaments seem to span the entire
length of TNTs; however heterogeneity in the cytoskeletal content, depending on the
diameter of TNTs, has been reported (Onfelt et al., 2006).
In particular in the case of monocyte-derived macrophages TNTs with a diameter larger
than 700 nm contained both actin-filaments (F-actin) and microtubuli, while TNTs with
a diameter inferior to 700 nm contained only actin-filaments. The importance of F-actin
for TNT-formation and –stability was further supported by the fact that usage of H2O2
promoted actin polymerization, as well as the formation of TNTs in primary cultured rat
astrocytes (Zhu et al., 2005), a result further corroborated by the absence of TNTs upon
treatment of cell cultures with the actin-depolymerizing drug latrunculin B (Rustom et
al., 2004).
Since connections between cells were frequently observed between parting cells, (i.e.
cells previously with membrane contact moving away from each other), it was proposed
that TNTs could also exist between cells with abutting membranes (Onfelt et al., 2004).
In light of these results, TNTs could be a fascinating possibility for intercellular prion
for several reasons:
Fig. 34: Intercellular transfer of membrane content between differentially labelled co-cultured cell
populations. Left picture depicts the transfer of membrane-attached farnesylated enhanced Green
Fluorescent Protein (fEGFP) to another PC12 cell-population, previously stained in blue (size bar 20 µm)
(from (Rustom et al., 2004)). The box inset is a X-Z reconstruction, showing that the connection is not
attached to the substrate (white arrow). Right picture shows a previously transfected GFP-GPI chimeric
protein transferring from a immortalized B-cell to another B cell-population, previously stained in red
(size bar 10 µm) (from (Onfelt et al., 2004)). Note the heterogeneity in length and diameter between the
two presented examples.
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1) TNTs were shown to enable the transfer of plasma membrane components (Rustom
et al., 2004) including a GPI-anchored Green Fluorescent Protein (GFP-GPI) (Onfelt et
al., 2004)  (Fig. 34). Since PrPC has a GPI-anchor and its malconformed counterpart,
PrPSc, retains its GPI-anchor (Stahl et al., 1987) one could easily envision their
intercellular transfer by TNTs along the plasma membrane derived surface.
2) TNTs were reported to transfer lysosomes and other endosome-related vesicles
between cells (for overview refer to (Gerdes et al., 2007)). This is very interesting for
the prion-field, since PrPSc has been reported in endosomal structures, mainly late
endosomes and lysosomes (Peters et al., 2003; Pimpinelli et al., 2005; Shyng et al.,
1994) but also in the Golgi apparatus (Barmada and Harris, 2005; Taraboulos et al.,
1990).
3) TNTs can be produced between different cell types and dendritic cells (DCs) are
particularly apt at producing intercellular connections (Watkins and Salter, 2005).
Önfelt and colleagues could show that TNTs were able to connect B-cells and Natural
Killer cells (NK-cells), proving that TNTs are not restricted to cells of the same kind
(Onfelt et al., 2004). Additionally, another publication reported that DCs derived from
CD14+ peripheral blood monocytes from human donors are particularly apt at
producing TNTs between cells and elegantly demonstrated rapid intercellular
communication and exchange between these cells (Watkins and Salter, 2005).
Interestingly, CD14+ cells, from which these abovementioned DCs derived, have been
recently reported to be the population with highest prion infectivity in blood
(Andreoletti, Congress Prion2007). This makes TNTs an interesting candidate-
mechanism by which prions could “switch” from the immune system cells to the
peripheral nervous system in secondary lymphoid structures, possibly involving
dendritic cells passing prions directly to peripheral nervous endings.
4) The in vitro described TNTs could potentially have an in vivo counterpart as shown
for the wing imaginal discs from Drosophila melanogaster (Hsiung et al., 2005;
Ramirez-Weber and Kornberg, 1999) and could therefore also occur in whole
organisms. Cautious ex vivo preparations of wing imaginal discs enabled these
researchers to describe thin cytoplasmic extensions (length 700 µm, diameter 200 nm),
termed cytonemes, radiating into the center of the imaginal disc, connecting different
cells and enabling these to transfer vesicular structures. Provided that TNTs described
in vitro and cytonemes ex vivo in Drosophila melanogaster are closely related structures
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and that these structures occur also in tissues and intact organs of higher organisms,
these connections represent a novel means of cell-to-cell communication and might
have a major role in intercellular transfer of prions. Indeed, DCs were reported to be
very apt at producing TNTs and because they can be in intimate contact with neurons of
the peripheral nervous system (see III.15.2.5), this cell type could possibly produce
TNTs and allow prions the “switch” from the immune system to the peripheral nervous
system.
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IV. Working hypothesis
In spite of intensive research on prion diseases for almost a century, a number of
questions are still unanswered or not sufficiently covered in this field of
biological/medical research.
As mentioned in the introduction, Transmissible Spongiform Encephalopathies (TSEs)
can be subdivided into different forms based on their different clinical manifestations
and/or aetiologies. Specifically Creutzfeldt-Jakob disease (CJD) is arborized into four
subgroups:
1) Familial CJDs (fCJD) are the group of diseases where patients host a mutation in
the prnp-gene and therefore express a faulty PrPC-protein. As with all diploid
organisms, humans possess two alleles for each gene and the vast majority of
patients affected by fCJD express one healthy and one mutated allele of the prnp-
gene in the same cell.
2) Variant or new variant CJD (vCJD or nvCJD) is believed to derive from
ingestion of contaminated foodstuffs. Since BSE and vCJD share similar
characteristics in experimentally infected animals, ingestion of BSE-contaminated
beef could be a probable explanation as a cause for vCJD. Upon presumed entry by
the intestine of the host organism, prions invade the peripheral nervous system and
are retrogradely transported to the central nervous system (CNS). Cells involved in
this process and the mechanism by which prions are transported from the site of
entry to the CNS is not understood.
3) Iatrogenic CJD (iCJD) derives from accidental exposure to contaminated
materials during medical interventions. This occurs for instance when dura mater,
blood or cadaver-derived growth hormones originating from asymptomatic CJD-
carriers are administered to recipients. Surgical instruments previously utilized on
CJD-patients are also implicated in infection of new patients.
4) Sporadic CJD (sCJD) is a form of the disease believed to develop upon
spontaneous somatic DNA-mutation or spontaneous misfolding on protein-level and
is neither linked to an inherited mutation nor to ingestion of contaminated food nor
the medical exposure.
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In the course of my work on the prion protein I focused on the intracellular and
intercellular trafficking of mutant and pathological forms of PrP as found in fCJD and
vCJD and wanted to address specific aspects of these diseases:
• The intracellular trafficking and reciprocal influence of co-expressed wild-type
and mutant prion proteins as found in fCJD. This part of my studies is based on
the hypothesis that co-expressed wild-type and mutant proteins interact with each
other and possibly influence the glycosylation, the cellular localization or the
subcellular localization of one or the other form. This hypothesis was to be tested
by various biochemical and microscopical approaches. Additionally, we were
interested in understanding whether co-expressed wild-type and mutant proteins
were in close enough proximity that the mutant could imprint its malconformation
on the wild-type form. We planned to address this question by FRET
(fluorescence resonance energy transfer). Revealing anomalies linked to the
presence of both forms in the same cell could further explain the pathogenesis of
TSE-diseases and therefore might provide information on how to counter these
effects in afflicted individuals in the future.
• The intercellular trafficking of prion proteins from the intestinal entry site to the
CNS, as found in vCJD. This part of my thesis is based on the hypothesis that
intercellular spreading of exogenously derived prions starts with the sampling of
prions by dendritic cells (DCs). These could interact closely with the peripheral
nervous system (PNS) in secondary lymphoid organs (e.g. lymph nodes, spleen)
and transfer prions to the PNS. The mechanism for transfer of prions is also not
known. My hypothesis was to test the involvement of tunneling nanotubes (TNTs)
in this process. I planned to address this hypothesis by a microscopy-based
approach, imaging fixed and living cells and their interaction with each other.
With promising preliminary results obtained from studying immortalized
epithelial and neuronal cell lines, we decided to further test our hypothesis by
characterizing the interaction of primary cells, such as bone-marrow derived
dendritic cells (BMDCs) and primary hippocampal neurons. By setting up this in
vitro model of neuro-immune interaction, I tried to mimic the close interaction of
DCs and peripheral neurons I had previously found by immunohistofluorescence
experiment done with murine splenic tissue. Understanding the basics of the
spreading of prions and their mode of intercellular transfer, would not only
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answer a highly interesting scientific question but might provide information on
how to block their spreading in a clinical context (e.g. upon acute prion exposure).
V. Results
V.1: Manuscript 1
This manuscript has been submitted to the journal Traffic and we are currently
addressing the comments of the referees.
V.1.1: General Introduction
One of the large TSE-subgroups consists of the familial forms of TSEs, which are all
caused by insertions, deletions or exchanges in the prnp-gene. This newly produced
protein is generally termed PrPmut and sometimes named after the aminoacid exchange
it encodes for. Since the mutations are encoded on the nucleic acid level, they are
passed on to the offspring of the carrier following Mendelian rules.
In the first part of my thesis I concentrated on these hereditary forms of prion-diseases,
specifically on characterizing the interaction of co-expressed PrPC and inheritable
mutant forms of the prion protein in the same cell. With the vast majority of patients
affected by inheritable TSE-diseases being heterozygous, we were interested to simulate
this situation in vitro by co-expressing wild-type and mutant protein forms in the same
cells. Heterozygosity and its consequences for prion pathogenesis are a neglected topic
in prion research. In fact only one publication focused specifically on this aspect of
prion pathogenesis but this study was limited to the biochemical aspects of the
interaction and no reciprocal biochemical influence between the co-expressed proteins
was found (Lehmann et al., 1997).
For this reason we decided to address the problem using a different approach: First we
engineered a wild-type form of PrPC tagged with yellow fluorescent protein (YFP-
PrPwt) as well as several mutant forms of PrP-proteins tagged to cyan fluorescent
protein (CFP-PrPmut) (see below). In order to distinguish between the two forms
biochemically, we inserted into the mutant protein-forms a so-called 3F4-tag (aa 106-
126). This tag is expressed naturally in hamster PrPC and does not affect the
characteristics of the prion-protein (Kascsak et al., 1987). This sequence has the
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advantage to be specifically recognized by monoclonal antibodies and therefore allowed
us to discern between the tagged mutant prion-forms and the untagged wild-type prion-
form in our system (Bolton et al., 1991). These different plasmids were then stably co-
transfected in cell cultures and allowed us to study the interaction of wild-type and
mutant prion-protein forms in the same cells.
As cell-system for these experiments we chose a cell line called FRT (Fisher Rat
Thyroid) cells, a polarized epithelial cell line derived from rat thyroids (Nitsch et al.,
1985). We utilized these cells for two reasons: Firstly, these cells have been previously
utilized in studies on the trafficking of proteins (Campana et al., 2006; Sarnataro et al.,
2004; Sarnataro et al., 2002) and secondly, these cells do not express endogenous PrPC,
which might influence the study of the ectopically introduced co-expressed chimeric
proteins.
Murine PrPC was engineered to contain an N-terminally attached yellow fluorescent
protein (YFP) and once transfected in FRT-cells gave rise to the cell line termed YFP-
PrPwt.
The mutants we had chosen for this study were described as belonging to two different
subtypes of inheritable TSE-diseases. The first mutation, found in fCJD, is an exchange
from glutamic acid to lysine at amino acid (aa) position 200 (human numbering). This
resulted in a mutant chimeric protein N-terminally tagged to cyan fluorescent protein
(CFP). The FRT-cell line obtained by stable transfection was termed CFP-PrPE200K.
The second mutation, found in GSS, is an exchange from alanine to valine at aa position
117, giving rise to a fluorescently tagged protein and a stable FRT-cell line termed
CFP-PrPA117V. Additionally, by utilizing the FRT(YFP-PrPwt) cell line, we produced
two cell lines stably expressing YFP-PrPwt and one of the mutants. This gave rise to the
cell lines termed 2xEK (co-expressing YFP-PrPwt and CFP-PrPE200K) and 2xAV (co-
expressing YFP-PrPwt and CFP-PrPA117V).
Populations such as the Libyan Jews and others have an increased incidence of fCJD-
familial disorders, such as the E200K-mutation (100 times higher than the worldwide
population, i.e. approximately 100/Million) (Gabizon et al., 1994a; Gabizon et al.,
1994b; Kahana et al., 1974). Due to this, fCJD-diseases moved into scientific focus and
allowed several pathological and epidemiological studies on the E200K mutation.
However, considerable controversy on its cellular and subcellular characterization and
localization exists, making additional studies necessary (see below in Introduction of
Manuscript 1).
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The A117V mutation on the other hand, has only been studied with respect to some
very specific characteristics (see chapter III.6.2) and therefore required further studies
on cellular and subcellular localization.
In the course of this work, we included a third mutant in our studies, which we had
previously extensively characterized in our laboratory (Campana et al., 2006). This is a
glycosylation mutant-protein, which hosts a threonine to alanine exchange at aa position
182 and is utilized here as a CFP-chimeric form, termed CFP-PrP182A. This mutant has
been previously analyzed in the laboratory for subcellular localization, trafficking and
biochemical characteristics (Campana et al., 2006).
V.1.2: Objectives
Because previous results on the biochemistry and localization of these mutants were not
conclusive (Capellari et al., 2000; Goldfarb et al., 1992; Hegde et al., 1998; Hsiao et al.,
1989; Kovacs et al., 2001; Negro et al., 2001; Piccardo et al., 1998; Rosenmann et al.,
2001; Tateishi et al., 1990), we set out first to investigate the general traits (i.e. scrapie-
like properties such as insolubility and resistance proteinase K-digestion, glycosylation
pattern) of these chimeric proteins, comparing the chimeric proteins with their untagged
counterparts. Next we characterized the cellular localization of all chimeric proteins,
with our main emphasis being on the differences between the single-expressing cell
lines (YFP-PrPwt or CFP-PrPmut) and the double-expressing cell lines (2xAV, 2xEK).
Indeed, changes of localization of either the wild-type or the mutant protein caused by
the presence of its homologue might shed light on the pathogenesis of these diseases.
Next, we examined the subcellular compartmentalization (i.e. presence in detergent
resistant membranes (DRMs)) of proteins in single- and double-expressing cells, in
order to see whether the co-presence of wild-type and mutant proteins would somehow
affect their presence in lipid membrane domains. Differences in membrane
compartmentalization may not only provide information on possible mechanisms of
pathogenesis but might also shed light on the debated role of lipid domains in the
transconformation process of PrPC to PrPSc. Finally by utilizing FRET (fluorescence
resonance energy transfer), we addressed the question whether and where co-expressed
YFP-PrPwt and CFP-PrPmut would interact closely in the cell. Since this energy
transfer by FRET occurs only when fluorophores are in close proximity (3-10 nm)
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(reviewed in (Kenworthy and Edidin, 1998)), information obtained by this technique
may give important clues as to whether and where wild-type protein and its pathogenic
homologue are close enough to allow malconformation of the former by the latter and
possibly to reciprocally influence their function.
V.1.3: Summary of results
A plasmid encoding the murine form of PrPC (moPrPC) N-terminally linked to CFP and
containing a 3F4-tag was used to generate the mutant PrP forms by site-directed
mutagenesis. It is worthwhile to mention that moPrPC differs by one amino acid from
the human PrPC-form (see III.7.3), therefore mutations were shifted by one amino acid
(A117V in humans becomes A116V in mouse, E200K in humans becomes E199K in
the mouse system).
Following transfection we obtained several FRT-cell clones stably expressing either
YFP-PrPwt, CFP-PrPE199K or CFP-PrPA116V. Utilizing different antibodies directed
against either the N- or C-terminal region of the PrP-protein, we analysed both the size
and the level of expression of the chimeric proteins by western blot. All three chimeric
forms migrated at their expected molecular masses of approximately 58-60 kDa with
distinct bands representing the di-, mono- and unglycosylated forms of the protein (see
chapter III.8 and compare with Fig. 16). By utilizing an antibody directed against the
3F4-tag (expressed only in the CFP-PrPmut forms), we confirmed that we could
biochemically distinguish the mutant chimeras from the wild-type chimeric protein. We
also observed that the major band of CFP-PrPE199K protein migrates between the di-
glycosylated and mono-glycosylated forms of YFP-PrPwt and CFP-PrPA116V. Since
the second glycosylation site of the PrPC-protein is at position aa 197 (in human PrP)
(see chapter III.7.3 and Fig. 11 therein), this suggested an incomplete glycosylation of
this mutant. To test this we treated protein samples with the enzyme N-glycosidase F
(PNGase F), thereby removing attached N-glycans and analyzed these by SDS-PAGE
and western blotting. Upon this treatment all three samples (YFP-PrPwt, CFP-
PrPA116V and CFP-PrPE199K) revealed a sharp band at approximately 40-45 kDa
confirming our hypothesis that the observed differences in size are due to differential
glycosylation. Additionally we monitored the same difference in migration when YFP-
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PrPwt and CFP-PrPE199K were co-expressed, suggesting that the differential
glycosylation patterns are not affected by the simultaneous presence of both proteins.
Next we characterized the expressed proteins in the three single expressing cell lines for
insolubility and sensitivity to Proteinase K (PK)-digestion. We found that the CFP-
A116V-protein is soluble (10% sedimented) and sensitive to PK-digestion comparable
to the wild-type chimera, YFP-PrPwt. This result is in agreement with data obtained for
this mutant not fused to a fluorophore (Tateishi et al., 1990). However, CFP-E199K
showed an increased insolubility (35-40%) and was weakly resistant to PK-digestion, as
already reported by others for proteins not fused to fluorophores (Capellari et al., 2005;
Lehmann and Harris, 1996a; Lehmann and Harris, 1996b). These data indicated that the
chimeric proteins behaved as their wild-type counterparts, suggesting that the fusion
with the GFP does not alter the intrinsic characteristics of the proteins. As a next step
we sought to determine the cellular localization of the proteins in single- and double-
expressing cells. For this we utilized fluorescent microscopy on fixed and permeabilized
cells, assaying for colocalization of the fluorophore-attached chimeric PrP-proteins with
antibodies against markers of different intracellular organelles. We found that all
chimeric proteins (both the wild-type and the mutant forms) preferentially localized to
the Golgi apparatus and the plasma membrane. This intracellular localization was
maintained also in the case of cells co-expressing wild-type and mutant forms. Since
wild-type and mutant proteins colocalized extensively at the Golgi apparatus and on the
plasma membrane, we tested whether they occupied the same membrane microdomains.
We addressed this by extraction at 4°C in the presence of detergents (Triton X-100) and
subsequent centrifugation in a discontinuous sucrose gradient. The single-expressed
chimeric proteins associated with detergent resistant membranes (DRMs) to very
different degrees: 35%±11 of YFP-PrPwt, 18%±3 of CFP-PrPA116V and 50%±10 of
CFP-PrPE199K associated with detergent resistant membranes (n=3). Surprisingly, the
same assay performed on the double-expressing cells gave different results. Here, the
amounts of both the wild-type and mutant proteins found in the DRMs increased
dramatically. Cells co-expressing wild-type and the mutant A116V (2xAV) had
61%±13 of both forms in DRMs and when revealed with "3F4-antibody (recognizing
only the mutant prion protein) we found 59±14 of CFP-A116V floating in the DRM-
fraction. This increase was even more pronounced in the case of the cells co-expressing
YFP-PrPwt and CFP-E199K. Here we found 95%±20 of both proteins in DRMs, while
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the mutant itself floated with 86%±22. Co-expression of the CFP-PrPT182A mutant
with the YFP-PrPwt protein lead also to a substantial increase of wild-type protein in
DRMs (more than 80%), while the association with DRMs of the mutant protein
remained maximal (<90%) as previously seen in cells expressing the T182A-mutant
only.
DRMs and their protein composition did not appear to be generally disturbed in the
double-expressing cell lines, since controls with GM-1 and flotillin-1, two proteins
associated with DRMs, did not reveal any differences when single- and double-
expressing DRM-preparations were compared. Additionally, we could not find the same
increase in DRM-content when the wild-type protein was expressed as both YFP and
CFP (+3F4-tag) linked chimeric forms. This suggests that the increased localization in
DRMs is caused by the presence of the respective mutant protein forms and its
interaction with wild-type protein. Additionally, these data indicate that PrPwt and
PrPmut affect each other’s presence in membranes and therefore might interact in
cellular membrane subdomains. Analysis of the lipids, which co-immunoprecipitated
with PrPC and the mutant prion-proteins from single-expressing cells, showed no
qualitative or quantitative differences supporting the notion that these proteins occupy
the same membrane microdomains in cells and might interact with each other therein.
Additionally, analysis by FRET showed no differences between cells co-expressing
YFP-PrPwt and one of the CFP-linked mutants and control cells co-expressing YFP-
PrPwt and CFP-PrPwt at the level of the Golgi apparatus and on the plasma membrane,
arguing for a close interaction between the wild-type protein and the mutant forms both
at the level of the Golgi apparatus and on the plasma membrane. This was further
supported by colocalization experiments and confocal analysis in cells co-expressing
YFP-PrPwt and CFP-T182A. We found that when co-expressed with the T182A-
mutant, YFP-PrPwt, does not reach the surface but was retained intracellularly and
colocalized extensively with the mutant in the Golgi-apparatus suggesting that an
interaction with the mutant protein leads to its retention.
V.1.4: Discussion
In spite of intense studies for almost a century, the mechanisms of pathogenesis of TSE-
diseases remain largely enigmatic. The goal of this work was to simulate in cell-culture
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the heterozygous situation found in the majority of people affected by familial TSEs.
The mutant proteins we had chosen for our study belonged to the best-studied forms in
the prion field (Capellari et al., 2000; Goldfarb et al., 1992; Hegde et al., 1998; Hsiao et
al., 1989; Kovacs et al., 2001; Negro et al., 2001; Piccardo et al., 1998; Rosenmann et
al., 2001; Tateishi et al., 1990). However, differing results have been reported
concerning their characteristics and cellular and subcellular localization. Additionally,
the reciprocal influence of co-expressed wild-type and mutant forms in these systems
had been largely neglected or was limited to biochemical characterization (Lehmann et
al., 1997). The results we describe here show that the mutants A116V and E199K are
mainly PK-sensitive and detergent soluble, as shown previously for the T182a mutant
(Campana et al., 2006). This agrees with previous data published on the A116V
mutation (Piccardo et al., 1998; Tatzelt and Schatzl, 2007). For the E199K mutation,
our results agree with the data described for fibroblasts derived from human skin
(Rosenmann et al., 2001) but contrasts with the report of others, who showed in CHO-
cells, that this mutation conferred resistance to Proteinase K-digestion and insolubility
in detergents (Daude et al., 1997; Lehmann and Harris, 1996a; Lehmann and Harris,
1996b). These differences could be explained by the differences in the cell systems
used. On the other hand, our findings that the E199K mutant reaches the cell surface of
FRT-cells, is supported by the results from Lehmann et al. (Lehmann and Harris, 1996a;
Lehmann and Harris, 1996b) but is in conflict with the data presented by another group,
who could not find the bovine homologue of the E200K mutation on the plasma
membrane of several cell lines tested (Negro et al., 2001). The explanation for this
discrepancy might be that we, as Lehmann and colleagues, used the mouse homologues
of the human mutation (Lehmann and Harris, 1996a; Lehmann and Harris, 1996b),
while Negro and colleagues utilized the bovine homologue (Negro et al., 2001).
Alternatively, the differences at hand may be caused by different cell systems and
constructs utilized in the different works as shown in the case of PrPC. Indeed, our
laboratory has described murine PrPC as localized to the basolateral membrane of
polarized FRT-cells (Sarnataro et al., 2002), while very recently another group reported
the human protein’s localization to be apical in polarized Caco-2 cells (De Keukeleire et
al., 2007). This stresses the possibility that differences in localization and biochemical
traits might be linked to the use of different cell-lines and expression systems.
Membrane microdomains have long been implicated in prion pathogenesis, since both
PrPC and PrPSc have been found to localize to DRMs (Baron and Caughey, 2003; Baron
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et al., 2002; Botto et al., 2004; Naslavsky et al., 1997; Taraboulos et al., 1992;
Taraboulos et al., 1995) although their role (in protection or promotion of
transconformation) remains ambiguous (see III.14.2.2.4). In this work we show that the
mutant proteins expressed in isolation associate with DRMs in different proportions,
suggesting that these differences might be mutation-specific. Our finding that increased
amounts of wild-type and mutant prion proteins are observed in DRMs in double-
expressing cells underlines the notion that DRMs might have an important role in the
conversion process.
We undertook several controls to rule out artefacts: Most importantly co-expressing two
different wild-type forms, YFP-PrPwt and CFP-PrPwt (containing the 3F4 tag), did not
increase the DRM-content of these proteins. This suggests that neither the interaction of
the two fluorophores nor some ill-defined effect of the 3F4-tag is involved in the
findings described above. Additionally we believe that general disturbance of the
membrane can be ruled out, because two well-characterized markers for membrane
microdomains, GM1 and flotillin-1, did not show any increased sequestration in DRMs
of double-expressing cells. We believe that these controls suggest that the increased
DRM-content is caused by the co-expression of the wild-type and the mutant protein
and more importantly by reciprocal effects of one on the other. Another piece of
information that indicates the co-existence of the proteins in common domains is that
the lipid species co-immunoprecipitating with wild-type and mutant protein forms did
not show any qualitative or quantitative difference. This argues for the hypothesis that
these proteins occupy membrane rafts of the same kind and could therefore interact
therein. This is further supported by our FRET-data, which shows that wild-type and
mutant proteins are closely juxtaposed in the Golgi apparatus, as well as on the plasma
membrane. In addition the data on the T182A mutation showed that coexpression with
the wild type results in increased intracellular retention of the wild type, suggesting
once more that both proteins interact with each other.
As mentioned previously, membrane microdomains play an important, albeit hotly
debated role in prion pathologies. Some groups are ardent supporters of the hypothesis
that transconformation occurs in rafts, while others speak in favour of the idea that rafts
are an environment that protects against prion transconformation. As described in
chapter III.14.2.2.4, numerous scientific publications arguing for one or the other can be
found. Our finding that co-expressed proteins are enriched in DRMs unfortunately does
not resolve this debate, since it could be in agreement with both hypotheses. Our
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findings could nevertheless shed some light on the pathogenesis of TSE-diseases. As
mentioned before, a publication utilizing the same experimental approach could not find
a transfer of pathological characteristics from mutant to co-expressed wild-type protein
by biochemical means (Lehmann et al., 1997). This suggested that some other aspect
might cause pathology and led us therefore to look at other criteria. The increased
sequestration of both mutant and wild type forms in DRMs lead us to hypothesise that
PrPC and PrPmut interaction promotes a PrPC-disequilibrium in cell membranes (raft
versus non-raft), which might lead to the development of pathologies in heterozygous
carriers of these mutations. Unfortunately, with no clear function described for either
PrPC or PrPSc, this gives us no real basis for understanding the pathogenesis of these
enigmatic diseases. However, a number of hypotheses could be envisioned with respect
to how pathogenesis could occur:
• Gain of function of PrPC. Provided that PrPC serves a yet-to-be-defined function
in membrane rafts, the presence and the interaction with its mutant homologue,
could lead to its increased sequestration therein and thence to increased activity.
In cells, susceptible to these disturbances (e.g. neurons), this might consequently
lead to cell-toxicity.
• Loss of function of PrPC. The opposite of the hypothesis presented above could
also be envisioned. Assuming a function of PrPC outside of rafts, its interaction
with its mutant homologue leading to increased sequestration in membrane
domains could by consequence lead to a drop of its functional activity and
therefore to cell-toxicity in susceptible cells
• Indirect gain or loss of function. Other proteins or factors interacting with PrPC
or PrPmut (Protein X, see III.12), could be affected by the increased
sequestration of PrPC/PrPmut in DRMs and could lead to a Protein X-based
gain/loss of function.
• Gain/loss of function for PrPmut. As described above for PrPC the increased
sequestration of PrPmut into DRMs could produce a toxic effect in heterozygous
carriers of the mutation.
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2Abstract:
Transmissible spongiform encephalopathies
(TSEs) are a group of diseases of infectious,
sporadic and genetic origin, found in higher
organisms and caused by the pathological form
of the prion protein. The inheritable subgroup of
TSEs are linked to insertional or point mutations
in the prion gene prnp , which favour its
misfolding and are passed on to offspring in an
autosomal-dominant fashion. The large majority
of patients with these diseases are
heterozygous for the prnp gene, leading to the
co-expression of the wild-type form (PrP
C
) and
the mutant form (PrPmut) in the carriers of these
mutations. In order to mimic this situation in
vitro, we produced FRT cells coexpressing wild-
type PrP alongside mutant versions of PrP
including A117V, E200K and T183A relevant to
the human TSE-diseases Gestmann-Sträussler-
Scheinker Disease (GSS) and familial
Creutzfeldt-Jakobs-Disease (fCJD). We found
that co-expression of mutant PrP with wild-type
proteins does not affect the glycosylation
pattern nor the biochemical characteristics of
either protein. However we provide evidence
that the mutant form alters the subcellular
localization and the membrane environment of
the wild-type protein in co-transfected cells.
Specifically, co-expression of the wild-type and
mutant proteins leads to an increased
sequestration of both proteins in detergent
resistant membranes (DRMs), a site believed to
be involved in the pathological conversion of
the prion protein or protection thereof. Our data
indicate that altered membrane environment of
PrP may play a role in the development of these
diseases.
Introduction:
Prions are infectious proteins found in organisms as
far apart as animals and yeast. The group of
diseases caused by prions in higher organisms are
called transmissible spongiform encephalopathies
(TSEs), lethal neurodegenerative diseases which in
humans can have different aetiologies: genetic,
infectious and sporadic (1, 2). The common
denominator of all TSEs is believed to be the prion
protein, in its healthy form termed PrP
C
, a
glycosylphosphatidylinositol (GPI)-anchored protein
with unknown function, yet widely expressed in
tissues, particularly in cells of the immune system
and the central nervous system (3-5). The hallmark
of most TSEs is the appearance of a new isoform of
PrP, termed PrP
Sc
 which has undergone a refolding-
process from a formerly !-helix rich form to a "-
sheet enriched isoform which is partially protease-
resistant, insoluble in detergents and is not released
from the plasma membrane by treatment with
phosphatidylinositol-specific phospholipase C
(PIPLC) (6). Whereas in infectious transmissions
the acquired PrP
Sc
 could originate from ingestion of
contaminated food, all the inheritable forms (about
10% of human TSEs) are linked to mutations in the
coding region of the prion protein gene (prnp), which
is found on chromosome 20 in humans (7).
Presently, more than 20 nonsense-, insertion- and
point-mutations leading to disease have been
described and due to their clinicopathological traits,
these autosomal-dominant diseases have been
divided into three subgroups, namely familial
Creutzfeldt-Jakob-Disease (fCJD), Fatal Familial
Insomnia (FFI) and Gerstmann-Sträussler-
Scheinker Syndrome (GSS). Although it is believed
that PrP
Sc
 acts as a catalyst for imprinting its
malconformation on PrP
C
 (8), where in the cell and
how this process of pathological conversion occurs
and why this leads to pathology is yet to be resolved
(rev. in (9)). Therefore, understanding the
subcellular localization and the membrane
environment in which PrP
C
 and PrP
Sc
 could
physically interact --for the latter to induce
malconformation of the former — is vital for
understanding the pathogenesis of these disorders.
An important role in the conformational conversion
process has been attributed to specialized detergent
resistant membrane domains (DRM or lipid rafts)
enriched in cholesterol and sphingolipids. Indeed it
has been shown that PrP
C
 and PrP
Sc
 associate to
these domains (10, 11) and that DRM-associated
PrP
C
 needs its malconformed counterpart PrP
Sc
 to
be inserted into contiguous membranes in order to
allow conversion (12). Furthermore, cholesterol
depletion decreased the amount of PrP
Sc
 production
in infected cells (13), while depletion of specific
sphingolipids increased the amount of PrP
Sc
 (14).
These data suggest that the major components of
DRMs (cholesterol and sphingolipids) have an effect
on prion conversion. In addition it has been shown
that immature PrP
C
 is already associated with
DRMs in the endoplasmatic reticulum (ER) and that
misfolding of PrP
C
 is increased upon cholesterol
depletion (15, 16), suggesting that DRM association
in the ER might be required for the correct folding of
PrP. This seems also to be the case for some PrP-
mutants (16) although the site of misfolding in the
infectious and inherited forms of the disease could
be different (rev. in (9, 17)).
Alteration in the intracellular trafficking of the prion
protein could also have a role in the pathology of the
inherited disease as evidenced by the fact that
some pathological mutants have a different
intracellular localization compared to the wild-type
protein. We and others have previously studied the
biogenesis, intracellular pathway and subcellular
localization of T182A, a pathological glycosylation
mutant found in a familial form of CJD (16, 18, 19).
Here we analyzed two different mutants, E200K
(glutamate to lysine amino acid exchange at
position 200) and A117V (alanine to valine
exchange at position 117) associated with fCJD and
GSS diseases respectively (20-23). Although these
two mutants are among the best-characterized,
controversial results have been published regarding
their biochemical characterstics and subcellular
localization. Specifically, while some groups
reported that E200K, is detergent insoluble, PK-
resistant and localized to the cell surface (24-26),
others found that it was soluble in detergents, PK-
sensitive and segregating into cholesterol-enriched
microdomains in transgenic mice, as well as in
primary fibroblasts from fCJD-patients but not in
brain extract of the same patients (27, 28). In
addition the bovine form of PrP harbouring the
3bovine homolog of the human E200K mutation was
reported to accumulate in the ER and in the Golgi
but not on the plasma membrane and was shown to
associate with cholesterol-enriched microdomains
(27).
From the group of GSS-diseases, one of the best
studied mutants in terms of membrane insertion and
neuropathology, is the A117V mutant, exchanging
alanine for valine (A117V) (23, 29, 30). This
substitution belongs to a remarkable group of
mutations that were shown to be responsible for the
increased production of a transmembrane form of
PrP
C
, termed 
Ctm
PrP (Ctm for transmembrane, with
its COOH-terminus in the ER lumen and the NH2-
terminus in the cytosol) which possibly causes or at
least contributes to the neurotoxic effect of PrP-
A117V (21). However its biochemical characteristics
and intracellular localization are largely unknown.
Another notable characteristic of the familial TSE-
diseases that has been somewhat neglected is the
fact that the majority of patients are heterozygous
for the mutations of the prnp-gene (31). We were
interested in characterizing this clinically relevant
situation of heritable prion disease by mimicking
heterozygosity in a cell culture model in order to
examine the phenotypic effect of the heterozygous
genotype at the subcellular and biochemical level.
To this aim we co-expressed each of the mouse
analogs of these three PrP-mutants, E199K, A116V
and T182A, together with mouse PrP
C
 in Fischer
Rat Thyroid (FRT) cells, which have been
extensively characterized for the trafficking of PrPwt
and some PrP mutants (15, 16, 32). In these cells,
we analyzed the trafficking and metabolic
characteristics of both the wild-type and the mutant
forms. We found that co-expression of wild-type and
one of the mutant PrP-forms does not alter their
respective glycosylation patterns nor their
subcellular localization in the Golgi-apparatus or on
the basolateral plasma membrane. However, upon
co-expression, the amount of both forms was
substantially increased in DRMs, suggesting that
the presence of both forms in the same cell perturbs
the membrane distribution of PrP
C
 and of its mutant
counterpart. This indicates a possible interaction of
the two forms in this domain, which could lead to the
progress of the pathology in heterozygous patients.
Materials and Methods:
Reagents and antibodies
Cell culture and reagents were purchased from
Gibco Laboratories (Grand Island, NY). The !-PrP
antibodies SAF32 (recognizing the octa-repeat
region (aa 59-88 in human numbering) located in
the N-terminal part of PrP) and SAF61 (recognizing
the amino acids 142-160 (human numbering) of the
C-terminal part of PrP) were a kind gift from J.
Grassi (CEA, Saclay, France). The !-GFP
antibodies (A11120) used for immunoprecipitation
were purchased from Molecular Probes. Protein-A-
Sepharose was bought from Pharmacia Diagnostics
AB (Uppsala, Sweden). Antibodies against calnexin
and EEA1 were from StressGen Biotechnologies
Corp. (Victoria, BC, Canada). The antibody against
giantin was from BAbCO (Berkeley Antibody
Company, Richmond, CA). The antibody against
flotillin-1 was from Transduction Laboratories
(Beckton Dickinson).
PrP constructs, transfection and cell culture
MoPrP
C
 was previously engineered for expression
in a pEYFP-C1-plasmid, containing a Zeocin-
resistance (YFP-PrPwt). Plasmid encoding for
moPrP
C
, N-terminally linked to cyan fluorescent
protein (CFP-PrPwt) in a pCFP-C1, containing a
3F4-tag and a G418-resistance was used to
generate mutant PrP forms by site-directed
mutagenesis using the QuickChange II XL site
directed mutagenesis kit (Stratagene). The alanine
to valine exchange at position 116 in the moPrP
C
was made by the ol igonucleotide 5'-
AGGGGCTGCGGTAGCTGGGGCAGT-3', for the
lysine to glutamate change at position 199 in
moPrP
C
,  t h e  o l i g o n u c l e o t i d e  5 ' -
GGGGAGAACTTCACCAAGACCGATGTGAAGAT
GA-3' were obtained from Stratagene (Amsterdam,
NL) was used. The constructs were stably
transfected with Lipofectin Reagent from Invitrogen
(Carlsbad, CA). Stable clones were selected with
Zeocin for YFP-PrPwt and G418 for CFP-PrPA116V
and CFP-PrPE199K. FRT cells stably expressing
the different constructs were cultured in F12 Coon's
modified medium from Euroclone (Milan, Italy)
containing 5% FBS.
N-glycosidase F treatment
Samples were eluated in 50µl of 50mM PBS, 10mM
EDTA, 0.5% TX-100, 0.1 SDS, 1% "-Mercapto-
Ethanol, boiled for 5 minutes at 100°C and then
incubated with 5U PGNase F at 37°C for 16 hours.
Then samples were incubated with 5U PGNase F
for 2 more hours, incubated with Laemmli-Buffer for
10 minutes at 100°C and run on 12%
polyacrylamide gels and revealed by Western-Blot.
Assays for scrapie-like properties
Triton/Doc insolubility
Triton/DOC insolubility assay wasperformed as
previously described (32). Briefly, cells were lysed in
Triton/Doc buffer (0.5% Triton X-100, 0.5 Na
deoxycolate, 150mM NaCl and 100 mM Tris, pH7.5)
for 20 minutes and cleared lysates were centrifuged
at 265000Xg for 40 minutes in a TLA 100.3 rotor of
Beckman Optima TL ultracentrifuge. Supernatant
was isolated from pellet and the proteins from both
fractions was recovered by Trichloroacetic acid-
precipitation (TCA). It was previously shown that in
these condit ions PrP-forms with PrP
Sc
-
characteristics are preferentially found in the
pelleted fraction (26).
Proteinase K (PK) digestion
Assay was performed as previously described (32).
Briefly, lysates were digested with PK (3,3 µg/mg of
total protein) for 2, 5 and 10 minutes, TCA
precipitated and then visualized by SDS/PAGE and
western blot.
Fluorescence microscopy
FRT cells stably expressing the different constructs
were grown either for 2 days on coverslips or 4-5
days on transwell filters, washed with PBS, fixed in
2% paraformaldehyde, permeabilized with 0.075%
4saponin  and processed for  ind i rec t
immunofluorescence using specific antibodies. In
some cases PrPwt and its mutated homologs were
visualized with SAF32/SAF61 as primary antibodies
and FITC- or TRITC-conjugated secondary
antibodies, while calnexin, giantin and EEA1 were
revealed with TRITC-conjugated secondary
antibodies using a Zeiss laser scanning confocal
microscope (LSM 510). For lysosome staining, cells
were incubated for 1 hour with Lysotracker (1:
10000) in complete medium, washed and fixed.
Biotinylation assays
Confluent monolayers were achieved by culture for
4-5 days on transwells, biotinylated and processed
for immunoprecipitation as described elsewhere
(33). To recover the immunoprecipitated proteins,
the samples were boiled in Laemmli buffer for 10
minutes at 100°C and then loaded on 12%
polyacrylamide gels. After transfer on nitrocellulose
by western blot, biotinylated PrP
C
 and PrPmut were
revealed by horseradish-peroxidase (HRP)-
conjugated streptavidin (Amersham).
Sucrose density gradients
Sucrose gradient analysis of TX-100-insoluble
material was done after protocols published
elsewhere (34, 35). Briefly, after lysis in TNEV/1%
TX-100 buffer on ice, cells were scraped off,
homogenized and brought to 40% sucrose and
placed at the bottom of centrifuge tubes. On top, a
discontinuous sucrose gradient (30% first, then 5%
sucrose on top) covered the lysates. These were
centrifuged at 39,000 rpm for 17 hours in an
ultracentrifuge (SW41 from Beckman Coulter).
Fractions of 1ml were cautiously taken off from the
top to the bottom of the gradients, run on 12%
polyacrylamide gels, blotted and revealed by
western blot.
To reveal the distribution of GM1 in the gradient,
20µl of each fraction were spotted on nitrocellulose
membrane and detected with HRP-conjugated
cholera toxin B subunit (Sigma-Aldrich).
Results:
All three chimeric proteins have the predicted
size but different patterns of glycosylation
Fisher Rat Thyroid cells (FRT) as well as other
epithelial cells have previously been shown to be a
good model for studying prion trafficking (15, 16, 25,
26, 32, 36-38). FRT cells have been used to study
the exocytic pathway of murine PrP
C
, of a hereditary
mutant (PrPT182A) and of an anchorless form of
PrP (PrP#GPI
 
(15, 16, 32, 38). In order to study the
biochemical properties and subcellular localization
of two inheritable pathological mutant forms found in
familial CJD (E200K) and in GSS (A117V) and their
interaction with PrPwt, FRT cells were stably
transfected with cDNAs encoding for murine PrPwt
or the two mutants fused at the N-terminus either to
Yellow Fluorescent Protein (YFP-PrPwt) or to Cyan
Fluorescent Protein (CFP-PrPA116V, CFP-
PrPE199K). Furthermore, in order to biochemically
distinguish wild-type from mutant PrP, a 3F4-tag
was introduced into the mutant PrP variants (39-41).
Different FRT clones, stably expressing either YFP-
PrPwt, CFP-PrPA116V or CFP-PrPE199K were
analysed for the size and the level of expression of
the chimeric proteins by western blot, using different
antibodies directed against either the N- or C-
terminal region of PrP or against the 3F4-tag (where
inserted). Compared to YFP-PrPwt the two mutants
were expressed at lower levels and all three
chimeric forms migrated at the expected molecular
masses of approximately 58-60 kDa (Fig. 1A).
However the ratios between di-, mono- and
unglycosylated bands were different, among the
chimeric proteins (Fig. 1A). In particular the major
glycosylation form of CFP-PrPE199K migrates
between the di-glycosylated and mono-glycosylated
forms of YFP-PrPwt or CFP-PrPA116V, suggesting
an incomplete glycosylation of this mutant (Fig. 1A,
left and center) as shown before (24). When
incubated with an anti-3F4-tag antibody, no
reactivity was seen with YFP-PrPwt, while the
mutant expressing cell lines showed the same
differences between the different isoforms (Fig. 1A,
right).
In order to understand whether the above
mentioned differences in size were related to
different glycosylation patterns for the different
mutants, we immunoprecipitated cell lysates of FRT
cells expressing either YFP-PrPwt, CFP-PrPA116V
or  CFP-PrPE199K and t rea ted  the
immunoprecipitates with N-Glycosidase F (PNGase
F) in order to remove N-Glycans (Fig. 1B). Upon
deglycosylation all three samples revealed a sharp
band at approximately 40-45 kDa, indicating that the
observed differences in size are due to differential
glycosylation (Fig. 1B).
It had been previously reported that during the
normal cycling of PrP
C
 between the plasma
membrane and intracellular compartments, C-
terminal fragments of the protein with sizes of 27-
30, 22 and 18 kDa are generated. These forms
represent C-terminal fragments of the highly
glycosylated (27-30 kDa), intermediate (22 kDa) and
unglycosylated (18 kDa) forms (42-44). However
this seems to be cell-specific and was never
observed in large amounts in FRT cells (15). In
order to rule out the possibility that the transfected
chimeric proteins were subjected to proteolysis,
which would result in the loss of the N-terminally
linked fluorophore, we immunoprecipitated the cell
lysates using an ! -GFP antibody. The
immunoprecipitates were analyzed by western
blotting with !-PrP antibodies directed either against
the N-terminus or the C-terminus of PrP
C
 or by an
!-GFP antibody. In all three cases, the strongest
band appeared at a height of 48-60 kDa,
representing the intact chimeric proteins of interest
(Fig. S1A). In addition to the main band, other minor
bands of approximatively 30 to 37 kDa appeared in
the western Blots revealed with the ! -PrP
antibodies. Most likely these bands represented
fluorescent protein-linked degradation products.
Because they constituted only a minor fraction of
the signal, we did not investigate these bands
further (Fig. S1A).
In parallel to the biochemical experiments described
above, we approached the question of the possible
loss of the GFP fluorophore by proteolysis of the
PrP-fusion proteins by immunofluorescence
5microscopy. For this purpose we performed
immunofluorescence experiments and confocal
analysis and compared the signals deriving from the
YFP- or CFP-linked chimeric proteins with the signal
derived from indirect immunofluorescence using
antibodies directed against either the N- or C-
terminal part of PrP or with an !-GFP antibody. We
found that there was an almost complete
colocalization between the YFP and CFP signals of
the transfected chimeric proteins and the signal
from each of the three antibodies used. These
experiments showed that there was no detectable
f luorescent signal coming from fluorescent
molecules (YFP or CFP) not linked to PrP (Fig.
S1B), confirming that in our conditions the majority
of the chimeric proteins are intact.
CFP-PrPE199K is more insoluble and less
sensitive to Proteinase K treatment than the
YFP-PrPwt and CFP-PrPA116V chimeric proteins
Next we analyzed the PrP
Sc
-like traits of the
chimeric proteins in single expressing cells by
centrifugation of Triton/DOC cell lysates at 265,000
Xg for 40 minutes, a treatment which had been
reported to sediment detergent insoluble PrP
Sc
-like
aggregates but not PrP
C
 (45, 46). While about 10%
of YFP-PrPwt and of CFP-PrPA116V sedimented,
CFP-PrPE199K repeatedly showed a higher
percentage of insolubility (35-40%) (Fig. 1C). CFP-
PrPE199K also repeatedly proved to be more
resistant to PK-digestion. After 2 minutes of
treatment with 3,3, !g of PK/1mg of total protein,
approximately 20% was still present and after 10
minutes approximately 5% was still detectable by
western blot while YFP-PrPwt and CFP-PrPA116V
were completely digested (not shown). Taken
together these experiments suggest that neither
YFP-PrPwt nor the CFP-PrPA116V chimeric
proteins display PrP
Sc
-like characteristics similar to
what was shown for the same proteins not fused to
fluorophores (23). On the other hand CFP-
PrPE199K seems to be more insoluble in
detergents and shows a slightly higher PK-
resistance, supporting the notion that this mutation
confers minor PrP
Sc
-like traits as shown before for
the same PrP-mutant form not linked to GFP (24-
26). These experiments also indicate that the fusion
of GFP to the different PrP-forms does not alter the
intrinsic characteristics of these proteins.
Both PrP mutants show a preferential
localization to the Golgi-apparatus and the
plasma membrane in single transfected cells
In order to analyze the intracellular localization of
the two chimeric proteins, we performed indirect
immunofluorescence experiments on permeabilized
cells expressing either each of the mutants or
PrPwt, utilizing several antibodies directed against
well-characterized markers of different intracellular
organelles (Fig. 2).
YFP-PrPwt, as well as CFP-PrPA116V and CFP-
PrPE199K colocalized extensively with Giantin, a
marker of the cis- and medial Golgi apparatus,
whereas we could not see any colocalization with
calnexin, a marker for the endoplasmatic reticulum
(ER), or with any markers of the endocytic pathway,
such as EEA1 for early endosomes and
LysoTracker for lysosomes (Fig. 2). In addition all
three chimeric proteins were found on the plasma
membrane of cells. This localization is consistent
with the localization observed for PrPwt (15) and the
original A116V and E199K mutants constructs not
fused to GFP when transfected in FRT cells (not
shown), indicating that the GFP-tag did not affect
the appropiate trafficking/sorting of the proteins.
YFP-PrPwt and CFP-PrPmut chimeric proteins
maintain their glycosylation pattern and their
intracellular localization upon co-expression in
the same cell
Because we were interested in directly comparing
the localization and eventually following the
interaction between PrPwt and PrPmut in the same
cell, we produced FRT clones stably co-expressing
either YFP-PrPwt and CFP-PrPA116V (2XAV) or
YFP-PrPwt and CFP-PrPE199K (2XEK) (Fig. 3).
When revealed with anti-PrP antibodies against the
N- or C-terminus (Fig. 3, left and center), we
observed the di-, mono- and unglycosylated forms
of YFP-PrPwt, as previously described in cells
expressing only YFP-PrPwt (compare Fig. 3 with
Fig. 1). When the same samples were revealed by
western blotting with an !3F4-antibody (Fig. 3,
right), we could see that the cells expressing both
YFP-PrPwt and CFP-PrPA116V (2XAV) produced a
mutant form with a strong diglycosylated form and a
minor monoglycosylated subform, while the cells co-
expressing YFP-PrPwt and CFP-PrPE199K (2XEK)
produced only one strong band at a lower molecular
weight than the diglycosylated form of either YFP-
PrPwt or CFP-PrPA116V. These results suggest
that the glycosylation pattern of each PrP-form is
maintained despite the co-existence of the wild-type
and mutant PrP-forms in one cell (Fig. 3, compare
with Fig. 1).
We then analyzed whether the co-expression of
PrPwt and PrPmut in the same cell could produce a
change in their respective intracellular localization.
To this aim we analyzed the intracellular localization
of wt and mutant PrP by confocal microscopy using
specific organelle markers (Fig. 4A and B), as we
did for the single expressing clones (Fig. 2). A clear
colocalization on the plasma membrane and with
Giantin in the cis- and medial Golgi, was found in
the case of the double expressing cells YFP-
PrPwt/CFP-PrPA116V as well as YFP-PrPwt/CFP-
PrPE199K, while no colocalization could be seen
with neither calnexin, nor EEA1 nor LysoTracker
(Fig. 4A and B). These results indicate that when
co-expressed both forms colocalize at the same
sites (cis-, medial Golgi and plasma membrane) and
that neither PrPwt nor PrPmut seem to interfere with
the intracellular trafficking of the other.
Because our laboratoy among others (32, 37) had
previously shown a preferential basolateral
localization for PrP
C
 in polarized cells, we analyzed
whether this was also the case for YFP-PrPwt and
for the two CFP-linked mutants (Fig. S2). To this
end, we performed a biotinylation assay on filter-
grown polarized cells. We found a strong signal on
the basolateral site for PrPwt and PrPmut in both
6single- and double expressing cells (Fig. S2A).
Quantification of these results showed that
approximately 80% of the signal was localized to the
basolateral site in all cases, suggesting that the co-
expression of PrPwt together with PrPmut in the
same cells does not alter their trafficking to the
plasma membrane (Fig. S2B). These results were
also confirmed by confocal microscopy of polarized
cells grown on filters (not shown).
Co-expression of YFP-PrPwt and CFP-PrPmut
strongly increases their association with DRMs
Because PrPwt and PrPmut colocalize extensively
at the Golgi apparatus and on the plasma
membrane, we analysed whether they occupied the
same membrane microdomains. Since PrP
C
 had
been found in DRMs in FRT and other cells (10, 32,
37, 47, 48), we analyzed the presence of the
chimeric proteins in detergent resistant membranes
(DRMs) in single and double expressing clones (Fig.
5). We found that each of the chimeric proteins
associated with DRMs to different degrees. In single
expressing cells, quantification showed 35%±11 of
YFP-PrPwt, 18%±3 of CFP-PrPA116V and 50%±10
CFP-PrPE199K in the floating fraction (Fig. 5A
upper panel for blots, 5C for quantification).
Interestingly, when we performed the same assay
on the double expressing cell lines, the amount of
the proteins found in the DRMs increased
dramatically. In the case of the cells co-expressing
YFP-PrPwt/CFP-PrPA116V we found 61%±13  o f
both PrP-forms in DRMs and revealed with !3F4-
antibody, 59%±14 of CFP-PrPA116V floating in the
DRM-fraction. For the cells co-expressing YFP-
PrPwt/CFP-PrPE199K the increase was even more
pronounced, since we found 95%±20 of both
proteins to be localized to the DRMs and 86±22
when assayed for the CFP-PrPE199K-protein by
!3F4-antibody (Fig.5B upper, 5C for quantification).
The highly increased amount of both PrP-forms in
the co-expressing cells was not due to a general
disturbance of DRMs, since GM-1 and flotillin-1, two
proteins associated with DRMs, were equally
present in the DRM-fractions of single and double-
expressing cells (Fig. 5 and not shown). These data
strongly suggest that PrPwt and PrPmut are
restricted to the same membrane subdomains
where they might interact with each other. Because
the differences in the migration of the bands
corresponding to the wt and mutants were too
subtle to appreciate (see Fig. 1 and Fig. 3), we
could not  carry out  convincing co-
immunoprecipitation experiments to prove
interaction of PrPwt with PrPmut. Nevertheless, the
enhanced enrichment into DRMs indicated that the
mutant proteins could be influencing the localization
of the PrPwt. However, since both mutants as well
as PrPwt exhibit similar subcellular distributions, a
subtle redistribution within membranes due to this
interaction might occur but could not be detected.
Therefore, we utilized a previously characterized
mutant, PrP-T182A, known to exhibit a distinctly
different subcellular distribution as previously shown
(16, 19).
Interestingly, we found by immunofluorescence that
when co-expressed with the T182A-mutant, YFP-
PrPwt, does not reach the surface but was retained
intracellularly and colocalized extensively with the
mutant (Fig. 6A and inset). Also in this case, we
found increased amounts of both forms in the DRM
fractions of sucrose gradients, when co-expressed
(Fig. 6B, compare upper with lower blots).
Quantification showed that while in single
expressing cells YFP-PrPwt associated with
approximately 40% to DRMs (as also shown in Fig.
5A), the CFP-PrPT182A mutant associated to
DRMs for more than 90%. In contrast to this,
double-expression of the wild-type and the mutant
protein, revealed a substantial increase in DRM
association for YFP-PrPwt (more than 80%), while
the association with DRMs of the mutant protein
remained maximal (<90%).
Taken together these data suggest that mutant
forms of PrP are able to interact with their wild-type
counterpart, increase their DRM association and
influence their intracellular localization.
Discussion:
In spite of intense research the pathogenesis of
TSE-diseases is still only poorly understood. For
example, inheritable human prion diseases such as
familial CJD and GSS have been studied now for
almost a century (the first case being described by
Hans-Gerhard Creutzfeldt in 1920) while the
mechanisms of pathogenesis remain enigmatic. The
aim of this work was to simulate in a cell-culture
system the heterozygous situation found in the
majority of patients with inheritable TSE-diseases
(31, 49, 50). Thus both PrP
C
 and PrPmut were
expressed in the same cell, in order to analyze
whether and how each of the two proteins affected
the biochemistry, as well as the cellular and
subcellular localization of each other. Although
these mutants b e l o n g to the best studied
pathological mutations found in inheritable prion
diseases (18-20, 22, 51-53) differing results have
been published about their characteristics and
subcellular localization. Furthermore the reciprocal
influence of mutants and PrP
C
 have not been
specifically addressed (23-30) or were only
characterized by biochemical means (54). A
previous study, in which PrPwt was coexpressed
with a mutant called PG11 in an in vitro system,
revealed no transfer of mutant characteristics onto
the coexpressed PrPwt-protein but the scope of this
report was limited to an examination of the
biochemical characteristics of the proteins (54). Our
results indicate that both mutant forms (A116V,
E199K) are mainly PK-sensitive and detergent
soluble (Fig. 1). For the A116V mutation these
findings corroborate previous data (23, 30). In the
case of the E199K mutation, our findings resemble
the results described by Rosenmann et al. in
fibroblasts derived from human skin (28) but are in
contrast to earlier reports, where it was shown that
the E200K mutation conferred PK-resistance and
detergent insolubility (25, 26, 36). These
discrepancies might be due to the different cells
used in the different studies. On the other hand, our
data, showing that the E199K mutant reaches the
cell surface of FRT-cells, confirms the results
described by Lehmann et al. (25, 26) but contrasts
7the report of Negro et al. (27), who showed that the
bovine homologue of the E200K mutation was not
detectable on the plasma membrane of neither
HeLa, CHO nor N2a cells. This could be explained
by the fact that we, as Lehmann et al. (25, 26), used
the mouse homologues of the human inheritable
diseases, while Negro et al. (27) studied the bovine
homologue of E200K. Therefore it is possible that
the difference in localization is linked to the different
strains used as recently reported for human PrPwt
(55).
Cholesterol-enriched membrane microdomains or
lipid rafts as well as the GPI anchor are believed to
be essential for PrP
C
 to PrP
Sc
 conversion, since
exchanging the GPI-anchor for a transmembrane
domain which prevents PrP
C
-raft association lead to
the block of PrP
Sc
 formation in infected cells (56). In
addition, reduction of the intracellular levels of
cholesterol, an integral compound of DRMs, also
reduces the amount of newly made PrP
Sc
 in infected
cells (13). Here we show that both mutants, E199K
and A116V, are correctly transported to the plasma
membrane and associate in different amounts to
DRMs, supporting the hypothesis that these
differences could be mutation-specific. Interestingly,
the percentage of the protein floating in the DRM-
fraction of sucrose gradients changed significantly
when each of the mutants was co-expressed with
PrPwt. In both co-expressing cell lines the floatation
of YFP-PrPwt as well as CFP-PrPmut was
increased when compared to the single-expressing
cell lines (Fig. 5C). The findings we describe here
are not caused by an additive effect of PrPwt and
PrPmut in the floating fraction because not only total
PrPwt was increased but also the PrPmut fraction
by itself, thus suggesting that co-expression of
PrPwt and PrPmut leads to their increased
sequestration in DRMs. Thus, although the wild-type
and mutant protein do not seem to interfere with the
metabolism and glycosylation of the other (Fig. 3
and 4), they appear to influence each others’
sequestration in subdomains of the plasma
membrane and might affect their reciprocal
localization. This hypothesis was confirmed by using
an additional mutant, PrPT182A, previously shown
to be blocked in the ER and in the cis-Golgi
apparatus (16, 19). Indeed, co-expression of this
mutant with PrPwt, lead to a specific increase of
PrPwt in DRMs but also to the intracellular retention
of PrPwt (Fig.6). Thus we hypothesize that the
increased sequestration in DRMs as well as the
delocalization might be a consequence of the
interaction between the wild-type and mutant forms
of PrP. This could also occur in the case of
heterozygous carriers of mutations and therefore be
involved in the pathogenesis and development of
the hereditary heterozygous form of the disease.
The role of DRMs in the pathology of TSEs is still
under debate, since it had been postulated that
DRMs represent a site responsible for pathological
conversion from PrP
C
 to PrP
Sc
 (11, 13, 56). On the
other hand we have shown that DRMs could fulfil
the exact opposite role, because impairment of
DRM-association by cholesterol-depletion
significantly increased the amount of misfolded PrP
C
as well as that of the mutant form PrPT182A (15,
16). This protective role of rafts is also supported by
the biochemical studies on membrane interaction of
PrP
C
 and PrP
Sc
 (rev. in (57)). The finding that
increased amounts of PrP
C
 and PrPmut in DRMs
only in double-expressing cells underlines the notion
that DRMs are an important site for pathological
conversion or protection thereof and needs to be
further investigated. Why the amounts of PrPwt and
PrPmut in DRMs increased when the two proteins
were co-expressed, remains unclear. However one
could imagine that their possible interaction could
trigger a signal of increased sequestration into
DRMs and therefore produce a disequilibrium in the
membrane. This anomaly in turn could lead to a
toxic effect specifically in neurons where PrP
C
exerts its function (rev. in (58)). Whether the
recruitment in lipid rafts and delocalization of PrP
C
leads either to an impairment of PrP
C
-function or to
the toxic accumulation of the misfolded form, and
how this contributes to the pathology in
heterozygous carriers of these mutations needs to
be further investigated.
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Figure Legends:
Figure 1: Biochemical characterization of YFP-
PrPwt, CFP-PrPA116V and CFP-PrPE199K
mutant forms
(A) FRT cells stably expressing either YFP-PrPwt,
CFP-PrPA116V or CFP-PrPE199K were lysed with
Lysis Buffer and upon normalization to total protein
content subjected to SDS/PAGE and western blot
using an !-PrP antibody recognizing a N-terminal
part of PrP (left panel) or an !-PrP antibody directed
against the C-terminal part of PrP (center panel) or
an !-3F4 antibody (right panel).
(B) FRT cells stably expressing either YFP-PrPwt,
CFP-PrPA116V or CFP-PrPE199K were lysed in
Triton/Doc Buffer and immunoprecipitated with an
antibody directed against the N-terminus of PrP.
Immunoprecipitates were incubated in the presence
or absence of N-Glycosidase F at 37°C as
described in Materials and Methods. Samples were
subjected to SDS/PAGE and WB and revealed by
!-PrP antibody directed against the N-terminal part
of PrP.
(C) FRT cells expressing either YFP-PrPwt, CFP-
PrPA116V or CFP-PrPE199K were grown in
100mm dishes to confluency, lysed with Triton/Doc
lysis buffer for 20' on ice and centrifuged as
described in Materials and Methods. The resulting
supernatant was divided from the pellet, and the
pellet was resuspended in Triton/Doc lysis buffer at
30°C. Both, supernatant and resuspended pellet
were subjected to SDS/PAGE and revealed by
8western blot with an anti-C terminal PrP antibody
(Fig. 1C, left panel). Blots were quantified by
ImageJ (n=3) (Fig. 1C, right panel).
Figure 2: Intracellular localization of YFP-PrPwt
or CFP-PrPA116V or CFP-PrPE199K in stably
transfected FRT cells
 (A-C) FRT cells stably expressing YFP-PrPwt
(Fig.2, left panel) or CFP-PrPA116V (Fig.2, center
panel) or CFP-PrPE199K (Fig.2, right panel) were
grown on cover slips, fixed with 2% PFA,
permeabilized with PBS/Gelatine (0,2%)/Saponin
(0,075%) and incubated with antibodies, directed
against proteins well established as intracellular
markers, or with LysoTracker, a dye staining
lysosomes. Upon mounting the cover slips were
assayed by Confocal Microscopy. Size bars are
10µm.
Figure 3: Biochemical characterization of FRT
cells co-expressing YFP-PrPwt and either of the
two mutants
FRT cells stably co-expressing either YFP-PrPwt
and CFP-PrPA116V (here referred to as 2XAV) or
YFP-PrPwt and CFP-PrPE199K (here referred to as
2XEK) were lysed with Lysis Buffer and upon
normalization to total protein content subjected to
SDS/PAGE and western blot with an !-PrP antibody
recognizing a N-terminal part of PrP (left panel),
with an ! -PrP antibody directed against the C-
terminal part of PrP (center panel) and with an !-
3F4 antibody (right panel).
Figure 4: YFP-PrPwt/CFP-PrPA116V or YFP-
PrPwt/CFP-PrPE199K colocalize in double
expressing cells
FRT cells stably co-expressing either YFP-PrPwt
and CFP-PrPA116V (Fig. 4A) or YFP-PrPwt and
CFP-PrPE199K (Fig. 4B) were grown on cover slips
fixed with 2% PFA permeabilized with PBS/Gelatine
(0,2%)/Saponin (0,075%) and incubated with
antibodies, directed against proteins well
established as intracellular markers, or with
LysoTracker, a dye staining lysosomes. Upon
mounting the cover slips were assayed by Confocal
Microscopy. Size bars are 10µm.
Figure 5: Characterization of DRM association of
YFP-PrPwt, CFP-PrPA116V and CFP-PrPE199K
in single and double expressing FRT cells.
(A) FRT cells expressing either YFP-PrPwt, CFP-
PrPA116V or CFP-PrPE199K were grown on
150mm dishes. Upon confluency, cells were lysed in
1% Triton X-100 and the cell lysates were run on a
two-step (5-30%) sucrose density gradient. After
centrifugation to equilibrium, twelve fractions were
collected from top to bottom. Upon SDS/PAGE and
western blot, YFP-PrPwt, CFP-PrPA116V or CFP-
PrPE199K were revealed by an antibody against the
C-terminal part of PrP (Fig. 5A upper part). In order
to assay the efficacy of the fractionation, a sample
of each fraction was hybridized on a Dot Spot with a
subunit of Cholera-Toxin linked to Peroxidase, a
molecule interacting strongly with GM-1 which is a
typical marker of DRMs. (Fig. 5A, bottom part).
(B) FRT cells co-expressing either YFP-PrPwt and
CFP-PrPA116V (here 2XAV) or YFP-PrPwt and
CFP-PrPE199K (here 2XEK) were grown on
150mm dishes. Upon confluency, cells were lysed in
1% Triton X-100 and the cell lysates were run on a
two-step (5-30%) sucrose density gradient. After
centrifugation to equilibrium, twelve fractions were
collected from top to bottom. Upon SDS/PAGE and
western blot, YFP-PrPwt, CFP-PrPA116V or CFP-
PrPE199K were revealed by an antibody against the
C-terminal part of PrP (termed PrP total), in parallel
the same amounts of each fraction were run and
revealed by the antibody 3F4, showing only the
amounts of PrPmut in the respective fraction
(termed PrP mutant only)
(B, lower panel) In order to assay the efficacy of the
fractionation, a sample of each fraction was
hybridized on a Dot Spot with a subunit of Cholera-
Toxin linked to Peroxidase, a molecule interacting
strongly with GM-1, which is a typical marker of
DRMs (lower panel).
(C) Blots of Sucrose-Two Step gradients were
quantified by ImageJ (n=3). Results of single
expressing cell-lines are depicted in black. Results
of double-expressing cell-lines are depicted in grey.
Figure 6: Co-expression of YFP-PrPwt and CFP-
PrPT182A in FRT cells leads to partial retention
of YFP-PrPwt in the ER and increases the
amount of YFP-PrPwt in DRMs.
(A) (upper panel) Confocal image of FRT cells co-
expressing YFP-PrPwt and CFP-PrPT182A. Shown
is a clone, expressing YFP-PrPwt in 100% of cells
but which had partially lost expression of CFP-
PrPT182A (in the center of image). Note that while
in the cells expressing only PrPwt, the majority of
the protein is on the plasma membrane (central part
of left panel), in the cells expressing both wild-type
and mutant form, PrPwt is retained intracellularly
and colocalizes extensively with the mutant
(highlighted in lower set of panels) suggesting that
the interaction with CFP-PrPT182A leads to a partial
intracellular retention of YFP-PrPwt. Size bar is
10µm. A magnification of rectangle from upper row
is shown in the lower panel. Complete colocalization
between YFP-PrPwt and CFP-PrPT182A was
observed.
(B, two upper blots) Sucrose Density Gradients of
cells expressing either YFP-PrPwt or CFP-
PrPT182A. Treatment of cells as described in
Figure 5A.
(B, two lower blots) Sucrose Density Gradients of
cells co-expressing YFP-PrPwt and CFP-PrPT182A
(here 2XTA). PrPwt and PrPmut were revealed by
an antibody against the C-terminal part of PrP (blot
termed PrP total), in parallel the same amounts of
each fraction were run and revealed by the antibody
3F4, showing only the amounts of PrPmut in the
respective fraction (termed PrP mutant only).
Figure S1: The majority of PrPwt and PrPmut are
expressed as fluorophore-linked, chimeric
proteins
9(A) FRT cells stably expressing either YFP-PrPwt or
CFP-PrPA116V or CFP-PrPE199K were lysed in
Triton/Doc Buffer and immunoprecipitated overnight
(ON) with an !-GFP antibody. Immunoprecipitates
were subjected to SDS/PAGE and revealed by
western blot using an !-PrP antibody against the N-
terminal part of PrP (left panel), the C-terminal part
of PrP (center panel) or with an !-GFP antibody
(right panel).
(B) FRT cells stably expressing either YFP-PrPwt
(left panel) or CFP-PrPA116V (center panel) or
CFP-PrPE199K (right panel) were grown on cover
slips, fixed with 2% PFA, permeabilized with
PBS/Gelatine (0,2%)/Saponin (0,075%) and
incubated with antibodies against the N-terminal
part of PrP (upper panel), the C-terminal part of PrP
(center panel) and with an !-GFP antibody (lower
panel). Size bars are 10µm.
Figure S2: YFP-PrPwt, CFP-PrPA116V and CFP-
PrPE199K are strongly localizing to the
basolateral membrane in single- and double
expressing polarized FRT cells
(A) FRT cells stably expressing YFP-PrPwt, CFP-
PrPA116V and CFP-PrPE199K or the combination
of YFP-PrPwt with one of the mutants were grown
on Transwell filters for 4 days. Upon measuring of
the transepithelial resistance, filters were either
treated with biotin from the apical or basolateral side
for two times 25'. After extensive washings, cells
were lysed and immunoprecipitated ON at 4°C with
an antibody against the C-term part of PrP or in the
case of the double-expressing cells, when assayed
for PrPmut,  wi th an ! -3F4 ant ibody.
Immunoprecipitates were subjected to SDS/PAGE,
protein bands were revealed with Streptavidin-
Peroxidase (Fig. S2A).
(B) Blots (n=3) were quantified by ImageJ. Results
from single expressing cell-lines are depicted in
black, double expressing cell-lines are depicted in
grey (Fig. S2B).
Sources:
1. Collinge J. Human prion diseases and
bovine spongiform encephalopathy (BSE). Hum Mol
Genet 1997;6(10):1699-1705.
2. Prusiner SB. Prions. Proc Natl Acad Sci U
S A 1998;95(23):13363-13383.
3. Ford MJ, Burton LJ, Morris RJ, Hall SM.
Selective expression of prion protein in peripheral
tissues of the adult mouse. Neuroscience
2002;113(1):177-192.
4. Kitamoto T, Muramoto T, Mohri S, Doh-Ura
K, Tateishi J. Abnormal isoform of prion protein
accumulates in follicular dendritic cells in mice with
Creu t z fe l d t - Jakob  d i sease .  J  V i r o l
1991;65(11):6292-6295.
5. Prusiner S. Prion Biology and Diseases.
2nd ed. New York: Cold Spring Harbor Laboratory
Press; 2004.
6. Meyer RK, McKinley MP, Bowman KA,
Braunfeld MB, Barry RA, Prusiner SB. Separation
and properties of cellular and scrapie prion proteins.
Proc Natl Acad Sci U S A 1986;83(8):2310-2314.
7. Prusiner SB. Prion diseases and the BSE
crisis. Science 1997;278(5336):245-251.
8. Pan KM, Baldwin M, Nguyen J, Gasset M,
Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick
RJ, Cohen FE, et al. Conversion of alpha-helices
into beta-sheets features in the formation of the
scrapie prion proteins. Proc Natl Acad Sci U S A
1993;90(23):10962-10966.
9. Campana V, Sarnataro D, Zurzolo C. The
highways and byways of prion protein trafficking.
Trends Cell Biol 2005;15(2):102-111.
10. Naslavsky N, Stein R, Yanai A, Friedlander
G, Taraboulos A. Characterization of detergent-
insoluble complexes containing the cellular prion
protein and its scrapie isoform. J Biol Chem
1997;272(10):6324-6331.
11. Vey M, Pilkuhn S, Wille H, Nixon R,
DeArmond SJ, Smart EJ, Anderson RG, Taraboulos
A, Prusiner SB. Subcellular colocalization of the
cellular and scrapie prion proteins in caveolae-like
membranous domains. Proc Natl Acad Sci U S A
1996;93(25):14945-14949.
12. Baron GS, Wehrly K, Dorward DW,
Chesebro B, Caughey B. Conversion of raft
associated prion protein to the protease-resistant
state requires insertion of PrP-res (PrP(Sc)) into
contiguous membranes. Embo J 2002;21(5):1031-
1040.
13. Taraboulos A, Scott M, Semenov A,
Avrahami D, Laszlo L, Prusiner SB. Cholesterol
depletion and modification of COOH-terminal
targeting sequence of the prion protein inhibit
formation of the scrapie isoform. J Cell Biol
1995;129(1):121-132.
14. Naslavsky N, Shmeeda H, Friedlander G,
Yanai A, Futerman AH, Barenholz Y, Taraboulos A.
Sphingolipid depletion increases formation of the
scrapie prion protein in neuroblastoma cells infected
with prions. J Biol Chem 1999;274(30):20763-
20771.
15. Sarnataro D, Campana V, Paladino S,
Stornaiuolo M, Nitsch L, Zurzolo C. PrP(C)
association with lipid rafts in the early secretory
pathway stabilizes its cellular conformation. Mol Biol
Cell 2004;15(9):4031-4042.
16. Campana V, Sarnataro D, Fasano C,
Casanova P, Paladino S, Zurzolo C. Detergent-
resistant membrane domains but not the
proteasome are involved in the misfolding of a PrP
mutant retained in the endoplasmic reticulum. J Cell
Sci 2006;119(Pt 3):433-442.
17. Harris DA. Trafficking, turnover and
membrane topology of PrP. Br Med Bull
2003;66:71-85.
18. Nitrini R, Rosemberg S, Passos-Bueno
MR, da Silva LS, Iughetti P, Papadopoulos M,
Carrilho PM, Caramelli P, Albrecht S, Zatz M,
LeBlanc A. Familial spongiform encephalopathy
associated with a novel prion protein gene mutation.
Ann Neurol 1997;42(2):138-146.
19. Lehmann S, Harris DA. Blockade of
glycosylation promotes acquisition of scrapie-like
properties by the prion protein in cultured cells. J
Biol Chem 1997;272(34):21479-21487.
20. Goldfarb LG, Brown P, Mitrova E,
Cervenakova L, Goldin L, Korczyn AD, Chapman J,
Galvez S, Cartier L, Rubenstein R, et al.
10
Creutzfeldt-Jacob disease associated with the
PRNP codon 200Lys mutation: an analysis of 45
families. Eur J Epidemiol 1991;7(5):477-486.
21. Hegde RS, Mastrianni JA, Scott MR,
DeFea KA, Tremblay P, Torchia M, DeArmond SJ,
Prusiner SB, Lingappa VR. A transmembrane form
of the prion protein in neurodegenerative disease.
Science 1998;279(5352):827-834.
22. Hsiao K, Meiner Z, Kahana E, Cass C,
Kahana I, Avrahami D, Scarlato G, Abramsky O,
Prusiner SB, Gabizon R. Mutation of the prion
protein in Libyan Jews with Creutzfeldt-Jakob
disease. N Engl J Med 1991;324(16):1091-1097.
23. Tateishi J, Kitamoto T, Doh-ura K, Sakaki
Y, Steinmetz G, Tranchant C, Warter JM, Heldt N.
Immunochemical, molecular genetic, and
transmission studies on a case of Gerstmann-
Straussler-Scheinker syndrome. Neurology
1990;40(10):1578-1581.
24. Capellari S, Parchi P, Russo CM, Sanford
J, Sy MS, Gambetti P, Petersen RB. Effect of the
E200K mutation on prion protein metabolism.
Comparative study of a cell model and human brain.
Am J Pathol 2000;157(2):613-622.
25. Lehmann S, Harris DA. Two mutant prion
proteins expressed in cultured cells acquire
biochemical properties reminiscent of the scrapie
isoform. Proc Natl Acad Sci U S A
1996;93(11):5610-5614.
26. Lehmann S, Harris DA. Mutant and
infectious prion proteins display common
biochemical properties in cultured cells. J Biol Chem
1996;271(3):1633-1637.
27. Negro A, Ballarin C, Bertoli A, Massimino
ML, Sorgato MC. The metabolism and imaging in
live cells of the bovine prion protein in its native form
or carrying single amino acid substitutions. Mol Cell
Neurosci 2001;17(3):521-538.
28. Rosenmann H, Talmor G, Halimi M, Yanai
A, Gabizon R, Meiner Z. Prion protein with an
E200K mutation displays properties similar to those
of the cellular isoform PrP(C). J Neurochem
2001;76(6):1654-1662.
29. Kovacs GG, Ertsey C, Majtenyi C,
Jelencsik I, Laszlo L, Flicker H, Strain L, Szirmai I,
Budka H. Inherited prion disease with A117V
mutation of the prion protein gene: a novel
Hungarian family. J Neurol Neurosurg Psychiatry
2001;70(6):802-805.
30. Piccardo P, Dlouhy SR, Lievens PM,
Young K, Bird TD, Nochlin D, Dickson DW, Vinters
HV, Zimmerman TR, Mackenzie IR, Kish SJ, Ang
LC, De Carli C, Pocchiari M, Brown P, et al.
Phenotypic variability of Gerstmann-Straussler-
Scheinker disease is associated with prion protein
heterogeneity. J Neuropathol Exp Neurol
1998;57(10):979-988.
31. Simon ES, Kahana E, Chapman J, Treves
TA, Gabizon R, Rosenmann H, Zilber N, Korczyn
AD. Creutzfeldt-Jakob disease profile in patients
homozygous for the PRNP E200K mutation. Ann
Neurol 2000;47(2):257-260.
32. Sarnataro D, Paladino S, Campana V,
Grassi J, Nitsch L, Zurzolo C. PrPC is sorted to the
basolateral membrane of epithelial cells
independently of its association with rafts. Traffic
2002;3(11):810-821.
33. Zurzolo C, Lisanti MP, Caras IW, Nitsch L,
Rodriguez-Boulan E. Glycosylphosphatidylinositol-
anchored proteins are preferentially targeted to the
basolateral surface in Fischer rat thyroid epithelial
cells. J Cell Biol 1993;121(5):1031-1039.
34. Brown DA, Rose JK. Sorting of GPI-
anchored proteins to glycolipid-enriched membrane
subdomains during transport to the apical cell
surface. Cell 1992;68(3):533-544.
35. Zurzolo C, van't Hof W, van Meer G,
Rodr iguez -Bou lan  E .  V IP21 /caveo l i n ,
glycosphingolipid clusters and the sorting of
glycosylphosphatidylinositol-anchored proteins in
epithelial cells. Embo J 1994;13(1):42-53.
36. Daude N, Lehmann S, Harris DA.
Identification of intermediate steps in the conversion
of a mutant prion protein to a scrapie-like form in
cultured cells. J Biol Chem 1997;272(17):11604-
11612.
37. Morel E, Fouquet S, Chateau D, Yvernault
L, Frobert Y, Pincon-Raymond M, Chambaz J, Pillot
T, Rousset M. The cellular prion protein PrPc is
expressed in human enterocytes in cell-cell
junctional domains. J Biol Chem 2004;279(2):1499-
1505.
38. Campana V, Caputo A, Sarnataro D,
Paladino S, Tivodar S, Zurzolo C. Characterization
of the properties and trafficking of an anchorless
form of the prion protein. J Biol Chem 2007.
39. Lehmann S, Harris DA. A mutant prion
protein displays an aberrant membrane association
when expressed in cultured cells. J Biol Chem
1995;270(41):24589-24597.
40. Bolton DC, Seligman SJ, Bablanian G,
Windsor D, Scala LJ, Kim KS, Chen CM, Kascsak
RJ, Bendheim PE. Molecular location of a species-
specific epitope on the hamster scrapie agent
protein. J Virol 1991;65(7):3667-3675.
41. Kascsak RJ, Rubenstein R, Merz PA,
Tonna-DeMasi M, Fersko R, Carp RI, Wisniewski
HM, Diringer H. Mouse polyclonal and monoclonal
antibody to scrapie-associated fibril proteins. J Virol
1987;61(12):3688-3693.
42. Chen SG, Teplow DB, Parchi P, Teller JK,
Gambetti P, Autilio-Gambetti L. Truncated forms of
the human prion protein in normal brain and in prion
diseases. J Biol Chem 1995;270(32):19173-19180.
43. Mishra RS, Gu Y, Bose S, Verghese S,
Kalepu S, Singh N. Cell surface accumulation of a
truncated transmembrane prion protein in
Gerstmann-Straussler-Scheinker disease P102L. J
Biol Chem 2002;277(27):24554-24561.
44. Shyng SL, Huber MT, Harris DA. A prion
protein cycles between the cell surface and an
endocytic compartment in cultured neuroblastoma
cells. J Biol Chem 1993;268(21):15922-15928.
45. Caughey B, Raymond GJ, Ernst D, Race
RE. N-terminal truncation of the scrapie-associated
form of PrP by lysosomal protease(s): implications
regarding the site of conversion of PrP to the
protease-resistant state. J Virol 1991;65(12):6597-
6603.
46. McKinley MP, Meyer RK, Kenaga L,
Rahbar F, Cotter R, Serban A, Prusiner SB. Scrapie
prion rod formation in vitro requires both detergent
extraction and limited proteolysis. J Virol
1991;65(3):1340-1351.
11
47. Hugel B, Martinez MC, Kunzelmann C,
Blattler T, Aguzzi A, Freyssinet JM. Modulation of
signal transduction through the cellular prion protein
is linked to its incorporation in lipid rafts. Cell Mol
Life Sci 2004;61(23):2998-3007.
48. Russelakis-Carneiro M, Hetz C, Maundrell
K, Soto C. Prion replication alters the distribution of
synaptophysin and caveolin 1 in neuronal lipid rafts.
Am J Pathol 2004;165(5):1839-1848.
49. Parchi P, Gambetti P. Human prion
diseases. Curr Opin Neurol 1995;8(4):286-293.
50. Prusiner SB, Hsiao KK. Human prion
diseases. Ann Neurol 1994;35(4):385-395.
51. Kovacs GG, Laszlo L, Bakos A, Minarovits
J, Bishop MT, Strobel T, Vajna B, Mitrova E,
Majtenyi K. Increased incidence of genetic human
prion disease in Hungary.  Neurology
2005;65(10):1666-1669.
52. Mitrova E, Belay G. Creutzfeldt-Jakob
disease with E200K mutation in Slovakia:
characterization and development. Acta Virol
2002;46(1):31-39.
53. Miyakawa T, Inoue K, Iseki E, Kawanishi C,
Sugiyama N, Onishi H, Yamada Y, Suzuki K,
Iwabuchi K, Kosaka K. Japanese Creutzfeldt-Jakob
disease patients exhibiting high incidence of the
E200K PRNP mutation and located in the basin of a
river. Neurol Res 1998;20(8):684-688.
54. Lehmann S, Daude N, Harris DA. A wild-
type prion protein does not acquire properties of the
scrapie isoform when coexpressed with a mutant
prion protein in cultured cells. Brain Res Mol Brain
Res 1997;52(1):139-145.
55. De Keukeleire B, Donadio S, Micoud J,
Lechardeur D, Benharouga M. Human cellular prion
protein hPrPC is sorted to the apical membrane of
epithelial cells. Biochem Biophys Res Commun
2007;354(4):949-954.
56. Kaneko K, Vey M, Scott M, Pilkuhn S,
Cohen FE, Prusiner SB. COOH-terminal sequence
of the cellular prion protein directs subcellular
trafficking and controls conversion into the scrapie
isoform. Proc Natl Acad Sci U S A 1997;94(6):2333-
2338.
57. Pinheiro TJ. The role of rafts in the
fibrillization and aggregation of prions. Chem Phys
Lipids 2006;141(1-2):66-71.
58. Caughey B, Baron GS. Prions and their
partners in crime. Nature 2006;443(7113):803-810.










109
V.1.5: Additional data requested by the reviewers
The reviewers chosen by the journal “Traffic” reacted overall positively on the
manuscript presented above. However, a few additional questions and controls were
asked, which I was able to cover and are shown here:
1) DRM-sequestration in the case of FRT-cells co-expressing two wild-type proteins.
As described in detail above, co-expression of YFP-PrPwt and a mutant form linked to
CFP (A116V, E199K, T183A) lead to a significant increase of PrPwt and PrPmut in
DRMs. To rule out the possibility that this is as an unspecific effect of overexpression
of two proteins and to show that this increase is mutant-specific we transfected the
YFP-PrPwt single-expressing cells with a CFP-PrPwt-construct (containing the 3F4-
tag) and performed a floatation assay (see Materials and Methods in Manuscript I).
Quantification of DRM-association from Western blots utilizing antibodies recognizing
either total PrP (black bar in quantification below, 40%±8) or only the 3F4-tag of CFP-
PrPwt (grey bar in quantification below, 39±5) showed both to be associated to DRMs
with similar amounts, as also seen for single-expressed YFP-PrPwt (35%±11). This let
us conclude that there is no increase in DRM-association, when two wild-type forms are
co-expressed and also suggests that the changes in DRM-sequestration, as observed in
cells co-expressing YFP-PrPwt and CFP-PrPmut, are probably mutant-specific. This
supports our hypothesis that the changes in DRM-association, as found with co-
expressed wild-type and mutant, might be relevant for pathology in heterozygous
carriers.
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Fig. 35: Co-expression of two wild-type forms, YFP-PrPwt and CFP-PrPwt (containing a 3F4-tag)
does not lead to an increased sequestration of PrP-proteins in DRMs. (above) Cells co-expressing
YFP-PrPwt and CFP-PrPwt (with 3F4-tag) were run on a discontinuous sucrose gradient after extraction
in cold detergents and revealed by Western Blot with antibodies recognizing both wild-type forms
(termed 2Xwt-PrP total) or only the 3F4-tagged CFP-PrPwt (termed 2Xwt--3F4-tag only). (below)
Quantification of amounts of protein associated to DRMs shows no difference between the total amount
of PrPwt (black bar) and the co-expressed CFP-PrPwt (grey bar).
2) Analysis of lipids co-immunoprecipitating with PrP-proteins
Another comment of the reviewers was related to the nature of the DRMs in which
PrPwt and PrPmut resided; specifically whether these lipid domains were the same or of
different kinds. To answer this question we purified DRMs by sucrose density gradients
from cells expressing different PrP-proteins (as specified in Fig. 36 below) from which
the different PrP-isoforms were immunoprecipitated. The lipids, which co-
immunoprecipitated with the different proteins of interest, were then subjected to
analysis by high-performance thin layer chromatography (HPTLC) (for detailed
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Materials and Methods see below). As shown in Fig. 36, we could not find any
significant qualitative or quantitative difference in lipids co-immunoprecipitating with
the proteins, suggesting that the proteins most probably occupy the same lipid domains
in cells.
Fig. 36: Analysis of lipds associated with different PrP-forms in detergent resistant membranes
(DRMs). Cells expressing the different PrP-proteins (see graph) were subjected to sucrose density
gradients. Proteins of interest were immunoprecipitated from the DRMs-fraction and co-
immunoprecipitated lipids were analyzed by high-performance thin layer chromatography (HPTLC).
Quantification of lipids associated to different proteins shows no significant quantitative or qualitative
difference.
The following is the detailed description of Material and Methods, as used for this
experiment (see also (Tivodar et al., 2006).
Sucrose density gradients
Cells that had just reached confluency in 150-mm dishes were subject to
ultracentrifugation on discontinuous sucrose gradients as previously described (Prinetti
et al., 2000). Briefly, cells harvested in PBS containing 0.4 mM Na3VO4 were
suspended in 1 ml lysis buffer (1% TX-100, 10 mM Tris buffer, pH 7.5, 150 mM NaCl,
5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF and 75 mU/ml aprotinin), allowed to stand
on ice for 20 min and homogenized. Post-nuclear supernatants (~ 8 mg proteins) were
mixed with an equal volume of 85% sucrose (w/vol) in 10 mM Tris buffer pH 7.5, 150
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mM NaCl, 5 mM EDTA, 1 mM Na3VO4, placed at the bottom of a discontinuous
sucrose gradient (30–5%) in the same buffer and centrifuged at 200,000 g for 17 hrs at
4°C. After ultracentrifugation, eleven 1 ml fractions were collected starting from the top
of the tube. Fraction 5 located at the interface between 5 and 30% sucrose was regarded
as the sphingolipid-enriched membrane fraction. The bottom fraction (fraction 11)
contained a pellet, which was carefully homogenized before analysis.
Immunoprecipitation
Aliquots of fraction 5 (800 ml) diluted with 200 µl lysis buffer (5% TX-100, 10 mM
Tris buffer pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF and 75
mU/ml aprotinin) were precleared twice with dynabeads for 2 hrs and incubated
overnight at 4°C with anti-PrP (Saf32) antibodies. Immunoprecipitates were recovered
using protein G-coupled magnetic beads
After washing 3 times with lysis buffer, lipids were extracted from the
immunoprecipitates and analyzed as described above and SDS-sample buffer was added
to the beads. 1/5 of the samples were analyzed by SDS-PAGE (not shown).
Analysis of lipids
The sucrose gradient fractions obtained were analyzed for content of lipids. Samples
were dialyzed and lyophilized, and lipids were extracted twice with 0.4 ml
chloroform/methanol 2:1 (v/v) (Riboni et al., 1992). Cholesterol was separated by
monodimensional high-performance thin layer chromatography (HPTLC) using the
solvent system hexane/diethylether/acetic acid, 80:20:1 (v/v/v) and quantified after
separation on HPTLC followed by visualization with 15% concentrated sulphuric acid
in 1-butanol. Phosphatidylcholine was separated by a two-run monodimensional
HPTLC using the solvent system chloroform/methanol 9:1 (v/v), followed by the
solvent system chloroform/methanol/acetic acid/water 30:20:2:1 (v/v/v/v) and
quantified after separation on HPTLC followed by specific detection with a molybdate
reagent. The quantity of cholesterol and phosphatidylcholine were determined by
densitometry and comparison with known amounts of standard lipids using the
Molecular Analyst program (Bio-Rad Laboratories).
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3) Interaction of co-expressed PrP-isoforms tested by Fluorescence resonance energy
transfer (FRET)
As a next question the reviewers asked whether co-expressed wild-type and mutant
proteins were in close enough proximity so that the mutant could modifiy the
conformation of the wild-type form. They proposed to test this by performing
Fluorescence resonance energy transfer (FRET)-experiments. Energy transfer by FRET
occurs only when fluorophores are in close proximity (3-10 nm) (reviewed in
(Kenworthy and Edidin, 1998)). Positive information obtained by this technique may
give important clues as to whether and where wild-type protein and its pathogenic
homologue are close enough to allow malconformation of the former by the latter and
possibly to reciprocally influence their function. To answer this question we cultured
FRT-cells expressing the proteins of interest on coverslips. After fixation in
paraformaldehyde (2%) cells were mounted in PBS/Glycerol (1:1) and assessed for
FRET by photobleaching of the acceptor (for description of the technique see
(Kenworthy and Edidin, 1998)) on a SP 5 Leica-confocal microscope (Leica, Germany)
utilizing the supplied software. The results of the measurements (n!15 for each) are
shown in Fig. 37 below. Cell lines co-expressing YFP-PrPwt and each of the CFP-
linked mutants (A116V (termed 2XAV), E199K (termed 2XEK), T182A (termed
2XAT)) presented intracellularly the same FRET-efficiency as the positive control co-
expressing two wild-type forms (YFP-PrPwt and CFP-PrPwt, termed 2Xwt). This
suggests that wild-type and mutant molecules are in close proximity at the level of the
Golgi-apparatus. When FRET-efficiency was measured on the plasma membrane, cells
co-expressing YFP-PrPwt and CFP-PrPE199K (2XEK) showed comparable efficiencies
as the positive control (2Xwt). Interestingly, the cells co-expressing YFP-PrPwt and
CFP-PrPA116V (2XAV) showed a somewhat diminished FRET-efficiency, which
suggests that these two molecules interact more closely intracellularly and less once
arrived on the plasma membrane. As expected, cells expressing CFP-PrPA116V only,
serving here as a negative control, showed only a minimal amount of FRET-efficiency.
We are currently reproducing these data to have better statistical validity. However it
seems to be clear that for all analyzed mutants there is a close interaction with the wild-
type form on the plasma membrane as well as intracellularly, thus supporting our
hypothesis.
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Fig. 37: FRET-efficiency measurements shows that wild-type and mutant PrP-forms are in close
proximity. FRT-cells expressing different constructs were grown on coverslips, fixed and assayed for
FRET-efficiency. FRT-cells co-expressing two wild-type forms (YFP-PrPwt, CFP-PrPwt, termed 2Xwt)
served as positive control, while cells expressing CFP-PrPA116V only were utilized as negative control.
Quantification shows that cells co-expressing YFP-PrPwt and either of the CFP-linked mutants (A116V
(termed 2XAV), E199K (termed 2XEK), T182A (termed 2XAT)) presented FRET-efficiencies as high as
the positive control in the Golgi-apparatus. On the plasma membrane, 2XAV presented somewhat
diminished FRET-efficiencies when compared to 2Xwt.
4) Colocalization studies of mutants not linked to CFP-fluorophores in FRT-cells.
As a last question the reviewers wanted us to test whether the attachment of
fluorophores affects the trafficking of the mutant proteins. To answer this question we
transfected FRT-cells with the plasmids encoding only for murine PrP, hosting the
alanine to valine change at position 116 and the glutamate to lysine change at position
199. Cells expressing either PrP-A116V or PrP-E199K were grown on coverslips and
fixed with PFA (2%), then incubated with an antibody directed against the N-terminal
part of the PrP-protein and antibodies directed against various organelle markers
(calnexin in the case of the endoplasmatic reticulum, Giantin for cis- and medial Golgi
and LysoTracker for lysosomes) (see Materials and Methods of Manuscript I). Image
acquisition and analysis was performed by confocal microscopy (Zeiss LSM 510). As
shown in Fig. 38, the PrPmut-proteins behaved just as their fluorophore-attached
counterparts (see Manuscript I), colocalizing with Giantin and also localized to the
plasma membrane. This was also consistent with the previously published data for the
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PrP-T182A mutant (Campana et al., 2006; Sarnataro et al., 2004). This suggests that the
attachment of the CFP-fluorophore does not affect their intracellular trafficking.
Fig. 38: Colococalization studies for the mutants PrP-A116V and PrP-E199K. Immunofluorescence
and confocal microscopy on fixed cells, expressing the non-CFP-attached forms of the PrP-mutants
A116V and E199K, shows colocalization with the utilized Golgi-marker (Giantin) and deposition on the
plasma membrane.
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V.2: Manuscript 2
This manuscript has been submitted to the journal Science and is currently under
revision.
V.2.1: General introduction
In the second part of my thesis I focused on the acquired forms of prion-diseases,
specifically on the question of how prions are transmitted from cell to cell and which
cells could be involved in the process of transmission of the disease from the periphery
to the central nervous system. As described in chapter III.15, the most common route of
infection with exogenous prions is by oral uptake of contaminated foodstuffs. Based on
results from in vivo and in vitro studies, the common belief is that the entrance into the
affected organisms occurs by a transcytotic mechanism by microfold cells (M cells) of
the intestinal system (Heppner et al., 2001). By inspecting samples from animals,
sacrificed at various times post oral exposure, researchers found that prions radiated
away from the intestinal entry site and infected adjacent secondary lymphoid organs
within days to weeks prior to neuronal invasion (Bruce, 1985; Bueler et al., 1993;
Rubenstein et al., 1991). Due to their first appearance in lymphoid organs, it was
hypothesized that cells of the immune system might play a role in the spread of prions
throughout the organism and as of late numerous immune cell types, such as
macrophages, B cells and dendritic cells (DCs) have been implicated in this process (see
III.15.2 and references therein). Follicular dendritic cells (FDCs) have also been
proposed to be involved in prion diseases, however their role remains enigmatic
(III.15.2.4). Specifically, the spleen received much attention in prion diseases and early
works have already emphasized its role in acquired prion diseases (Clarke and Haig,
1971). Lately, the gut associated lymphatic tissue (GALT) has received increased
attention from researchers and is now considered to be the first site of prion
accumulation following oral inoculation (Glaysher and Mabbott, 2007). A common trait
of the spleen and GALT is their strong innervation by the peripheral nervous system
(III.15.1); their role as access points for prions to the central nervous system (CNS) is
uncontested. The sympathetic nervous system (SNS) is believed to play a decisive role
in handing prions from an unspecified immune system cell to the CNS, since it was
shown that sympathectomy prior to or just after oral prion challenge significantly
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delayed the progression of the disease, while splenic hyperinnervation significantly
reduced the peripheral incubation period and lead to a more rapid invasion of the CNS
(Clarke and Haig, 1971; Glatzel et al., 2001). As described in detail in III.15.2 evidence
suggests that the immune cells transferring prions from their entry site to the secondary
lymphoid organ must be mobile and should not destroy sampled antigens. This would
explain the radiation of prions from the intestinal entry site and their still active
infectivity after transportation to the secondary lymphoid organs. Additionally these
immune system cells should interact closely with the peripheral nervous system in order
to allow the transfer of prions from the immune system cell to the peripheral nervous
system (Beekes and McBride, 2007).
These prerequisites make dendritic cells (DCs) a suitable candidate, because they are
highly mobile and because they do not necessarily destroy sampled antigens, as shown
for PrPSc (Huang et al., 2002). In addition these cells are in close interaction with the
peripheral nervous system (Aucouturier et al., 2001; Defaweux et al., 2005; Dorban et
al., 2007) and could therefore allow intercellular transfer by an unknown mechanism
(see paragraph III.15.2.5).
Until now a variety of mechanisms for intercellular transfer have been suggested:
GPI-painting, an ill-understood process, in which GPI-anchored proteins transfer from
the plasma membrane of one cell to another cell has been shown for PrPC (Liu et al.,
2002). Since PrPSc, like PrPC, contains a GPI-anchor (Stahl et al., 1987), one could
envision that this also occurs for the pathogenic form.
Another possibility for intercellular prion transfer is via exosomes (see paragraph
III.15.3.1). These vesicular structures with a diameter of 30 to 100 nm are derived from
multivesicular endosomes, contain cell-derived proteins and are excreted by a number
of cell-types such as DCs, lymphocytes, mast cells, platelets and epithelial cells (Thery
et al., 2002). Additionally, they have been shown to contain PrPSc and are able to infect
animals when inoculated intracerebrally in enriched amounts (Fevrier and Raposo,
2004). As mentioned above, DCs were shown to excrete high amounts of exosomes and
emphasizes once more the potential role of these cells in transferring prions to the
peripheral nervous system. However it must also be stressed that although Fevrier et al.
proposed exosomes to be a means of intercellular transfer of prions, they only showed
this in an indirect way by inoculating animals intracerbrally with enriched preparations
of exosomes.
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Another intriguing possibility for how prions might transfer intercellularly is via the
recently described tunneling nanotubes (TNTs) (Onfelt et al., 2006; Onfelt et al., 2004;
Rustom et al., 2004). These structures are described in depth in paragraph III.16, where
I also discuss why TNTs could be another (not necessarily exclusive) means by which
prions could transfer intercellularly. Here as an overview the arguments that speak in
favour of TNTs as a means for intercellular transfer of prions:
i) GPI-anchored proteins and endosomal-derived organelles can transfer intercellularly
via TNTs, which makes these structures very interesting for the prion-field, since PrPSc
retains its GPI-anchor (Stahl et al., 1987)  and is also found in endosomal structures,
such as lysosomes and endosomes (Peters et al., 2003; Shyng et al., 1993).
ii) TNTs connect cells of different origin and DCs are particularly apt at producing
these structures, allowing quick intercellular transfer (Watkins and Salter, 2005).
iii) TNTs may also be produced in vivo, since structures resembling TNTs, termed
cytonemes, were described in ex vivo preparations from Drosophila melanogaster
(Hsiung et al., 2005; Ramirez-Weber and Kornberg, 1999).
V.2.2: Objectives
Due to the reasons stated above I believe that TNTs, possibly involving dendritic cells
as one of the participating cell-types, could be a means by which prions could transfer
from cell to cell. TNTs, supposedly used by cells as a novel means for cell-cell
communication, are very fine and dynamic structures and therefore require a
microscopy-based approach in fixed, ideally in living cells for their study. We decided
to first work with HEK 293 cells, since these were reported to produce TNTs (Rustom
et al., 2004). We reasoned that this robust immortalized cell line would allow us to set
up the appropiate conditions for studying these structures, since the study of living cells
is a non-trivial approach and requires fine-tuning. Once protocols and techniques were
established we switched to an immortalized neuronal cell-line more relevant to prion
pathology. For this part of my studies we decided to work with CAD-cells, a murine
cell line of catecholaminergic origin (Qi et al., 1997). These cells were reported to
produce structures reminiscent of TNTs (Li et al., 2007b). Additionally this cell-line is
easily transfectable with plasmids and infectable with prions (personal communication
from H. Laude). Thus we used a CAD-cell line, chronically infected with the scrapie
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strain 139A (scCAD) (kind gift from H. Laude), which allowed us to advance our
studies more rapidly. The undoubtedly most ambitious part in this work was to
understand the in vivo relevance of the data we had obtained in vitro. For this we set up
the coculture of primary cell lines of different origins and tested whether the cells would
produce TNTs and whether PrPSc would transfer between them via these structures. For
the reasons stated in the introduction and in paragraph III.15.2.5, we considered the
interaction of dendritic cells with neurons to be the most interesting scenario. For these
experiments several techniques and protocols had to be established in the laboratory.
The culture of murine bone-marrow derived dendritic cells (BMDCs) and the culture of
murine hippocampal neurons was established. These cells were then cocultured in order
to simulate the neuro-immune interaction in vitro. In order to be able to distinguish the
neurons by fluorescent microscopy we transduced them with a retroviral system coding
for green fluorescent protein (GFP) linked to murine wild-type PrP (GFP-PrPwt) that
was engineered in the laboratory. Traditional microscopic studies of PrPSc required up to
today fixation of cells and treatment with harsh chaotropic agents to reveal PrPSc-
specific epitopes (Taraboulos et al., 1990). In order to study PrPSc-transfer in living
cells, we decided therefore to purify PrPSc from the brains of terminally ill mice and
directly link this to Alexa-fluorophores by adapting a previously published protocol
(Magalhaes et al., 2005).
Utilizing the cell-systems and protocols described above we then were able to test the
hypothesis that TNTs are responsible for intercellular PrPSc-transfer.
V.2.3: Results
In order to determine whether we could observe tunneling nanotubes (TNTs) between
different cells, we transfected HEK 293 cells with GFP-PrPwt and cocultured these with
an unlabelled cell population. After fixation and immunofluorescent staining for various
cytoskeletal proteins (see below), we proceeded to confocal microscopy. Indeed, we
found tubes containing GFP-PrPwt connecting cells of the two populations, thereby
excluding incomplete cytokinesis of daughter cells. A hallmark of TNTs is that they are
not attached to the substratum (Rustom et al., 2004). X-Z reconstructions of cells
showed in our case that connections hovered freely in the cell medium without contact
to the substratum (see also movie S1 on CD). Additionally, as reported previously
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(Onfelt et al., 2006), we also observed cytoskeletal heterogeneity based on the diameter
of TNTs. In thicker TNTs (diameter 500-700nm) we observed positive staining for
filamentous actin (F-actin) and tubulin, while thinner connections (diameter
approximately 300nm) contained F-actin but little or no tubulin. These initial findings
lead us to conclude that we were indeed looking at the phenomena previously termed
tunneling nanotubes.
When TNTs were first described, the authors hypothesized based on their observations,
that cells interacting by TNTs could be subdivided into a donor and a recipient (the first
providing the tube and connecting to the latter) (Rustom et al., 2004). Studying
cocultures of differentially labelled cell populations, we monitored tubes deriving
exclusively from one of the labelled subgroups. This supported the initial hypothesis of
a donor and a receptor. In spite of this, when differently labelled cells were cocultured,
we repeatedly observed TNTs, which harboured GFP-PrPwt in one half of the tube and
the other fluorophore in the second half, thus suggesting that both cells might contribute
to the build-up of the TNT. For testing the dynamics of the formation of TNTs, we
utilized live cell microscopy, specifically a spinning disc confocal microscope. For this
experiment HEK 293 cells were labelled with TAMRA, a dye labelling lipids in
membranes, and then processed these cells for imaging (for example see also movie S4
on CD). Already at the beginning of the recording we found cells connected by TNTs.
Furthermore, we monitored the active build-up of a TNT, which lasted in the shown
example approximately 5 minutes and which connected two cells for about 13 minutes
(total recording time of this movie was 30 minutes). Interestingly, we repeatedly could
see that both cells participated in this process, thereby excluding incomplete cytokinesis
of daughter cells and demonstrating that both cells could participate in the formation of
TNTs.
Next we analyzed whether TNTs could transfer PrPC intercellularly. For this we
cocultured one cell-population transfected with GFP-PrPwt and labelled with
LysoTracker with another population labelled only with LysoTracker and imaged these
by live microscopy. The presented example shows that, during the course of 30 minutes
lysosomes were observed to exit from the GFP-PrPwt cells and move via a TNT to
another cell. These vesicles were measured at a speed of 40-60 nm/s, in agreement with
vesicular transport kinetics in TNTs as previously reported (Rustom et al., 2004).
Additionally, we observed the movement of GFP-PrPwt labelled membrane from one
cell to another, suggesting that GFP-PrPwt could spread intercellularly by plasma
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membrane transfer on TNTs (see also movie S5 on CD). Using cells labelled the same
way, we could also monitor transfer of vesicles containing GFP-PrPwt transferring
intercellularly via TNTs with a speed of 40-60 nm/s (for example see also movie S6 on
CD). Interestingly, we observed that GFP-PrPwt was transferred in vesicles of different
kinds, some of which were also positive for LysoTracker. This suggests that PrPC-
proteins can be transferred intercellularly contained in acidic vesicles as well as in other
vesicles. Based on colocalization data, Rustom and colleagues proposed the
involvement of molecular motors (e.g. myosin Va) in this process (Rustom et al., 2004).
We were therefore interested to analyze the characteristics of vesicular movement in
TNTs and did this by studying their so-called mean square displacement (MSD) (see
manuscript 2 Fig.S4 and Materials and Methods). We found that they moved with a
directed, non-brownian character, suggesting the use of molecular motors in the
transfer-process. Additionally, when fixed cells were analyzed for colocalization of
GFP-PrPwt-positive vesicles with different molecular motors, we found actin-based
motors such as myosin Va and myosin VI to colocalize with these vesicles
(approximately 50% each). On the other hand we found little colocalization with a
microtubule associated motor of the kinesin superfamily, Kif 3a. These data taken
together confirmed the involvement of actin based molecular motors in the transfer of
vesicles by TNTs.
We could also observe transfer of GFP-PrPwt in tubulovesicular structures, which filled
the length of the TNT between cells. To examine this further we utilized X, Y and Z
information and reconstructed one of these examples while applying a threshold for
GFP-PrPwt content (blue stands for high GFP-PrPwt content, grey for lower amounts)
(see movie S8 on CD). Here, GFP-PrPwt appears to be transferred in tubulo-vesicular
structures reminiscent of the trans-Golgi-network (TGN). Nascent PrPC is known to
pass through the Golgi-apparatus before transferring to the plasma membrane (see
paragraph III.14.1.1) and PrPSc was described to localize partially in the Golgi-
apparatus . Others have hypothesized that TNTs could be involved in the intercellular
transfer of the TGN (Galkina et al., 2001). This prompted us to test whether GFP-PrPwt
could be transferred intercellularly while in the Golgi-apparatus (Taraboulos et al.,
1990). For this we transfected HEK 293 cells with GFP-PrPwt and cocultured these
with unlabelled cells for 24 hours. Then, we fixed and labelled them with antibodies
directed against Golgi-markers, such as Giantin (a marker for cis- and medial Golgi).
We observed TNTs connecting differentially labelled cells, which contained both the
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Golgi-marker and GFP-PrPwt. These data taken together suggest that Golgi-derived
material containing GFP-PrPwt can be transferred intercellularly via TNTs.
With these encouraging results, I decided to switch to the aforementioned immortalized
neuronal CAD-cell line (Qi et al., 1997).
We first analyzed whether we could repeat the coculture experiments with two
differently labelled populations as described above. Coculture of GFP-PrPwt-
transfected cells with cherry-rab 6 (a Golgi marker) transfected cells for 48 hours,
produced typical TNTs not attached to the substratum (as shown by X-Z
reconstructions). Additionally we observed GFP-PrPwt-transfer via both membrane
“surfing” and vesicular structures. We could as well repeat the experiments showing
transfer of GFP-PrPwt contained in Golgi-derived vesicles in both fixed cells and in
living cells (see also movie S9 on CD). Altogether these data indicate that GFP-PrPwt
can be transferred between cells of neuronal origin by transfer on the PM of TNTs or by
vesicular transport inside of TNTs.
Next step was to study whether endogenous PrPC and PrPSc can also transfer
intercellularly via TNTs. In fixed samples we could indeed observe vesicles inside of
TNTs containing endogenous PrPC in the case of non-infected CAD-cells and PrPSc in
CAD-cells chronically infected with the prion strain 139A (scCAD). Some of the
transferring vesicles also contained lyso-bisphosphatidic acid (LBPA), a marker of late
endosomes (Kobayashi et al., 1998). Because discerning between PrPC and PrPSc
required fixation of cells and a pre-treatment with guanidium hydrochloride, this
approach was limited to studying fixed cells. Thus, in order to be able to observe the
transfer of PrPSc in living cells, we decided to produce fluorescently-labelled PrPSc
(Alexa-PrPSc) (labelled with Alexa-568nm) by adapting a previously published protocol
(Magalhaes et al., 2005). scCAD-cells were charged with Alexa-PrPSc for 6 days,
extensively washed and cocultured for 24 hrs with non-infected CAD-cells, which were
previously transfected with a GFP-GPI construct. We could monitor TNTs, unattached
to the substratum, between the two populations, which also contained Alexa-PrPSc
particles. Upon close inspection we could also observe fluorescent particles, which had
already been transferred into the lumen of the recipient cell. This demonstrates that
fluorescently labelled PrPSc can transfer by TNTs to other cells, showing that TNTs
could represent a means to spread prion infection between cells of neuronal origin.
Finally, we wanted to understand whether TNTs could support the transfer of Alexa-
PrPSc between primary cells of different origins. By immunohistofluorescence we could
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observe dendritic cells closely juxtaposed to sympathetic neurons in murine spleen-cuts,
supporting the hypothesis that these two cell-types were in close enough proximity to
support the intercellular transfer of PrPSc via TNTs. Because the resolution of current
imaging systems does not allow the analysis of TNTs in living tissues, we simulated the
interaction of DCs with neurons by coculturing murine bone marrow derived dendritic
cells (BMDCs) with primary murine hippocampal neurons in vitro. After 24 hours of
coculture we found TNTs between neurons and BMDCs, which were not attached to the
substratum (see movie S10 on CD). Furthermore, using cocultures of BMDCs,
previously stained with LysoTracker, and neurons, previously transduced with GFP-
PrPwt, we observed LysoTracker-positive vesicles within neurons in close vicinity to
TNTs beween the two cell-types. This suggests that lysosomal vesicles can transfer via
TNTs from BMDCs to neurons.
When BMDCs were charged with Alexa-PrPSc and were cocultured with GFP-PrPtwt-
transduced hippocampal neurons, we found TNTs connecting the two different cell
types as well as the presence of Alexa-PrPSc in the neuronal cell bodies and neurites
close to the intercellular connection. These data taken altogether show that DCs can
interact with neurons via TNTs and that intercellular transfer of prions between these
two cell types can occur via these connections.
V.2.4: Discussion
In diseases such as variant CJD (vCJD) exogenous PrPSc is believed to enter the
organism by contaminated foodstuffs. Comparison of mice experimentally infected with
prions from BSE-cattle and patients who succumbed to vCJD, led researchers to
conclude that the most likely cause for vCJD in humans was the consumption of BSE-
contaminated beef (Bruce et al., 1997; Hill et al., 1997). It is generally assumed that
prions from contaminated foodstuffs enter the body via M-cells in the intestine
(Heppner et al., 2001). As discussed in depth in paragraph III.15.1, following oral
challenge, prions spread from the entry site, concentrate in the adjacent secondary
lymphoid organs and are found in the spleen within days and reach a plateau after a few
weeks (Bruce, 1985; Bueler et al., 1993; Rubenstein et al., 1991) (rev. in (Daude,
2004)). Due to the fact that secondary lymphoid organs close to the site of entry were
found to concentrate prions in the organism, researchers concluded that the immune
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system plays a decisive role in the peripheral progression of the disease. These findings
were substantiated by the fact that splenectomy shortly before or during oral challenge
of animals with prions lead to a significant prolongation of the incubation, thus
suggesting that the spleen might play an important role in the peripheral invasion of the
disease (Fraser and Dickinson, 1970; Kimberlin and Walker, 1989).
As the disease progresses, it is believed that the peripheral sympathetic neuronal system
(SNS) serves as a portal for prions to enter the central nervous system. This is
emphasized by findings that sympathectomy in animals immediately before or after oral
challenge significantly delays the onset of disease, while sympathetic hyperinnervation
of the spleen and other lymphoid organs leads to a significant shortening of the
incubation period (Clarke and Haig, 1971; Glatzel et al., 2001). Upon intraperitoneal
challenge, prions manifest themselves first in neurons of the thoracic spinal cord in
regions corresponding to the entry site of the splanchnic nerves of the sympathetic
nervous system (Beekes et al., 1996; Cole and Kimberlin, 1985). Prions were also
shown to accumulate in sympathetic ganglia (McBride and Beekes, 1999), underlining
the probable involvement of the peripheral sympathetic neuronal system. Nevertheless
it is worthwhile to mention that sympathectomized mice succumb to the disease,
although with some delay compared to control animals, indicating the existence of other
less efficient entry routes, possibly via the vagal nerve (Baldauf et al., 1997; Beekes et
al., 1998).
Dendritic cells, a highly mobile cell-population of the immune system, have frequently
been reported to be in close physical contact with peripheral nerve terminations
(Goehler et al., 2000; Goehler et al., 1999; Hosoi et al., 1993). Due to this and their
ability to preserve antigens undegraded, dendritic cells have been proposed to play a
role in the “switch” of prions from the immune system to the peripheral nervous system
(Aucouturier et al., 2001; Defaweux et al., 2005; Dorban et al., 2007).
However, the mechanism as to how this presumed transfer from immune system cells to
peripheral neurons occurs remains enigmatic. Proposed mechanisms include transfer via
exosomes, membrane-coated viruses or a process termed GPI-painting (see paragraph
III.15.3).
Tunneling nanotubes (TNTs) are structures, which have been recently described in vitro
(Rustom et al., 2004) and presumably serve as a means for cell-cell communication.
Specialists from the field suggest that TNTs might have a counterpart in vivo, termed
cytonemes, which were described in ex vivo preparations of the wing imaginal disc from
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Drosophila melanogaster and are presumably involved in decapentaplegic-signalling
(Hsiung et al., 2005; Ramirez-Weber and Kornberg, 1999).
In this part of my thesis I wanted to analyze whether prions could exploit tunneling
nanotubes for intercellular spreading in vitro and whether this might occur in vivo
between dendritic cells and peripheral neurons in secondary lymphoid organs such as
the spleen.
In the work presented here we demonstrate that TNTs are built between cells of
different populations, therefore excluding incomplete cytokinesis of daughter cells.
Additionally, we have contributed to the understanding of the mechanism how TNTs
are built up between cells. By utilizing differentially labelled cell population, we found
TNTs labelled for one half with membrane from one cell and for the other half with
membrane derived from the other cell population. This suggests that both cells can
contribute to the building of the TNT, in contrast to the previous hypothesis of a donor
and an acceptor cell (Rustom et al., 2004). Additionally in living cells, we observed that
both cells could initiate the TNT-build-up in a spatio-temporal controlled manner,
strongly suggesting either the existence of even finer physical connections escaping the
detection by the microscope or the existence of secreted messengers. The mechanism as
to how cells initiate the construction of TNTs and as to how cells utilize cytoskeletal
elements for stabilizing these tubes remains largely unclear and represents an interesting
avenue for future research. We could find cytoskeletal heterogeneity depending on the
diameter of TNTs in agreement with previous work (Onfelt et al., 2006). Utilizing
sophisticated measurement methods (see Material and Methods of Manuscript 2) we
could establish a cut-off number for diameter thickness (approximately 500nm) and
cytoskeleton differences deriving from there: TNTs with a diameter of 300nm contained
filamentous actin (F-actin) but little or no tubulin. In contrast, TNTs with thicker
diameters always contained F-actin and microtubules. Why difference in diameter leads
to this cytoskeletal heterogeneity remains unanswered, but it could be envisioned that
thicker connections need additional stabilizing cytoskeletal elements such as
microtubules. Also this question needs to be further examined.
In the course of this work, I believe to have demonstrated that prions utilize TNTs for
intercellular transfer both by plasma membrane and by vesicular transfer:
1) Plasma membrane transfer. We could show in fixed and living cells that a GFP-
linked, ectopically expressed protein (GFP-PrPwt) can transfer by “surfing” on the
plasma membrane of TNTs from one cell to another. This is consistent with previous
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findings as shown for proteins attached to the inner side of the plasma membrane
(farnesylated EGFP) (Rustom et al., 2004), to the external side of the plasma membrane
(GFP-GPI, a GPI-anchored GFP-molecule) (Onfelt et al., 2004) and also for pathogens
such as Mycobacterium bovis and Murine Leukemia Virus (MLV) (Onfelt et al., 2006;
Sherer et al., 2007). These findings suggest that plasma membrane and associated
elements can exchange between cells by TNTs. The mechanism underlying this
exchange of plasma membrane content remains to be further investigated.
2) Vesicular transfer. We could show that GFP-PrPwt is transferred by TNTs in vesicles
of lysosomal origin, in Golgi-derived structures as well as other vesicular carriers. By
analyzing the mean square displacement (MSD) of vesicles contained in TNTs (see
Manuscript 2 and Materials and Methods therein), we concluded that their motion is of
a non-brownian, directed nature. This suggested the participation of molecular motors,
which was further substantiated when we found that several actin-based molecular
motors such as myosin Va and myosin VI colocalized with GFP-PrPwt-positive vesicles
inside TNTs. On the other hand, we could not find colocalization between a
microtubule-based motor (Kif 3a) and PrP-containing vesicles inside TNTs, thus
suggesting no involvement of this motor in the transfer of GFP-PrPwt-positive vesicles
via TNTs. These data suggest that actin-based motors but not microtubules motors
might be involved in the process of intercellular transfer via TNTs. Importantly, in cells
of neuronal origin we found that not only ectopically expressed GFP-PrPwt is
transferred via TNTs but also endogenous PrPC and PrPSc, as well as Alexa-labelled
PrPSc. This strongly suggests that prions can transfer in vitro between neurons via TNTs.
Based on our coculture experiments with primary neurons and bone marrow derived
dendritic cells in which lysosomes and Alexa-PrPSc efficiently transferred to neurons via
TNTs, we propose that this transfer occurs also in vivo. The fact that we observed
dendritic cells in close proximity to peripheral sympathetic neurons in spleen by
immunohistofluorescence, underlines the plausability of our hypothesis. In conclusion
we propose that TNTs may represent one of the possible means of transfer of infectious
PrP from the periphery to the central nervous system (CNS) and within cells of the
CNS. If this holds true, it will be important to develop methods that temporarily inhibit
production of TNTs and/or knock-down of dendritic cells as a treatment against acute
prion exposure.
1Prions hi-jack tunneling nanotubes for intercellular spread
Edwin Schiff1,2, Duncan T. Browman1, Zrinka Marijanovic1, Bo Zhang3, Philippe Casanova1,
Anna Caputo1,4, Angelo Martino5, Jost Enninga6, Jaqueline Vinatier1, Jean-Christophe Olivo-
Marin3, Daniela Mannel2 and Chiara Zurzolo1,4, §
1 Unité de Trafic Membranaire et Pathogénèse, Institut Pasteur, 25 rue du Dr.Roux, 75724
Paris Cedex 15, France
2 Department of Immunology, University of Regensburg, F.-J.-Strauss-Allee, 93042
Regensburg, Germany
3 Unité d’Analyse d’Images Quantitative, Institut Pasteur, 25 rue du Dr.Roux, 75724 Paris
Cedex 15, France
4 Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università degli Studi die
Napoli “Federico II”, via Pansini 5, 80131 Naples, Italy
5 Unité de recherché de Génétique Mycobactérienne, Institut Pasteur, 25 rue du Dr.Roux,
75724 Paris Cedex 15, France
6 Unité de Pathogénie Microbienne Moléculaire, Institut Pasteur, 25 rue du Dr.Roux, 75724
Paris Cedex 15, France
§ Author to whom correspondence should be addressed:
Dr. Chiara Zurzolo
e-mail: zurzolo@unina.it, zurzolo@pasteur.fr
Abstract:
In the infectious variant of Creutzfeldt-Jacobs disease (vCJD), prions (PrPSc) enter the body
by oral exposure with contaminated foodstuffs. Prions may then spread from the intestinal
entry site to the central nervous system (CNS) by intercellular transfer from the lymphoid
system to the peripheral nervous system. However, the mechanism of cell-to-cell spread
remains elusive. Tunneling nanotubes (TNTs) have recently been identified as a novel means
of cell-cell communication. Here we show that TNTs transfer cellular PrP and PrPSc between
cells of the same and different origin. Significantly, we observed fluorescently-labelled PrPSc
transferring via TNTs from dendritic cells to primary neurons. Thus, TNTs sustain
intercellular prion transfer and may be involved in its spread from the periphery to the CNS
by neuro-immune interactions.
2Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases of
either genetic or acquired origin. The suspected cause of these diseases is a malconformed
and infectious form of the naturally expressed PrPC-protein, termed PrPSc or prion (1). In the
case of one of the TSEs, variant Creutzfeldt-Jacobs disease (vCJD), prions enter organisms by
oral exposure with contaminated foodstuffs. The mechanism by which exogenously acquired
PrPSc invades the CNS from peripheral sites of infection remains enigmatic. It is hypothesized
that PrPSc passes from the gut through the lymphoreticular system (LRS) and lymphoid organs
to the peripheral nervous system (PNS) and finally to the central nervous system (CNS) (2-4).
It is generally believed that the initial phase of prion replication occurs in the lymphoid
organs and that transfer from LRS to PNS occurs by cellular interactions therein (5, 6).
Several mechanisms have been proposed for these intercellular transfer events, including
hitch-hiking on membrane-coated viruses, transfer via exosomes or by GPI-painting (7-9) and
may involve diverse cell types such as dendritic cells, follicular dendritic cells or
macrophages (10-12).
Recently, a novel mode of cell-cell communication, consisting of thin membrane tubes
interconnecting cells, termed tunneling nanotubes (TNTs) or cytonemes, has been described
both in vitro and in vivo. (13-17). Proteins attached to the plasma membrane by lipid-based
moieties (such as farnesyl groups or GPI-anchors) can be transferred from cell to cell via
TNTs (14, 16). This is particularly interesting regarding the mechanism of intercellular spread
of prions, because both PrPC and PrPSc contain a GPI-anchor (18). To determine whether
cellular PrP (PrPC) could be transferred between cells by TNTs, we transfected HEK 293 cells
(previously shown to form TNTs (16)) with a cDNA encoding mouse PrPC fused to GFP
(GFP-PrPwt) (20) . Tubular connections containing GFP-PrPwt were observed between two
different cell populations (Fig. 1A). We could exclude that this was due to incomplete
cytokinesis of daughter cells because we found connections between GFP-PrPwt expressing
cells and non-expressing cells (Fig. 1A). In order to characterize the cytoskeletal content of
these connections we stained cells for F-actin and alpha-tubulin and measured their thickness
and length (for measurements see (20)). We found heterogeneity with respect to thickness and
cytoskeletal content. While thicker connections (diameter 500-700nm,), contained both F-
actin and tubulin (Fig. 1A), thinner connections (diameter 300 ± 50nm,) contained F-actin but
little or no tubulin (Fig. S1). Similar differences in thickness and length have also been
observed in human macrophages (19). Connections between cells were also very diverse in
length, varying between approximately 5 µm and more than 50 µm (not shown), and also
3form networks of tubes (Fig. S2A) as previously reported (14, 16, 21). Furthermore, X-Z
reconstructions revealed that these connections were not attached to the substratum, a
characteristic of TNTs (Fig. 1B, Fig. S1, Movie S1) (16).
When TNTs were first described, it was hypothesised that cells interacting by TNTs could be
subdivided into a donor and a recipient, (i.e., a cell providing the tube and a cell receiving the
tube (16, 22). Coculturing differentially labelled cell populations, we observed tubes deriving
exclusively from cells of either one or the other population, supporting this hypothesis (Fig.
1C, compare tubes connecting cells 1 and 2). However, TNTs, which harboured both colours,
were also observed, suggesting that both cells can participate in their formation (Fig. 1C,
compare tube connecting cell 1 and 3). To test this hypothesis, we examined the dynamics of
TNT-formation by live cell microscopy. HEK 293 cells in suspension culture were stained
with a membrane dye to visualize the plasma membranes and imaged over the course of 30
minutes. At the beginning of the recording a number of cells were generally found connected
by TNTs (see Fig. 1D, cells 1 and 2 in panel 0s, and Movie S4). In addition, we observed the
active build-up of TNTs, which could involve either one or both cells and connected them for
several minutes (for a representative example see Fig. 1D, cells 1 and 3 in panels 112s to
panel 896s). In the case shown here, both cells participated in establishing a connection and
after approximately 5 minutes one full TNT had formed and lasted for 13 minutes (see Fig.
1D, panel 112s to 448s). Therefore both cells can participate in establishing a TNT,
suggesting that the current model of one donor and one recipient might be incomplete (22).
We also show that these TNTs were functional because they could transfer lysosomes (Movie
S2 and S3), as previously reported (22).
Our next objective was to analyze whether these structures could transfer PrPC. We therefore
co-cultured one HEK 293 cell-population transfected with GFP-PrPwt (22) and labelled with
LysoTracker with another population of cells labelled only with LysoTracker and imaged
these by live microscopy (20). During the course of 30 minutes LysoTracker-positive vesicles
were observed to exit from the GFP-PrPwt positive cell (Fig. 2A, cell 1) towards a recipient
cell with a speed of 40-60 nm/sec (for speed measurements see (20)) (see Fig. 2A, thin arrows
in all panels), in agreement with lysosomal vesicles transport kinetics previously described in
TNTs (16). Additionally, movement of GFP-PrPwt labelled membrane from the donor cell
towards the recipient cell was observed (Fig. 2A, cell 2), suggesting that PrPC could spread
intercellularly by plasma membrane-transfer along the surface of the tube (Movie S5).
In addition to membrane “surfing”, vesicular structures have been reported to transfer
intercellularly inside TNTs, including lysosomes, synaptophysin-positive vesicles and
4mitochondria (16, 19, 22). PrPC and its pathogenic conformer, PrPSc, can be found in
endosomal structures, such as lysosomes and late endosomes (23-25) as well as in the Golgi-
apparatus (26, 27). Thus, we analyzed whether PrPC could also be transferred intercellularly
through TNTs in cytosolic vesicles. To this end we monitored HEK 293 cells, transfected
with GFP-PrPwt and stained with LysoTracker (for example see Fig. 2B). We repeatedly
observed transfer of GFP-PrPwt-positive vesicles via TNTs. As shown in figure 2B, a vesicle
double-positive for GFP-PrPwt and LysoTracker (thin arrow in all panels, Fig. 2D and Fig. S3
for quantifications of fluorescence) followed by a single positive GFP-PrPwt vesicle (Fig. 2B,
thick arrow in all panels and Fig. 2D) transferred from one cell to another via a TNT over a
time of approximately eighteen minutes (movie S6). 3-D reconstruction of the images
confirmed that the vesicles moved inside the tube (Fig. 2C and movie S7) with a mean speed
of 40-60 nm/s (20). Altogether these data demonstrate that GFP-PrPwt can be transferred via
TNTs in cytosolic vesicles of both lysosomal and non-lysosomal origin (Fig. S2B).
Measurements of the mean square displacement (MSD) (20) of vesicles suggested the
involvement of molecular motors in vesicular transfer (Fig. 2E, details on MSD calculation
are described in Fig. S4). Indeed, approximately 50% of GFP-PrPwt containing vesicles
colocalized in TNTs with the actin-based molecular motor myosin Va (Fig. S5), as previously
found for vesicular transfer in TNTs (16, 22). In addition we found that approximately 45% of
GFP-PrPwt positive vesicles colocalized with Myosin VI, another motor involved in
organelle transport (28), while there was no colocalization of vesicles with Kif 3a, a
microtubule-associated motor belonging to the kinesin superfamily (Fig. S5) (29).
GFP-PrPwt was also observed inside TNTs in tubulovesicular structures, which filled the
length of the nanotube (diameter 600nm) from donor to recipient cell (Fig. 2F and movie S8).
One example is shown as a three dimensional reconstruction of Fig. 2F, in which we applied a
colour threshold to distinguish differences in GFP-PrPwt content. Here, GFP-PrPwt appears
to be inside the TNT in tubulo-vesicular structures reminiscent of the TGN (Trans Golgi
Network) (movie S8), which had been previously suggested to transfer by TNTs (30).
Nascent PrPC passes through the Golgi-apparatus before reaching the plasma membrane (31)
and, as expected, in HEK 293 cells intracellular GFP-PrPwt extensively colocalizes with
Giantin, a well-defined marker of the cis and medial Golgi-apparatus (Fig. S6). To analyze
whether GFP-PrPwt could be transferred by TNTs when in the Golgi apparatus, HEK 293
cells expressing GFP-PrPwt were cocultured with untransfected cells for 24 hrs, fixed and
labelled with antibodies directed against Giantin. TNTs connecting the two cell populations
and containing both the Golgi-marker and GFP-PrPwt were observed (Fig. 2G). Thus, Golgi
5derived vesicular and tubulovesicular structures containing GFP-PrPwt can be found in TNTs,
suggesting that GFP-PrPwt may also be transferred intercellularly within these structures.
To examine whether TNTs represent a possible means for prions transfer in neuronal cells, we
utilized CAD-cells, a mouse neuronal cell line of catecholaminergic origin. These cells have
the advantage of being infectable with prions (Fig. S7) and have been recently shown to
produce cellular extensions reminiscent of TNTs (reviewed in (32)).
Co-culture for 48-72 hours of GFP-PrPwt-transfected CAD-cells (CAD(GFP-PrPwt)) with
another population of CAD-cells transfected with either cherry-rab 6 or labelled with
LysoTracker produced typical TNT-connections containing GFP-PrPwt on their surface and
inside vesicular structures of lysosomal and Golgi origin (Fig. S8 A-C). TNT-based transfer
between CAD cells was also observed in live cells by labelling cells with GolgiTracker (Fig.
S9 and Movie S9). Like for HEK 293 cells, these data indicate that exogenously expressed
GFP-PrPwt can be transferred between cells of neuronal origin by “surfing“ on the plasma
membrane of TNTs and by vesicular transport inside of TNTs.
Next, we wanted to evaluate whether endogenous PrP can transfer via TNTs, and more
importantly whether this represents a means of intercellular spread of PrPSc from infected to
non-infected cells. In order to address these questions, we first analyzed the transfer of PrP
between either non-infected CAD-cells or CAD-cells infected with the 139A-prion strain
(scCAD) (33) in fixed samples (Fig. 3 A, B and Fig. S10). In both cases we found PrPC and
PrPSc within vesicular structures inside TNTs, indicating transfer ocurring between cells.
Some of the vesicles inside TNTs were also positively stained for lyso-bisphosphatidic acid
(LBPA) (Fig. 3 A-D and Fig. S10), a marker of late endosomes (34).
The experiment described above with infected CAD cells had to be performed in fixed
conditions because of lack of antibodies specifically recognizing PrPSc in live cells. To follow
PrPSc transfer in live conditions we produced fluorescently-labelled PrPSc (Alexa-PrPSc) by
adapting (20) a previously published protocol (35) (Fig. S11). ScCAD-cells were loaded with
Alexa-PrPSc (Fig. 3E, cell 1), washed extensively, co-cultured for 24 hrs with CAD cells
previously transfected with GFP-GPI (Fig. 3E, cell 2) and imaged by live microscopy. We
could detect TNTs (Fig. S12) containing Alexa-PrPSc between cells of the two populations
(Fig. 3E, arrowheads) and found Alexa-labelled particles in the lumen of a non-loaded cell
(Fig. 3E arrows and inset E1). Importantly we could not detect any fluorescence, when adding
the supernatant from the Alexa-PrPSc-loaded cells to another unlabelled cell population (data
not shown). This excludes transfer of fluorescently labelled PrPSc via the supernatant and
6shows that PrPSc transferred from a loaded cell to recipient cells via TNTs, suggesting that this
could be a means to spread the infection between neurons.
We next addressed whether TNTs could support the transfer of PrPSc between cells of
different origin. TNTs may also be produced in vivo, as shown for the closely related
structures termed “cytonemes“ in ex vivo preparations of the wing imaginal discs of
Drosophila, (13, 15), and may therefore represent an efficient mechanism for the transfer of
PrPSc, sampled by cells at the peripheral entry-site, to neurons in vivo. Dendritic cells (DCs)
have been shown to sample and transport PrPSc from the gut to peripheral lymphatic organs
and also to be sufficient for de novo infection when adoptively transferred from infected
animals to healthy animals (10, 36). It has also been reported that DCs are particularly apt at
producing TNTs (21). Lymphatic organs like the spleen are innervated by the sympathetic
nervous system (SNS), mainly ensheathing local blood vessels, called central arterioles; in
infected animals the SNS has been shown to contain PrPSc in abundance (37, 38). Intriguingly,
DCs were repeatedly found in close proximity to peripheral nerve endings and so it has been
hypothesized that DCs could be involved in transferring prions to the peripheral nervous
system (10, 39, 40).
By performing immunohistofluorescence-experiments on splenic sections we found DCs
closely juxtaposed to neurites (Fig. 4A, arrows) of the SNS emanating from the central
arteriole (Fig. 4A asterisk). Since current imaging systems do not have sufficient resolution to
analyze TNTs in spleen tissue, we simulated the interaction between DCs and neurons by
examining the interaction between bone-marrow-derived dendritic cells (BMDCs) and murine
hippocampal neurons (20) in vitro (Fig. S13). After 24 hours of coculture, typical TNTs not
attached to the substratum (Movie S10) were observed to connect neurons labelled in green
(transduced with GFP-PrPwt (for details see (20))) with BMDCs (stained in red with
LysoTracker) (Fig. 4B, arrowhead). Furthermore, we found LysoTracker-stained vesicles
inside neurites connected to BMDCs by TNTs, suggesting transfer of LysoTracker-positive
vesicles from BMDCs to neurons (Fig. 4B, arrows). In order to follow PrPSc-transfer, BMDCs
were loaded with Alexa-PrPSc and cocultured with GFP-PrPwt-transduced hippocampal
neurons. Also in these conditions we found TNTs connecting the two different cell types (Fig.
4C, arrowheads). Importantly we observed Alexa-PrPSc in the TNT itself, in the neuronal cell
bodies and in the neurites close to the intercellular connection (Fig. 4C, arrows, Fig. S14).
These data demonstrate that BMDCs interact with neurons via TNTs and suggests that
transfer of prions between these two cell types occurs via these structures.
7We demonstrate here that the cell-to-cell communication mechanism of TNTs is exploited by
prions for intercellular transfer in vitro and may serve as a means of cross-infection in vivo.
This is substantiated by several findings: i) exogenously expressed GFP-PrPwt can be
actively transferred via TNTs in immortalized cells of epithelial and neuronal origin; ii)
endogenous PrPC and PrPSc can be transferred via TNTs between infected and non-infected
cells of neuronal origin and iii) fluorescently labelled PrPSc can be transferred via TNTs from
primary BMDCs to non-infected primary neurons. We therefore propose that TNTs mediate
intercellular transfer of PrPSc in vivo. Similar structures, termed cytonemes, have been
described in Drosophila and may represent an evolutionarily conserved mechanism of cell-
cell communication (13, 15). Since DCs may interact with peripheral neurons in lymphoid
organs, intercellular transfer would allow neurons to retrogradely transport prions to the CNS
(41). Interestingly, it was recently shown that in blood from orally infected sheep, CD14+
cells (which include a subpopulation of DCs) contain the major part of infectivity (42), thus
adding another layer of complexity for the involvement of DCs in spreading of prions from
the blood flow. The finding that pathogens as diverse as viruses (17), bacteria (19) and prions
can exploit TNTs for invading eukaryotic cells, implies an ancient evolutionary origin for
these structures.
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Figure legends:
Figure 1:
 HEK cells produce thick TNTs containing GFP-PrPwt.
A) Actin and tubulin content. HEK 293 cells were transiently transfected with a GFP-PrPwt
construct and cocultured for 48-72 hrs with unlabelled cells; samples were fixed and labelled
with phalloidin for staining actin filaments and an antibody against !-tubulin and imaged by
confocal microscopy (Zeiss). Z-reconstruction of several planes is shown. Except where
differently indicated, all scale bars represent 10 µm.
B) Inset representing an X-Z reconstruction of A), showing that the tube is not attached to the
substratum (see arrow and also also Movie S1).
C) Both cells can contribute to TNT-formation. HEK 293 cells were either transiently
transfected with a GFP-PrPwt-construct or stained with LysoTracker. After 24 hrs of
coculture, cells were fixed and processed for imaging (Zeiss). Note that some tubes contain
both GFP-PrPwt and LysoTracker.
D) Live analysis of TNT-formation. HEK 293 cells were mildly trypsinized, in order to
detach them from the culture dish and labelled with TAMRA, a lipid dye, to visualize the
plasma membrane. After extensive washing, cells were processed for live imaging on a
Perkin-Elmer spinning disc confocal. Selected frames of a video sequence are shown,
demonstrating that TNT-formation is an active process in which two cells can participate
(build-up 5 minutes, duration of connection approximately 13 minutes) (see also Movie S4, 2
frames/s over 30 minutes). Shown is a Z-reconstruction of several planes.
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Figure 2:
 GFP-PrPwt transfers via TNTs between HEK 293 cells.
A) Transfer by membrane surfing. Two populations of HEK 293 cells were either double-
labelled by staining with LysoTracker and transient transfection with a GFP-PrPwt-construct
or stained with LysoTracker only. After 24 hrs of coculture, cells were processed for live
imaging on a Perkin-Elmer spinning disc confocal. Selected frames of a video sequence are
shown (see also corresponding Movie S5, 2 frames/s over 30 minutes). Thin arrows indicate
LysoTracker-positive vesicles, while the thick arrow marks the front edge of the GFP-PrPwt-
containing membrane. Shown is a Z-reconstruction of several planes.
B) Transfer of vesicles of both lysosomal and non-lysosomal origin. HEK 293 cells were
transiently transfected with GFP-PrPwt, cultured for 24 hrs and then incubated with
LysoTracker. After extensive washing, cells were processed for live imaging on a Perkin-
Elmer spinning disc confocal. Selected frames of a video sequence are shown (see also
corresponding Movie S6, 2 frames/s over 30 minutes). The thin arrow marks a GFP-PrPwt-
and LysoTracker-positive vesicle; the thick arrow marks a GFP-PrPwt positive vesicle, which
both, in a course of 18 minutes transferred from one cell to another with a speed of 40-60
nm/s. Z-reconstruction of several planes is shown.
C) 3D reconstruction of Fig. 2B and Movie S6. The background  is displayedin grey in order
to better depict the TNT and the contained vesicles. Selected frames of the second part of
Movie S7 are shown (the first part of Movie S7 is a 360° spin with the tube as the longitudinal
axis).
D) Analysis of fluorescence contained in the vesicles shown in Fig. 2B and 2C. Concurrent
increase of signals at position of vesicle 1 (thick arrow) shows colocalization of GFP-PrPwt
and LysoTracker therein, while the second vesicle (thin arrow) contains GFP-PrPwt only,
suggesting a non-lysosomal origin (see also Fig. S3 and (20)).
E) Analysis of vesicle-movement by mean square displacement (MSD) suggests involvement
of molecular motors in vesicle transfer. The data obtained from Movie S6 were analyzed by
MSD plot. Slope of MSD-graphs describes the nature of the motion (slope inferior to 1
corresponds to diffuse undirected movement of objects while superior to 1 indicates actively
transported objects). At beginning the green vesicle presents a slope inferior to one (closed
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triangles) but changes later to slope higher than one. The red vesicle showed a slope higher
than one. Symbols utilized: closed triangles (green vesicle in part 1 of movie (0’-10’)), open
triangles (green vesicle in part 2 of movie (10’-20’)), circles (green vesicle in part 3 of movie
(20’-30’)), rectangles (double-positive vesicle in part 1 of movie (0’-10’)) (see Fig. S4 and
(20) for further detail).
F) TNT contain tubulovesicular structures. HEK 293 cells, transfected with GFP-PrPwt, can
form TNTs that are not attached to the substrate (see X-Z, upper part) and transfer GFP-PrPwt
containing material in long tubulovesicular structures reminiscient of TGN (see movie M8).
Images were acquired with spinning disc confocal (Andor).
G) TNTs contain Golgi-structures. HEK 293 cells were transfected with GFP-PrPwt,
cocultured with an unlabelled population, fixed after 24 hrs and immunostained for Giantin (a
marker for cis- and medial-Golgi) and imaged by confocal microscopy on a Zeiss LSM 510.
Shown is a TNT which contains GFP-PrPwt as well as the Giantin, suggesting transfer of
Golgi-content by TNTs.  A Z-reconstruction of several planes is shown.
Figure 3:  Endogenous PrPC and PrPSc transfer by CAD-cells and scCAD-cells via TNTs.
A) Transfer of endogenous PrPC in late endosomes. PrPC and late endosomes were detected by
immunofluorescence with anti-prion antibodies and an antibody against a marker of late
endosomes (LBPA) in CAD-cells. Cells connected by a TNT transferring PrPC in late
endosomes (arrows) are shown. Images were acquired using epifluorescent microscope
(Marianis).
B) Transfer of endogenous PrPSc in late endosomes. Cultured scCAD-cells were fixed and
treated with GndHCl to reveal PrPSc-epitopes and then immunostained anti-prion and anti-
LBPA antibodies. Cells connected by a TNT transferring PrPSc in late endosomes (arrows) are
shown.
C) Fluorescence values (ordinate/arbitrary units) of PrPC (green rectangles) and LBPA (red
triangles) from Fig. 3A were measured along the tube in a single confocal plane using ImageJ
and plotted against the distance of the tube (abscissa/µm). Concurrent increases of the signals
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at the same points along the tube (arrows depict vesicle 1, 2 and 3 from Fig. 3A) shows
localization of PrPC within late endosomal vesicles (see also Fig. S10).
D) Fluorescence values (ordinate/arbitrary units) of PrPSc (green rectangles) and LBPA (red
triangles) from Fig. 3B were measured along the tube in a single confocal plane and plotted
against the distance of the tube (abscissa/µm). Concurrent increase of the signals at the same
points along the tube (arrows depict vesicle 1 and 2 from Fig. 3B) shows localization of PrPSc
within late endosomal vesicles (see also Fig. S10).
E) Alexa-labelled PrPSc is transferred from scCAD-cells to CAD-cells. CAD-cells were
infected with Alexa-PrPSc and kept in culture for 6 days for efficient uptake and breakdown of
absorbed Alexa-PrPSc aggregates. Cells in suspension were washed several times to ensure
loss of possible extracellular Alexa-PrPSc and then cocultured for 24 hrs with CAD-cells,
previously transfected with GFP-GPI,. A TNT, connecting cells of the two populations with
Alexa-PrPSc-particles contained within the tube (arrowheads) and the recipient cell (arrows
and inset E1). Inset E1 depicts a slightly magnified zone of cell 2 with enhanced intensity in
red channel for better visualization of Alexa-PrPSc-particles. Note that in order to visualize all
Alexa-PrPSc molecules, high laser power was utilized, therefore highly fluorescent Alexa-
PrPSc-particles are also weakly detected in the green channel. Cells were imaged by spinning
disc confocal microscopy (Andor Revolutions).
Figure 4:  Purified and fluorescently labelled PrPSc transfers via TNTs from bone-
marrow derived dendritic cells to primary neurons.
A) Immunohistofluorescence of murine spleen. Antibodies recognizing specific markers of
DCs (CD11c, red) and sympathetic neurons (Tyrosine-Hydroxylase, green) were utilized on
cryo-cuts of spleen tissue from C57/BL6 mice. Arrows mark DCs in close interaction with
neurites extending away from central arteriole (asterisk). Images were obtained by confocal
microscopy on a Zeiss LSM 510. The scale bar represents 5 µm.
B) LysoTracker-positive vesicles transfer from DCs to primary hippocampal neurons. Bone-
marrow derived dendritic cells (BMDCs) were stained with LysoTracker. After extensive
washing, BMDCs were cocultured for 24 hours with primary hippocampal neurons,
previously transduced with a GFP-PrPwt-encoding viral vector and imaged by confocal
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microscopy. A BMDC interacting with a neurite via a TNT (arrowhead) is shown; the
presence of several LysoTracker-positive vesicles inside the neurite (arrows), suggests
intercellular transfer. Images were obtained by confocal microscopy on a Zeiss LSM 510.
C) PrPSc transfers from DCs to primary hippocampal neurons. Bone-marrow derived dendritic
cells (BMDCs) were infected with Alexa-PrPSc for 4 days. After extensive washing BMDCs
were cocultured for 24 hours with hippocampal neurons, previously transduced with a GFP-
PrPwt-encoding viral vector, and imaged by confocal microscopy. A BMDC charged with
Alexa-PrPSc is shown interacting with a neurite via TNTs (arrowheads). Several Alexa-PrPSc-
particles are observed: some at the base of the TNTs and inside of the neurite and several in
the cell body of the neuron (arrows and Fig. S14). Images were obtained by confocal
microscopy on a Zeiss LSM 510.
Supplementary Figures:
S1) HEK 293 cells produce thin TNTs, which contain actin but no tubulin.
As shown by others for human macrophages (1), TNTs are structurally distinct and
distinguishable by their diameter and cytoskeletal content. Önfelt et al. (1) reported that a
TNT-diameter less than 700 nm contained only actin filaments as cytoskeletal elements but
no microtubulin, in contrast to the TNTs with a diameter superior to 700 nm. When HEK 293
cells were transiently transfected with a GFP-PrPwt construct, cocultured for 48-72 hrs with
unlabelled cells, fixed and labelled with Alexa-546-Phalloidin for actin filaments and an
antibody against !-tubulin and imaged by confocal microscopy, tubes with a diameter inferior
to 500 nm (here 300 ± 30nm) were found with little to no microtubule content (2). Inset
represents an X-Z reconstruction, showing that the tubes are not attached to substratum.
Shown is a Z-projection of several confocal planes. Except where differently indicated, all
scale bars represent 10 µm.
S2) HEK 293 cells produce TNT-networks containing both actin and tubulin.
A) Shown is a network of thick TNTs connecting several cells of different populations. HEK
293 cells were transiently transfected with GFP-PrPwt and cocultured with an unlabelled
population for 24 hrs. After fixation, cells were immunostained with Alexa-546-phalloidin
(for actin-cytoskeleton) and anti-tubulin antibodies and imaged by confocal microscopy.
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B) Cells were treated as in A). Note the arrow which marks a GFP-PrPwt-vesicle inside of a
thick, microtubule-positive TNT, suggesting its transfer therein.
S3) Quantification of fluorescence of GFP-PrPwt and LysoTracker in vesicles inside of
TNTs.
Fluorescence values (ordinate/arbitrary units) of GFP-PrPwt (green curve) and LysoTracker
(red curve) from Fig. 2B were measured along the tube in a single confocal plane and plotted
against the distance of the tube (abscissa/nm) (see lower images for numbering of vesicles
(left) and measuring distance (right)). Concurrent increase of the signals at the position of
vesicle 1 shows colocalization of GFP-PrPwt and LysoTracker therein, while the second
vesicle contains GFP-PrPwt only, suggesting its non-lysosomal origin. Measurements of
fluorescence values were obtained using ImageJ software.
S4) Mean square displacement (MSD) measurements suggests the involvement of
molecular motors in vesicular transfer by TNTs. The definition of MSD is given by
MSD("t) := <|x(t+"t) – x(t)|2>. Here, |x(t+"t) – x(t)| is the distance travelled by the object
over a time interval of duration "t, and the squared magnitude is averaged (as indicated by the
angle brackets) over many such time intervals. The MSD is usually fitted by a power law, i.e.,
f("t) := C "ta, where the exponent a typically characterizes the movement. If an object is
undergoing a free Brownian motion, its MSD will exhibit a linear relation, (i.e., a = 1 with C
proportional to the diffusion constant). A super-linear relation (a > 1) indicates actively
transported objects showing directional movements; a sub-linear growth (a < 1) indicates
confined diffusive movements. In order to calculate the parameters (C, a) we computed a
fitted MSD-data set (shown in B) from the raw MSD-data set (shown in A).
A. the MSDs computed from the trajectories of the vesicles;
B. the fitted MSDs with a power law f("t) := C "ta.
We found that the green vesicle in the first recorded movie (out of three) exhibited a sub-
linear MSD (a = 0.50), and super-linear relations for the remainder (a = 1.34 for the second
part and a = 1.49 for the third part), suggesting confined diffusive movement at the beginning
and switch to motor-based directed movement afterwards; the double-positive vesicle
displayed a super-linear MSD with the highest slope among all the vesicles (a = 1.50).
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Altogether this suggests the involvement of molecular motors for transferring vesicles by
TNTs.
S5) Myosin Va and Myosin VI but not Kif3a colocalize with GFP-PrPwt containing
vesicles inside of TNTs. HEK 293 cells were transiently transfected with GFP-PrPwt and
cocultured with an unlabelled population for 24 hrs. After fixation, cells were immunostained
with antibodes directed against either Myosin Va, Myosin VI or Kif3a. TNTs connecting
GFP-PrPwt-expressing cells with unlabelled cells (thereby excluding incomplete cytokinesis)
were chosen (n>10) and GFP-PrPwt positive vesicles colocalizing with the respective
molecular motors MyoVa, MyoVI or Kif3a were quantified (total number of vesicles>20).
Quantitative analysis shows that GFP-PrPwt-positive vesicles colocalized with MyosinVa in
approximately 55% of cases and in approximately 50% of cases with Myosin VI. In contrast
to this GFP-PrPwt-positive vesicles colocalized in only ca. 5% of cases with Kif3a. These
data suggest the involvement of actin-bound MyoVa and MyoVI and no involvement of
microtubuli-bound Kif3a as molecular motors for the transport of GFP-PrPwt-positive
vesicles by TNTs.
S6) GFP-PrPwt is localized in the Golgi-apparatus in HEK 293 cells
HEK 293 cells were transiently transfected with GFP-PrPwt. After fixation, cells were
immunostained with Giantin, a cis- and medial Golgi-marker, and imaged by confocal
microscopy (Zeiss). Note the high percentage of colocalization between GFP-PrPwt and
Giantin intracellularly.
S7) scCAD, murine catecholaminergic cells, are chronically infected with PrPSc which is
resistant to Proteinase K-digestion. CAD cells and scCAD cells (infected with prion strain
139A) were lysed and incubated with Proteinase K (PK) where indicated. Samples were run
on SDS/PAGE-Gel and analyzed by Western Blot utilizing anti-PrP-antibodies for detection
of PrPC/PrPSc-proteins. Note the complete digestion of PrPC from CAD cell lysates treated
with proteinase K-enzyme (PK) and the appearance of PK-resistant products at 25, 20 and 15
kDa in the case of scCAD cells.
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S8) CAD cells produce TNTs and are able to transfer GFP-PrPwt intercellularly on the
plasma membrane as well as in vesicles.
A) (upper) CAD-cells transfer GFP-PrPwt by the plasma membrane in long TNTs. CAD-cells
were transfected with either GFP-PrPwt or cherry-rab 6 (a Golgi marker), cocultured for 24-
48 hrs and imaged by confocal microscopy. A particularly long TNT (length 48 µm, diameter
1 µm) is shown, connecting cells from the two populations. Note that plasma membrane-
bound GFP-PrPwt is apparently transferred to the recipient cell along the TNT as has been
shown for GPI-anchored GFP by others (3, 4). Images acquired by spinning disc confocal
microscopy (Andor).
(lower) TNTs in CAD-cells are not attached to the substratum and transfer plasma membrane-
bound GFP-PrPwt to other cells. An X-Z reconstruction of cells from Fig. S8 A is shown. The
TNT in green is not in contact with the substratum, a characteristic feature of TNTs (3).
B) TNTs in CAD-cells enable transfer of LysoTracker-positive vesicles and GFP-PrPwt-
containing vesicles. CAD-cells transfected with GFP-PrPwt and additionally stained with
LysoTracker connected by TNTs can transfer LysoTracker-positive vesicles and GFP-PrPwt-
containing (arrow) vesicles therein.
C )  Transfer of Golgi-positive material. CAD-cells were transfected with GFP-PrPwt,
cocultured with an unlabelled population of cells, fixed after 24 hrs and immuno-stained for
Giantin and imaged by confocal microscopy (Zeiss). Shown is a Z-reconstruction of several
planes in which cells are connected by a GFP-PrPwt-positive TNT that also contains
numerous giantin-positive vesicles (arrow).
S9) Transfer of Golgi-particles by TNTs shown in living cells by staining with
GolgiTracker.
A) Golgi-Tracker-positive material also containing GFP-PrPwt transfers intercellularly. CAD-
cells were transiently transfected with GFP-PrPwt, cocultured with an unlabelled population
for 24 hrs and then incubated with GolgiTracker. After extensive washing, cells were
processed for live imaging. The arrow marks a particle positive for GFP-PrPwt and
GolgiTracker, transferring from cell 1 to cell 2. Selected frames of a video sequence are
shown (see also Movie S9, 2 frames/s over 20 minutes).
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B) Fluorescence values of vesicles from Fig. S11A. Fluorescence values (ordinate/arbitrary
units) of GFP-PrPwt (green curve) and GolgiTracker (red curve) were measured along the
tube in a single confocal plane and plotted against the distance of the tube (abscissa/µm).
Concurrent increase of the signals at position of the white arrow (image lower left) shows
colocalization of GFP-PrPwt and GolgiTracker. Measurements of fluorescence values were
obtained using ImageJ software.
S10) Analysis of fluorescence values of vesicles from Fig. 3A and Fig. 3B.
A) Fluorescence values (ordinate/arbitrary units) of PrPC (green rectangles) and LBPA (red
triangles) from Fig. 3A were measured along the tube (ImageJ) in a single confocal plane and
plotted against the distance of the tube (abscissa/µm). Concurrent increase of the signals at the
same points along the tube (arrows depict vesicle 1, 2 and 3) shows colocalization of PrPC and
LBPA.
B) Fluorescence values (ordinate/arbitrary units) of PrPSc (green rectangles) and LBPA (red
triangles) from Fig. 3B were measured along the tube (ImageJ) in a single confocal plane and
plotted against the distance of the tube (abscissa/µm). Concurrent increase of the signals at
same points along the tube (arrows depict vesicle 1 and 2) shows colocalization of PrPSc and
LBPA.
S11) Production and analysis of fluorescently labeled PrPSc.
A) Scheme of PrPSc purification and its labelling with Alexa-568-succinimidyl esters. PrPSc-
containing brain homogenate from terminally ill mice was PTA-precipitated in order to enrich
the PrPSc content. Proteinase K (PK) digestion removed proteinaceous contaminants. The
remaining protein, highly enriched in PrPSc, was labelled with Alexa-Fluor-568-succinimidyl
esters according to manufacturers protocol (2).
B) Fischer Rat Thyroid cells, which do not express PrPC, were infected with proteinase K-
digested, fluorescently-labelled, PTA-precipitated material from PrPSc-infected mouse brain
(red). Cells were fixed, permeabilized and incubated in PBS (top panels) or guanidium
hydrochloride (lower panels). Subsequently, the cells were stained with anti-PrP antibody
SAF32 (green) and visualized by fluorescent microscopy. Images were acquired using
epifluorescent microscope (Marianis).
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C)  Fluorescently-labelled PTA precipitate was subjected to SDS-PAGE and analyzed by
fluorescent scanning or western blotting with anti-PrP antibody SAF32 as indicated. Arrows
indicate the three glycosylated isoforms of proteinase K-resistant PrPSc. Arrowhead indicates
undissociated PrPSc higher molecular weight complex.
S12) Z-reconstruction of Fig. 3E showing that the TNT is not attached to substrate. The
background behind the tube has been artificially coloured in grey in order to better depict the
TNT and the contained structures. Volocity and Osirix software were utilized.
S13) Characterization of bone-marrow derived cells.
Cells derived from bone-marrow (BM) of C57/Bl6 mice were characterized for dendritic cell-
markers by fluorescence activated cell sorting (FACS). The white histograms represent the
fluorescent intensities of the BM-derived cells labelled with antibodies against CD86 (left),
MHC II (centre) and CD11c (right). The black histogram represents signal from isotype
matched control antibodies.
S14) Intercellular transfer of Alexa-PrPSc between DCs and neurons via TNTs.
Bone marrow derived dendritic cells, charged with Alexa-PrPSc (red), are connected to
neurons, transduced with GFP-PrPwt-virus (green), via TNTs (white arrowheads). Different
confocal layers (Zeiss) (specified upper left) depict Alexa-PrPSc-molecules (yellow
rectangles) inside of TNT connecting the two cells (left lane), inside of the neurite (centre)
and at the distal end of another TNT (right lane). This suggests the intercellular transfer of
Alexa-PrPSc from DCs to neurons via TNTs.
Supplementary movies:
M1) X-Z reconstruction of HEK 293 cells, connected by a thick TNT. Several Z-planes
from Fig. 1A acquired by confocal microscopy were utilized. The movie shows a 360°-spin
around the tube, demonstrating that the tube is not attached to the substratum. The movie was
generated utilizing the LSM 510 software.
M2) Detached HEK 293 cells produce TNTs and can transfer LysoTracker-positive
vesicles therein.
HEK 293 cells were stained with LysoTracker and then mildly trypsinized in order to detach
them from the substratum. After extensive washing, the cells were allowed to recover for 30
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minutes and then processed for imaging on a spinning disc confocal microscope (Perkin
Elmer). The speed of the movie shows 6 frames/s. The recording time was 10 minutes. Note
LysoTracker-positive vesicles entering the tube from the lower cell and exiting the TNT on
the other side.
M3) X-Z reconstruction of the data from movie M2, showing a TNT between cells and
transfer of LysoTracker-positive vesicles therein.
LysoTracker-positive vesicles are shown in white, while membrane is coloured in red (for
better visualization).
M4) De novo TNT-formation can involve both cells.
HEK 293 cells were treated as described for Fig. 1D. The movie shows that TNT-formation is
an active process in which both cells can participate, demonstrating that the donor-receptor
subdivision as suggested by others (3) may not always apply. Live imaging was done with a
spinning disc confocal microscope (Perkin Elmer). Shown are 2 frames/s over 30 minutes.
M5) LysoTracker-positive vesicles and plasma membrane-bound GFP-PrPwt can
transfer intercellularly by TNTs. HEK 293 cells pretreated as described in Fig. 2A. Note
that LysoTracker-positive vesicles from the GFP-PrPwt expressing cell enter the tube readily
and transfer to the recipient cell with a measured speed of 40-60nm/s (see Materials and
Methods). Note also the movement of the plasma membrane containing GFP-PrPwt along the
TNT. This suggests transfer of plasma membrane and GFP-PrPwt therein by TNTs. Time of
recording is 30 minutes shown with 2 frames/s.
M6) Vesicles double-positive for LysoTracker and GFP-PrPwt or positive for GFP-
PrPwt alone transfer by TNTs intercellularly in HEK 293 cells. Cells were treated as
described in Fig. 2B. Pictures were acquired by spinning disc confocal microscopy (Andor
Revolution). Measured speed of vesicles were 40-60 nm/s. Time of recording is 3x10 minutes
shown with 2 frames/s.
M7) Reconstruction of movie M6. Computer-aided simulation of an excerpt from movie
M6. Shown first is a 360° spin utilizing the tube as the longitudinal spin-axis; thereafter the
view changes to the original angle and motion of vesicles is followed in time. The
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background has been coloured grey for better visualization. Computer-aided reconstructions
were accomplished with the ImageJ, Volocity and Osirix software programmes.
M8) Transfer of tubulovesicular structure by a TNT. Computer-aided highly detailed 3D-
reconstruction of images from Fig. 2F. A colour code for GFP-PrPwt content (blue for high
content, grey for low content) was applied, showing a clearly tubulovesicular structure with
high GFP-PrPwt-content transferring through the tube intercellularly. Computer-aided
processing of data was done with ImageJ, Volocity and Osirix software programmes.
M9) Intercellular transfer of a GFP-PrPwt and GolgiTracker-positive structure in CAD
cells.
Cells were treated as described in Materials and Methods. Pictures were acquired by spinning
disc confocal microscopy (Andor Revolution). Measured speed of particle was ca. 10 nm/s.
Time of recording was 20 minutes shown at 2 frames/s.
M10) Connections between primary hippocampal neuron and bone marrow derived
dendritic cell are not attached to the substratum.
Coculture of neurons with dendritic cells, labelled with TAMRA, a lipid intercalating dye, as
imaged by confocal microscopy. Shown is a whole Z-scan, starting at the bottom of the
substratum and ending with the top of the DC. Note that the fluorescence inside of the TNT
moves with each confocal layer (thickness 300nm). This demonstrates that the connection is
not attached to the substratum. The movie was done with LSM 510 software and Image J. The
scale bar represents 5 µm.
Materials and Methods:
Immortalized cell lines, transfections and transductions:
HEK 293 cells were cultured in DMEM (Sigma, St. Louis, USA) supplemented with 10%
fetal bovine serum in a humidified atmosphere with 5% CO2. CAD-cells (CAD wild-type and
CAD infected with prion strain 139A (scCAD)) were cultured in DMEM/F12 (Invitrogen)
supplemented with pyruvate (100 mM), HEPES (15 mM) (Invitrogen) and 10% fetal bovine
serum. Transient transfections were performed with Lipofectamine (Invitrogen) according to
the manufacter’s instructions. pEGFP-C1 (Clontech), was engineered to express mouse PrPC
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between the restriction sites Nhe I and EcoR I, while the signal peptide of mouse PrPC was
inserted 5’ of EGFP between the restriction sites NheI and PinaA I (kind gift from M.
Sorgato, University of Padua, Italy). Cherry-rab 6, expressing rab 6 linked to the fluorescent
protein “cherry”, was a kind gift from the laboratory of B. Goud (Institut Curie, Paris,
France). Murine wild-type PrP, was inserted in the vector pRRLsin.PPT.hPGK.GFPpre (kind
gift from J.-M. Heard, Institut Pasteur, Paris) utilizing the restriction sites Sal I and BamH I,
at a position 3’ of GFP. The lentiviral vector was produced and collected as described
elsewhere (5).
Primary cell lines:
Bone-marrow derived dendritic cells:
DCs were differentiated from bone marrow cells from 6- to 8-week-old C57 BL6 mice
according to a method adapted from Méderlé et al. (5). Briefly, bone marrow cells were
seeded at 2x106 cells per 100 mm diameter Petri dish (Falcon, Becton Dickinson Labware,
Franklin Lakes, NJ) in 10 ml of Iscove's modified Dulbecco's medium (IMDM; BioWhittaker
Europe, Verviers, Belgium) supplemented with 10% heat-inactivated foetal calf serum (FCS;
Dutscher, Brumath, France), 1.5% supernatant from a J558 cell line producing murine GM-
CSF (6), 50 U/ml penicillin, 50 µg/ml streptomycin, 50 µM 2-mercaptoethanol and 2 mM
glutamine (complete IMDM). Cultures were incubated at 37°C in a humidified atmosphere
with 7% CO2. On day 3, 10 ml of complete IMDM was added. On day 6, suspended cells and
loosely adherent cells were harvested using prewarmed 1% EDTA in Dulbecco's PBS without
Ca2+ and Mg2+ (Biochrom AG, Berlin, Germany). The recovered cells were further cultured
under the same conditions as above. On day 10, cells were harvested with EDTA as above
and distributed in hydrophobic 6-well plates (Evergreen Scientific, Los Angeles, CA) at a
concentration of 9x105 cells/well in 3 ml complete IMDM.
Embryonic hippocampal neurons were produced from C57/BL6 mice as published elsewhere
(7) and were grown on glass bottom culture dishes (Mattek, USA) coated with poly-L-lysine
(Sigma) according to the manufacturer’s instructions for 2 days. Then, neurons were
transduced with virus encoding GFP-PrPwt and cultured for another 3 days. Subsequently,
cells were utilized for coculture experiments.
Antibodies
Anti-PrP-antibodies, recognizing the C-terminal part of PrP-proteins, termed SAF61 (amino
acids 142-160, human numbering) were a kind gift from J. Grassi (CEA, Saclay, France).
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Anti-Myosin Va antibody (LF 18) was obtained from Sigma, the anti-Myosin VI antibody
was purchased from Sigma-Aldrich. The antibody against !-tubulin was obtained from
Chemicon (USA), phalloidin-Alexa 546 was purchased from Molecular Probes (Eugene,
USA). Antibodies against Giantin was purchased from Babco (Berkeley Antibody Company,
USA). Anti-LBPA antibody was a kind gift from J. Gruenberg (University of Geneva,
Geneva, Switzerland). The antibody against Tyrosine-Hydroxylase was obtained from
Chemicon; the anti-CD11c-antibody was purchased from BD Biosciences/Pharmingen;
biotin-conjugated anti-hamster IgG was purchased from Jackson ImmunoResearch/Dianova
and streptavidin-FITC was purchased from BD Biosciences/Pharmingen. All other secondary
antibodies were purchased from Molecular Probes. The Kif 3a antibody was a kind gift from
C. Petit (Institut Pasteur, Paris, France).
Staining of living cells with organelle-specific dyes
Lysosomal staining with LysoTracker:
Living cells were seeded out on Ibidi plastic bottom dishes (Ibidi, Germany) and incubated
with LysoTracker (Molecular Probes) (1:10000) for 1h at 37°C. After extensive washing cells
were utilized as specified in each experiment.
Staining of Golgi-apparatus with GolgiTracker:
Cells were cultured on Glass bottom culture dishes (Mattek, USA) coated with poly-L-lysine
(Sigma) according to the manufacturers instructions. Cultured cells were washed carefully
three times with HMEM (HEPES 13. 8 mM, NaCl 137 mM, KCl 5. 4 mM, Glucose 5.5 mM,
Glutamine 2.0 mM, KH2PO4 0.4 mM, Na2HPO4 0.18 mM, CaCl2•2H20 1.25 mM,
MgSO4•7H2O). Bodipy TR Ceramide (Molecular Probes) was complexed to BSA according
to the manufacturer’s protocol. Living cells were incubated with Bodipy TR Ceramide/BSA
solution (5 µM) for 1h at 37°C. Cells were carefully washed once more with HMEM and then
incubated for 1 h at 37°C in HMEM/1%FBS. Cells were washed three times with HMEM. To
remove residual surface staining, cells were incubated for 15 minutes at 10°C with 5% fatty
acid free BSA (Sigma) dissolved in HMEM and then washed three times with HMEM. This
step was repeated three times. Cells were subsequently processed for live imaging.
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Staining of fixed cells with antibodies
Cells cultured on plastic bottom dishes (Ibidi, Germany) were carefully washed and fixed
with 2% paraformaldehyde (PFA) for 30 minutes at room temperature. Then, cells were
incubated in NH4Cl 50 mM for 10 minutes at room temperature. Cells were permeabilized
with 0.1% Triton X-100 for 2 minutes at room temperature.
In experiments with scCAD-cells, cells were pretreated with guanidium hydrochloride as
published by others (8), in order to reveal endogenously expressed PrPSc. Cells were then
blocked with 2% BSA in PBS for 30 minutes at room temperature. In the case of
immunofluorescence with anti-LBPA antibodies, cells were blocked with 0.2 % BSA. Cells
were incubated with primary antibody for 30 minutes, carefully washed three times and
incubated with secondary antibody and washed again three times before imaging.
Proteinase K-digestion
CAD-cells and scCAD were lysed in lysis buffer (Tris HCl 10 mM, pH 8, NaCl 100 mM,
Triton X-100 0.5%, deoxycholate 0.5%). 500 µg of total protein was digested with 20µg/ml
of Proteinase K (Eurobio) for 30 minutes at 37°C. The reaction was stopped with 2 mM
PMSF for 10 minutes at room temperature. Lysates were centrifuged at 140000 rpm at 4°C
for 1 hour. Pellets were solubilized in lysis buffer and processed for 12% SDS-PAGE and
revealed by western blotting with the anti-PrP-antibody SAF61.
Imaging of cells
Cells were imaged by fluorescence videomicroscopy on Spinning Disc-Confocal Systems
Perkin-Elmer (Boston, USA) and Andor Revolution (Belfast, Ireland) as specified. Fixed cells
were imaged by confocal microscopy (Zeiss LSM 510, Germany), in the case of PrPSc with a
Marianis bright-field microscope (TripleI, Germany). All imaging systems for living cells
were equipped with a heated control chamber kept at 37°C (Pecon, Germany). For 3D
analysis stacks were taken at 300nm per z-section and where necessary combined utilizing
ImageJ. Advanced 3D and 4D-reconstructions were performed utilizing Volocity
(Improvision) and Osirix (Osirix Medical Imaging Software) software programmes.
Labelling of PTA-precipitated PrPSc with Alexa-568 nm
Whole brains from Tg20 mice infected with the 139A prion strain (a generous gift from
Hubert Laude) were weighed and 10% homogenates were made by dounce homogenization in
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1X PBS and subsequent passage through a 22 gauge needle for 10 strokes. Two millilitres of
this homogenate was mixed with 0.5 mL of a 4% sarkosyl (Fluka) solution in PBS and
incubated for 10 minutes at 37°C with agitation. Next, benzonase (Sigma) was added to a
final concentration of 50U/mL and the mixture incubated for 30 minutes at 37°C with
agitation. Next, a prewarmed (37°C) solution of 4% phosphotungstic acid (PTA; Sigma) in
PBS was added to a final concentration of 0.3% PTA and incubated further for 10 minutes at
37 °C with agitation. Subsequently, this mixture was centrifuged at 18 000 x g for 30 minutes
and the supernatant removed. The pellet was resuspended in 0.8 mL of a solution of 0.1%
sarkosyl in PBS and passed through a 261/2 gauge needle for 10 strokes. Next 0.6 mL of this
suspension was diluted with 0.4 mL of PBS and treated with proteinase K (5µg/mL final;
Eurobio) for 1 hour at 37°C with agitation. The reaction was quenched by the addition of
PMSF (Fluka) to a final concentration of 2 mM and centrifuged at 18 000 xg at 4°C for 1 hour
and resuspended in 0.2 mL PBS. This suspension was sonicated in a flat-bottomed,
borosilicate glass vial in a cuphorn sonicator (Sonics, USA) and then brought up to 0.9 mL
PBS. Next, 1mg of Alexa fluor 568 or 594 succinimidyl ester (Invitrogen) in 0.1 mL DMSO
(Sigma) was added and incubated at room temperature (RT) for 30 minutes with agitation
(under subdued light conditions from this point onward). The reaction was quenched with the
addtion of glycine in PBS to a final concentration of 50mM and incubated for 30 minutes at
RT followed by centrifugation at 18 000 x g for 15 minutes at RT.  The supernatant was
discarded and the pellet resuspended with 1mL of a solution of 10mM glycine in PBS and
incubated for a further 30 minutes at RT, followed by centrifugation at 18 000 x g for 15
minutes at RT. Subsequently, the pellet was washed 3 times by steps of resuspension with
1mL PBS and centrifugation for 15 minutes at 18 000 x g. Finally, the pellet was resuspended
with 0.2mL of PBS as the working stock.
Tracking of vesicles
We have developed a computer program for automated 4D tracking of fluorescent vesicles as
described elsewhere (9). Based on the extracted locations of vesicles, we calculated the mean
speed and MSD curves. For detailed description of MSD please refer to Figure Legend S5.
Length measurements of TNTs
The coordinates of the two end points of a tunnel were extracted in order to determine its
length. This was done in a semi-automatic way described as follows:
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1. Denoising: we applied a denoising algorithm (10), which is adapted to eliminate a
mixture of photon and readout noises. At the end of this step, the noise is well separated from
the image and the signal has better contrast.
2. End-points extraction: in the image treated as described above, the user manually selects
the two YZ slices, which delimit the region of the entire tunnel. A binarizing threshold can
easily segment the 2D intensity profile of the tunnel ends from these two slices, and the
intensity-weighted centroids is calculated for the segmented tunnel ends. In this way, the full
3D coordinates of the end points are obtained from which the length is derived.
Diameter measurements of TNTs
The mean tunnel diameter is measured as the average of the diameters at 5 different positions
along the tunnel. For each chosen spot, the corresponding YZ slice information is extracted.
We assume that the tunnel itself has a Gaussian intensity profile with a standard deviation
parameter sigma0 unknown. Our goal is to estimate this sigma0 and the tunnel diameter is
then estimated as 2*sigma0. Toward this goal, we use a Gaussian PSF approximation model
for the microscope (11). The parameters for the Gaussian PSF approximation can be
computed using the microscope configurations utilized for the acquisitions. As the PSF and
the tunnel profile are both approximated by Gaussian functions, the observed intensity also
has a Gaussian profile. As a result, we fit a 2D Gaussian function to derive the underlying
sigma0 from which the estimation of the diameter is computed. Since the image contains
unwanted photon and readout noises, the fit is actually done in a variance-stabilizing
transform domain. This transform is proposed in (10) to stabilize and gaussianize the noise.
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VI. Conclusion and Perspectives
In the first part of my thesis I mimicked heterozygosity, as found in the majority of
inheritable TSE-cases, by co-expressing wild-type and different mutant PrP-forms in
cell culture. This was performed in order to study the reciprocal effect of each form and
possibly find new causes for pathology. In my experiments I found that:
1) Co-expression does not affect the glycosylation pattern of the two different PrP-
forms.
2) In the case of two mutants (A116V, E199K) no significant change in cellular
localization (Golgi-apparatus, plasma membrane) occurred. A third mutant,
T182A, which is blocked intracellularly retained also the co-expressed wild-type
intracellularly.
3) Upon co-expression significantly higher amounts of wild-type and mutant
proteins localize to detergent resistant membranes. This phenotype is not found
when two different wild-type are co-expressed.
4) Co-expressed wild-type and mutant protein interact closely as shown by FRET
intracellularly and on the plasma membrane.
These data indicate that wild-type and mutant forms interact intracellularly and on the
plasma membrane and that this might affect the function and/or behaviour of the wild-
type proteins.
The most clinically relevant question resulting from the work on co-expressing mutant
and wild-type PrP-proteins is whether the aforementioned results on DRM-
sequestration are limited to in vitro cell systems or whether these results are applicable
to in vivo scenarios. To answer this question one might perform experiments in
transgenic mice, either expressing the human PrPC and its mutant counterpart or
expressing the murine version of the human mutation. In light of the conflicting results
obtained with different cell lines utilized by different groups in their experiments, the
described murine-based approach may or may not provide important information and
should therefore be utilized with caution. Carrying out similar experiments to ours on
post-mortem tissues obtained from deceased heterozygous patients, might overcome
these problems; however ethical concerns renders such investigation complicated.
Additional research on the function of PrPC and the implication of its presence in lipid
domains would also help in further interpreting of our data.
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In the second part of my thesis I wanted to study the mode of intercellular spreading of
prions and the role of dendritic cells (DCs) in this process. By using cocultures of
differently labelled cells (HEK 293, CAD) and cocultures of primary DCs and
hippocampal neurons I could show that:
1) Ectopically expressed GFP-PrPwt transfers via TNTs by “surfing” on the plasma
membranes and inside vesicles, probably involving actin-based molecular
motors.
2) Endogenous PrPC and PrPSc transfers via TNTs contained in vesicles between
immortalized neuronal cells.
3) Fluorescently labelled, purified PrPSc transfers via TNTs between immortalized
neuronal cells and from bone-marrow derived dendritic cells to primary neurons
in vitro.
These data shed light on a novel mechanism of intercellular prion-propagation and
emphasizes the possible role of dendritic cells in this process.
The findings of structures resembling TNTs in organisms as diverse as Drosophila
melanogaster (Hsiung et al., 2005; Ramirez-Weber and Kornberg, 1999), sea urchins
(Malinda et al., 1995) murine (Rustom et al., 2004) and human cells (Watkins and
Salter, 2005) suggests that this is a widespread phenomenon in nature. Interestingly,
similar-shaped structures have already been reported for Gram-negative bacteria in the
1950s with the advent of electron microscopy (EM). These structures, called fimbriae
by some (Duguid et al., 1955) and pili by others (Brinton, 1959; Brinton, 1965), are
subdivided into several subtypes of which subtype IV enables bacteria such as
Escherichia coli, Neisseria spp. and Pseudomonas spp. to exchange DNA-information
(e.g. virulence factors) between each other (Telford et al., 2006).
The finding that pathogens as diverse as viruses, bacteria and prions can exploit TNTs
for invading eukaryotic cells, implies an ancient evolutionary origin for these structures.
As often occurs in biological research the attempt to answer a question produces several
new ones. The description of TNTs and their exploitation by pathogens provides several
avenues of further research: The mechanism of how cells find and connect with each
other, why different cytoskeletal elements are utilized, which molecular motors serve
for plasma membrane and vesicular transfer and most importantly how pathogens can
be kept from exploiting these structures for spreading throughout affected organisms are
fascinating questions for the coming years.
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VIII. Summaries
VIII.1: Zusammenfassung
Transmissible spongiforme enzephalopathien (TSEs) ist eine Gruppe von tierischen
Krankheiten mit infektiöser, sporadischer oder genetischer Ätiologie, die durch die
pathologisch-missgefaltete Form des PrP-Proteins (Prion oder PrPSc) ausgelöst werden.
Mutationen im prnp-Gen, welche die Missfaltung des Proteins begünstigen, bilden die
Untergruppe der vererbbaren Erkrankungen. Diese Krankheiten werden an
Nachkommen autosomal-dominant weitervererbt, wobei die Mehrheit der Patienten
heterozygot sind, d.h. eine gesunde und eine fehlgebildtete Form des Proteins in Zellen
exprimieren. Im ersten Teil meiner Dissertation simulierte ich diese Situation in vitro
indem ich gesunde (PrPwt) und mutierte (PrPmut) Proteine in FRT-Zellen
koexprimierte. Da die Proteine an verschiedene fluoreszierende Varianten der GFP-
Familie gebunden waren, konnte man sie mikroskopisch unterscheiden. Desweiteren
enthielten die mutierten Versionen einen sogenannten „tag“, genannt 3F4, um sie auch
per Antikörper unterscheiden zu können. Mit diesen Mitteln wollte ich untersuchen, ob
phenotypische Veränderungen (biochemisch und/oder mikroskopisch) auftreten, die auf
die Interaktion der beiden Proteine zurück zu führen sind. Aufgrund von positiven
FRET-Ergebnissen, erscheint es wahrscheinlich, daß die koexprimierten Proteine eng
miteinander interagieren. Die koexprimierten Proteine kolokalisierten in der Zelle im
Golgi-Apparat und auf der Plasmamembran, scheinbar ohne den jeweiligen Phänotypen
zu beinflussen. Veränderungen im Phänotyp wurden jedoch auf subzellulärer Ebene
gefunden: Die Koexpression von wild-typ und mutierten Proteinen führte zu einer
signifikanten Erhöhung der beiden Proteine in sogenannten DRMs (detergent resistant
membranes). Dies konnte nur festgestellt werden, wenn wild-typ und Mutante
koexprimiert wurden, aber nicht in einer Kontrolle, die zwei unterschiedliche wild-typ
Proteine exprimierte. Im Ganzen betrachtet, bestätigen diese Ergebnisse die bereits
vorgeschlagene Bedeutung von DRMs in der Pathologie von TSE-Krankheiten,
allerdings durch einen neuen und vormals unbekannten Aspekt. Unser Ergebnis lässt
uns vermuten, daß die beschriebenen Erhöhungen in DRM-Sequestration zur Pathologie
in heterozygoten Patienten beitragen könnte.
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Im zweiten Teil meiner Dissertation wendete ich mich der Fragestellung zu, wie
Prionen von Zelle zu Zelle weiter wandern und wie Prionen dadurch in das periphere
Nervensystem (PNS) eindringen können um letztendlich in das zentrale Nervensystem
(ZNS) vorzudringen. TNTs (tunneling nanotubes) sind unlängst beschriebene, filigrane,
membranäre interzelluläre Zellverbindungen, die vermutlich der Zellkommunikation
dienen. Durch mikroskopische Studien an fixierten und lebenden Zellen epithelialer und
neuronaler Abstammung, konnte ich zeigen, daß Prionen TNTs für ihre eigene
Verbreitung mißbrauchen. Anhand von primären gemischten Zellkulturen konnte ich
zeigen, daß dendritische Zellen (DCs) mit hippokampalen Neuronen über TNTs
kommunizieren und, daß in diesem Prozess Lysosomen sowie aufgereinigtes,
fluoreszentes PrPSc von DCs zu Neuronen per TNTs transferieren. Die erfolgreichen
Experimente mit primären Zellen bekräftigte meine vorherigen Untersuchungen an
Zelllinien und führt zu meiner Hypothese, daß dieses Szenario ähnlich in vivo ablaufen
könnte. Dies wird desweiteren untermauert durch Immunohistofluoreszenz-
Experimente an murinem Milzgewebe, wo ich DCs sehr nahe mit Neuronen assoziert
fand. Dieser Teil meiner Dissertation liefert einen neuen Mechanismus, wie Prionen aus
der Peripherie eines oral infizierten Organismus ins ZNS vordringen können.
Informationen zur temporären Blockierung dieser Strukturen könnte sich als eine
vielversprechende Möglichkeit zur Inhibierung der Verbreitung von Prionen im
Organismus herausstellen.
VIII.2: Resumé
Les maladies causées par des prions (ESST, encéphalopathie subaiguës spongiformes
transmissibles) représentent un ensemble de maladies neurodégénératives fatales
affectant différentes espèces animales. Dans ces infections, la protéine PrPC s’accumule
sous une forme anormale dite PrPSc ou prions, forme supposée infectieuse. Le sous-
groupe des ESST héréditaires est lié à des mutations délétères dans le gène codant pour
la protéine PrPC (prnp). La majorité des patients affectés par des ESST héréditaires sont
hétérozygotes, exprimant alors une version saine (PrPwt) et une version mutée (PrPmut)
dans les cellules de leur organisme. Dans la première partie de ma thèse, j’ai reproduit
cette situation in vitro en co-exprimant un plasmide codant pour une protéine sauvage
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(dite «wild-type») avec des plasmides codants pour différentes versions mutées
(trouvées dans des ESST héréditaires). Toutes les protéines ont été couplées à des
étiquettes fluorescentes GFP, rendant leur visualisation possible en microscopie. De
plus, afin de distinguer la forme saugave versus mutantes, ces dernières ont été liées
avec une étiquette supplémentaire nomée 3F4 et reconnue par un anticorps spécifique.
Nos expériences de FRET suggèrent une interaction entre les protéines co-exprimées et
colocalisent dans l’appareil Golgi et sur la membrane plasmique, ne manifestant aucune
différence si comparées avec les contrôles.
Des changements ont été trouvés au niveau sub-cellulaire: la co-expression des
protéines entraine à une augmentation significative des protéines sauvages et mutantes
dans les «DRMs» (detergent resistant membranes). Cet effet était visible que dans le cas
de co-expression de formes sauvages et mutantes mais pas dans le cas contrôle de la co-
expression de deux versions sauvages différentes. Ainsi nos résultats soulignent le rôle
des «DRMs» dans les maladies ESST et suggèrent que les changements décrits de
séquestration dans les DRMs décrits contribueraient à la pathologie dans le cas des
patients hétérozygotes par un mécanisme inconnue.
Dans la deuxième partie de ma thèse, je me suis intéressé à la question de la
dissémination des prions entres les cellules et particulièrement à leur envahissement du
système périphérique neuronal (SPN). Les formes acquises sont probablement causées
en grande partie par l’ingestion d’aliments contaminés par des prions, Leur
dissémination intercellulaire après absorption intestinale reste énigmatique. Les
«TNTs» (tunneling nanotubes) ont récemment été décrits comme des tubes
membranaires très fins, dont les cellules se servent vraisemblablement pour la
communication intercellulaire. Basé sur des études de microscopique, je montre que les
prions exploitent les TNTs pour leur dissémination intercellulaire. En utilisant des
cellules primaires, j’ai réussi à montrer que les cellules dendritques (CDs) derivées de la
moëlle osseuse interagissent avec des neurones de l’hippocampe par la voie des TNTs
et qu’elles transfèrent des lysosomes et de la protéine PrPSc fluorescente par ces
structures. Des expériences de fluorescence immunohistologique sur la rate murine ont
montré une interaction étroite entre des CDs et neurones, suggèrant l’existence des
TNTs in vivo. Cette partie de mon travail propose un nouveau mécanisme par lequel les
prions pourraient se disséminer entre les cellules et envahir le SPN.
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VIII.3: Summary
Transmissible spongiform encephalopathies (TSEs) consist of a group of diseases of
infectious, sporadic and genetic origin, found in higher organisms and caused by the
pathological form of the prion protein (PrPSc). The inheritable subgroup of TSEs are
linked to deleterious changes in the prion gene prnp, which favour its misfolding and
are passed on to offspring in an autosomal-dominant fashion. The majority of patients
from this group of diseases are heterozygous, leading to the co-expression of the wild-
type form (PrPC) and the mutant form (PrPmut) in the same cells. In the first part of my
thesis I mimicked this situation in vitro by ectopically co-expressing plasmids encoding
for wild-type and various PrP-mutants in FRT-cells. Since the proteins were linked to
different fluorophores of the GFP-family and also contained protein-tags we could
distinguish between wild-type and mutant forms and were interested to find
phenotypical changes caused by the interaction of the two proteins by biochemistry and
microscopy. The co-expressed proteins occupied the same cellular sites (such as Golgi-
apparatus and plasma membrane) and probably interact (as seen by FRET) with no
apparent clear change of phenotype when compared with the single-expressing controls.
However significant changes were found on a subcellular level. Co-expression lead to
an increased segregation of wild-type and mutant forms into detergent resistant
membranes (DRMs). This was only seen in the case of co-expressed mutants but not
with a control expressing two wild-type proteins. Taken together these results underline
once more the importance of DRMs in TSE-pathology and suggest that the described
changes in DRM-sequestration could contribute to pathology in heterozygous carriers
by a yet to be defined mechanism.
In the second part of my thesis I focused on the question how prions propagate
intercellularly and how prions invade the peripheral neuronal system. Specifically the
infectious forms are believed to be mainly caused by oral exposure to contaminated
foodstuffs. A still enigmatic process is how prions, upon intestinal uptake, transfer from
cell to cell and how they invade the peripheral nervous system in order to be
retrogradely transported to the central nervous system. Based mainly on microscopic
techniques, we could show in fixed and living cell lines of epithelial and neuronal origin
that prions exploit for intercellular spread a novel cell-to-cell communication
mechanism consisting of fine intercellular membrane tubes, termed tunneling nanotubes
(TNTs). Additionally, utilizing primary cell cultures, we show that bone marrow
derived dendritic cells interact with hippocampal neurons via TNTs and that organelles
such as lysosomes, as well as Alexa-568nm-labelled purified PrPSc can transfer through
these membrane connections intercellularly. The experiments with primary cells
substantiate our findings with immortalized cell lines and lead us to hypothesize that
this scenario could also occur in vivo when immune cells, infected with prions, interact
closely with the peripheral sympathetic nervous system in secondary lymphoid organs
(as we could see by immunohistofluorescence of murine spleen). This part of my work
provides a new mechanism by which prions could propagate from the peripheral entry
site to the central nervous system. Knowledge on ways how to temporarily inhibit
formation of TNTs could serve as a powerful means to block the spread of prions upon
acute exposure.
